

PROGRAM BOOK



The 14th
Annual Meeting of
the Asian Organization for
Crohn's & Colitis
in conjunction with
The 9th International Meeting
on Intestinal Diseases and
the Annual Congress of
the Korean Association for
the Study of Intestinal Diseases

**Gut Health
Beyond
Today**

AOCC 2026 IMKASID 2026

**JUNE 25 (Thu.) - 27 (Sat.), 2026
COEX, SEOUL, KOREA**

Supported by



Contents

Welcome Message	001
Committee	002
Program at a Glance	005
Floor Plan	006
General Information	007
Presentation Information	015
Invited Faculty	018
Our Partners	024
Daily Program	025
• Day 1 - June 25 (Thu.)	
• Day 2 - June 26 (Fri.)	
• Day 3 - June 27 (Sat.)	
Poster Exhibition	066

Welcome Message

Dear Colleagues and Friends,

It is with great pleasure that we welcome you to the 14th Annual Meeting of the Asian Organization for Crohn's & Colitis (AOCC) held in conjunction with the 9th International Meeting on Intestinal Diseases and Annual Congress of the Korean Association for the Study of Intestinal Diseases (IMKASID 2026) from June 25 to 27, 2026 at COEX in Seoul, Korea.

Building on the continued growth and success of previous years, this congress will bring together experts, researchers, clinicians, and nurses from around the world to share knowledge, explore the latest advancements, and strengthen connections in the field of intestinal diseases. With the theme "Gut Health Beyond Today," we are excited to offer a dynamic platform for discussing cutting-edge research, advanced diagnostic strategies, and innovative treatments.

We are committed to making this congress an enriching experience for all attendees. Beyond the outstanding academic sessions, this event also provides opportunities to immerse yourself in the rich culture of Seoul, where tradition and modernity blend seamlessly.

We hope this congress inspires new ideas, fosters meaningful collaborations, and contributes to the continued advancement of gut health worldwide. Thank you for being part of this exciting journey. We wish you a rewarding and inspiring experience during your time here. We look forward to fruitful discussions, new collaborations, and lasting connections at this event.



Dong Il Park, MD, PhD

President of the Asian Organization for Crohn's & Colitis (AOCC)



Sung-Ae Jung, MD, PhD

Congress President of AOCC & IMKASID 2026
President of the Korean Association for the Study of Intestinal Diseases (KASID)

Committee

President of AOCC

Dong Il Park Sungkyunkwan University, Korea

Local Organizing Committee of AOCC 2026 in conjunction with IMKASID 2026

President

Sung-Ae Jung Ewha Womans University, Korea

President-Elect

Jeong-Sik Byeon University of Ulsan, Korea

Vice-Presidents

Jonghun Lee Dong-A University, Korea

You Sun Kim Hallym University, Korea

Secretary General

Byong Duk Ye University of Ulsan, Korea

Director of the Scientific Committee

Chang Hwan Choi Chung-Ang University, Korea

Director of Publications Committee

Eun Soo Kim Kyungpook National University, Korea

Director of the Information Committee

Hyuk Yoon Seoul National University, Korea

Director of the Insurance Committee

Sang-Bum Kang The Catholic University of Korea, Korea

Secretary of Liaison & Public Relations

Young Sun Kim Seoul National University, Korea

Director of the International Academic Exchange Committee

Sang Hyoung Park University of Ulsan, Korea

Director of the Medical Policy Committee

Su Bum Park Pusan National University, Korea

Director of the Education / Clinical Practice Guidelines Committee

Seong-Eun Kim Ewha Womans University, Korea

Director of the Research Committee

Jae Myung Cha Kyung Hee University, Korea

Treasurer

Jun Lee Chosun University, Korea

Director of the IBD Research Group

Sung Noh Hong Sungkyunkwan University, Korea

Director of the Intestinal Tumor Research Group

Yunho Jung Soonchunhyang University, Korea

Director of the Small Intestine Research Group

Ja Seol Koo Korea University, Korea

Director of the Microbiome Research Group

Seong-Joon Koh Seoul National University, Korea

Director of KASID Guidelines TFT

Won Moon Kosin University, Korea

Vice-Secretary Generals

Han Hee Lee The Catholic University of Korea, Korea

Eun Mi Song Ewha Womans University, Korea

Auditors

Chang Soo Eun Hanyang University, Korea

Kang-Moon Lee The Catholic University of Korea, Korea

International Scientific Committee

*alphabetical order by last name

Vineet Ahuja

All India Institute of Medical Sciences, India

Xiang Gao

The Sixth Affiliated Hospital of Sun Yat-sen University, China

Ida Hilmi

University Malaya, Malaysia

Tadakazu Hisamatsu

Kyorin University School of Medicine, Japan

Wee Chian Lim

Tan Tock Seng Hospital, National Healthcare Group, Singapore

Julajak Limsrivilai

Siriraj Hospital Mahidol University, Thailand

Zhanju Liu

Shanghai Tenth People's Hospital Tongji University, China

Joyce Wing Yan MAK

The Chinese University of Hong Kong, Hong Kong, China

Masayuki Saruta

Jikei University School of Medicine, Japan

Jose D. Sollano

University of Santo Tomas, Philippines

Shu-Chen Wei

National Taiwan University, Taiwan

Program at a Glance

 Session in Korean  Pre-registration Required


Time	Day 1-June 25 (Thu.)			Day 2-June 26 (Fri.)								Day 3-June 27 (Sat.)					
	Room B	Room C	Room D	Room A	Room B	Room C	Room D	Room E	Room F	Room G	Exhibition	Room A	Room B	Room C	Room D	Room E	
07:30					Breakfast with Master 1 (07:30-08:00)	Breakfast with Master 2 (07:30-08:00)	Breakfast with Master 3 (07:30-08:00)	Breakfast with Master 4 (07:30-08:00)	Breakfast with Master 5 (07:30-08:00)				Breakfast with Master 6 (07:30-08:00)	Breakfast with Master 7 (07:30-08:00)	Breakfast with Master 8 (07:30-08:00)	Breakfast with Master 9 (07:30-08:00)	
08:00															GO IMKASID Wrap up Session (08:00-08:30)		
08:30																	
09:00				Clinical Symposium 2 ADT (08:30-10:00)	Clinical Symposium 3 Big Data (08:30-10:00)	Translational Symposium Microbiome/Omics (08:30-10:00)	Clinical Symposium 4 Colorectal Neoplasm (08:30-10:00)					IBD Guidelines (08:30-10:00)	Clinical Symposium 8 AOCC for Surgeons (08:30-10:00)	Clinical Symposium 9 Colorectal Neoplasm (08:30-10:00)			
09:30																	
10:00				Coffee Break & Poster Viewing (10:00-10:20)								Coffee Break & Poster Viewing (10:00-10:20)					
10:30																	
11:00	AI Educational Workshop (10:30-12:00)	AOCC-IBUS Intestinal Ultrasound Workshop - Advanced (Module 3) (08:30-12:30)	RAPID Forum (09:30-11:30)	Opening Ceremony (10:20-11:20)								Clinical Symposium 10 IBD Masters (10:20-11:50)	Clinical Symposium 11 Strictures and Perianal Fistulas in CD (10:20-11:50)	AOCC for Nurses and Dietitians (10:20-11:50)			
11:30				AOCC Plenary Session (11:20-12:10)													
12:00			KASID-MSID Joint Symposium (11:30-12:30)										Luncheon Symposium 6 (11:50-12:30) 	Luncheon Symposium 7 (11:50-12:30) 			
12:30				Coffee Break (12:10-12:20)								Closing Ceremony Lucky Draw (12:30-13:00)					
13:00	Luncheon Symposium 1 (12:30-13:10) 				Luncheon Symposium 2 (12:20-13:00) 	Luncheon Symposium 3 (12:20-13:00) 											
13:30					Luncheon Symposium 4 (13:00-13:40) 	Luncheon Symposium 5 (13:00-13:40) 											
14:00				KASID General Meeting (13:40-14:20)	Poster Viewing (13:40-14:20)												
14:30	AOCC-ECCO Forum (13:30-15:30)	Basic Forum (KASID-KAI) (14:00-15:30)		Coffee Break (14:20-14:30)													
15:00				Oral Presentation 1 (14:30-15:10)	Oral Presentation 2 (14:30-15:10)	Oral Presentation 3 (14:30-15:10)	Oral Presentation 4 (14:30-15:10)	Oral Presentation 5 (14:30-15:10)	Oral Presentation 6 (14:30-15:10)	IMKASID for Young Researchers (14:30-16:00)							
15:30				Oral Presentation 7 (15:10-16:00)	Oral Presentation 8 (15:10-16:00)	Oral Presentation 9 (15:10-16:00)	Oral Presentation 10 (15:10-16:00)	Oral Presentation 11 (15:10-16:00)	Oral Presentation 12 (15:10-16:00)								
16:00				Coffee Break & Poster Viewing (16:00-16:20)								Meet the Expert (15:50-16:20) 					
16:30	Clinical Symposium 1 AI (15:50-17:20)	KASID PG Course (15:50-17:20)	MDT Case Discussion (15:50-17:20)	Clinical Symposium 5 Pregnancy & Obesity (16:20-17:50)	Clinical Symposium 6 Small Bowel & Nutrition (16:20-17:50)	KASID-GEST Joint Symposium (16:20-17:50)	Clinical Symposium 7 AOCC for Pediatricians (16:20-17:50)										
17:00																	
17:30																	
18:00				Booth Stamp Event Lucky Draw (17:50-18:10)													
18:30	Presidential Dinner *Invited person only (18:30~)																

Gut Health Beyond Today


Gut Health
Beyond
Today

Floor Plan


Coex 1F North



Booth No.	Company Name
BD1	Abbvie Korea
BD2	Celltrion Pharm
D1	TAKEDA
G1	Ferring Korea
E1	MedInTech
E2	OLYMPUS KOREA CO., LTD.
E3	Koreapharma
E4	Ahngook Pharm
E5	Hanall biopharma
E6	JW Pharmaceutical
E7	DAESANG Wellife
TD	Seoul City Tour Desk




Coex 2F North



Booth No.	Company Name
S1	Pfizer Pharmaceuticals Korea & Hanlim MS
S2	Eisai Korea Inc.
S3	YUHAN CORPORATION
S4	GSK
B1	Pharmbio Inc.
B2	Everest Medicines
B3	TAEJOON
A1	SAMIL PHARMACEUTICAL CO., LTD
A2	Hanmi Pharm. Co., Ltd.
A3	Korea Otsuka Pharmaceutical Co., Ltd
A4	HK inno.N
A5	Boditech Med Inc.
A6	Genomictree
E8	YUNGJIIN PHARM & B.BRAUN
E9	NPK Inc.
E10	PSI CRO
E11	GK Pharm & GC Wellbeing
E12	Han Wha Pharma Co., Ltd.

Coex 3F North



Booth No.	Company Name
BD3	Samsung Bioepis
BD4	Johnson&Johnson Innovative Medicine
G2	Daewoong Pharmaceutical
E13	KuhnIl Pharmaceutical Co., Ltd
E14*	Korea United Pharm
E15*	CJ Bioscience
E16*	DONG-A ST
E17*	ChongKunDang
E18*	MENFISKOREA
P1	AOCC 2027
P2	The China Crohn's & Colitis Foundation
P3	APDW 2026 Manila

* Single-day exhibition (Friday, June 26th only)

General Information

Registration

Date & Time	June 25 (Thu.), 07:30-18:00
	June 26 (Fri.), 06:30-18:00
	June 27 (Sat.), 06:30-13:00
Place	Outside Lobby, Left of Room A, COEX 3F

* The Kit Desk and Coat Room operate during the same hours as the Registration Desk.

Badge Policy

For security purposes, all participants including exhibitors are required to wear their name badges during the congress.

Congress Kit

All participants can get the congress kit after they check-in the registration at Kit Desk. Please show the QR code on your name badge to the staff when you collecting.

Coat Room

Any items stored in the Coat Room must be collected on the same day before the closing time. The secretariat is NOT responsible for any lost or stolen items after operation hours.

Certificate of Attendance & Presentation

All participants may download and print a Certificate of Attendance & Presentation from the My Page section of the AOCC 2026 website after the congress ends. The certificate will be available for download starting July 6.

AOCC 2026 & IMKASID 2026 Mobile App

The mobile app is available on the Apple App Store and Google Play, or via the QR code below. It provides convenient access to essential congress information and useful on-site resources to enhance your congress experience.

Search for

AOCC 2026

IMKASID 2026

대한장연구학회



JUNE 25 (Thu) - 27 (Sat), 2026
COEX, SEOUL, KOREA
AOCC 2026
IMKASID 2026

AI-Powered Real-Time Interpretation

Enhance your meeting experience with AI-powered real-time interpretation.



In Session Rooms (On-Screen Subtitles)

Real-time English-Korean subtitles



On Personal Devices

captions and audio will be available in Korean, English, Chinese, and Japanese via the official mobile app or by scanning the QR code at the entrance of each session room. Participants are kindly asked to use their own earphones or headphones when listening to audio on personal devices.

**Participants are kindly asked to use their own earphones or headphones when listening to audio on personal devices.*

대한의사협회 연수평점안내 (Information for Domestic Participants)

일자별 연수 평점

구분	6월 25일(목)	6월 26일(금)	6월 27일(토)
대한의사협회	최대 6평점	최대 6평점	최대 3평점
내과 분과 전문의	2평점	2평점	2평점
내과 전문의 평생교육	1평점	1평점	1평점
전공의 외부 학술회의		2평점	

출결 체크 방법

1. 각 세션 룸 입구에 비치된 리더기에 네임택의 바코드를 태그해 주시기 바랍니다.
2. 전자 출결 시스템을 사용하며 정확한 출결 기록이 남지 않는 경우, 해당 시간에 대한 평점 인정이 어려울 수 있습니다.
3. 각 세션 마다 출결(최초 입장/최종 퇴장) 태그를 해야 하며, 체류시간에 따라 평점이 인정됩니다.
4. 비강의 시간(휴식, 식사, 개회식/폐회식 등)은 평점 인정이 되지 않습니다.

평점 인정 기준

1. 대한의사협회

이수시간	인정평점
1시간 미만	평점 인정 불가
1시간 이상~2시간 미만	1평점
2시간 이상~3시간 미만	2평점
3시간 이상~4시간 미만	3평점
4시간 이상~5시간 미만	4평점
5시간 이상~6시간 미만	5평점
6시간 이상	6평점

예시)

50분 이수: 0평점

1시간 59분 이수: 1평점

3시간 2분 이수: 3평점

2. 내과 분과 전문의

세션 시간 기준 1일 3시간 이상 참석 확인 시 1일 2점씩 인정

3. 내과 전문의 평생교육

세션 시간 기준 1일 3시간 이상 참석 확인 시 1일 1점씩 인정

4. 전공의 외부 학술회의

대회 기간(3일) 중 1일 세션 시간 기준 3시간 이상 참석 시 2점 인정

* 1일 3시간 미만 참석 시 평점 인정 불가

Internet Lounge

The Internet Lounge is located within the Poster Exhibition Area 1 (GBR 105) on the 1st Floor.

Coffee Break

Location	Type	Menu	Operating Rule
1F	Barista Coffee	Hot / Iced	• Jun 26 (Fri.): Limited to once per person • Scan the QR code on your name badge
2F & 3F	Self-Serve	Hot Coffee & Snacks	• All day available

Breakfast with Master

Pre-registration is required for the Breakfast with Master sessions.

Breakfast with Master	Date & Time	Place	Sponsored by
Breakfast with Master 1	Jun 26 (Fri.), 07:30-08:00	ROOM B	 YUHAN
Breakfast with Master 2	Jun 26 (Fri.), 07:30-08:00	ROOM C	 Eisai Korea Inc.
Breakfast with Master 3	Jun 26 (Fri.), 07:30-08:00	ROOM D	 abbvie
Breakfast with Master 4	Jun 26 (Fri.), 07:30-08:00	ROOM E	 TAEJOON
Breakfast with Master 5	Jun 26 (Fri.), 07:30-08:00	ROOM F	 EVEREST MEDICINES
Breakfast with Master 6	Jun 27 (Sat.), 07:30-08:00	ROOM B	 GSK
Breakfast with Master 7	Jun 27 (Sat.), 07:30-08:00	ROOM C	 Pfizer  HANLIM MS
Breakfast with Master 8	Jun 27 (Sat.), 07:30-08:00	ROOM D	 SAMSUNG BIOEPIS
Breakfast with Master 9	Jun 27 (Sat.), 07:30-08:00	ROOM E	 Pharmbio Korea Inc.

Luncheon Symposium

Lunch will be served in Rooms B and C. Please use the lunch coupons in your badge. Vegetarian and Halal options are available for pre-bookers.

Luncheon	Date & Time	Place	Sponsored by
Luncheon Symposium 1	Jun 25 (Thu.), 12:30-13:10	ROOM B	
Luncheon Symposium 2	Jun 26 (Fri.), 12:20-13:00	ROOM B	SAMSUNG BIOEPIS
Luncheon Symposium 3	Jun 26 (Fri.), 12:20-13:00	ROOM C	Johnson & Johnson Innovative Medicine
Luncheon Symposium 4	Jun 26 (Fri.), 13:00-13:40	ROOM B	abbvie
Luncheon Symposium 5	Jun 26 (Fri.), 13:00-13:40	ROOM C	 Pharm CELLTRION
Luncheon Symposium 6	Jun 27 (Sat.), 11:50-12:30	ROOM B	
Luncheon Symposium 7	Jun 27 (Sat.), 11:50-12:30	ROOM C	 DAEWOONG

Meet the Expert

Meet the Expert	Date & Time	Place	Sponsored by
Meet the Expert 1	Jun 26 (Fri.), 15:50-16:20	Exhibition Booth (1F)	 Pharm CELLTRION
Meet the Expert 2	Jun 26 (Fri.), 15:50-16:20	Exhibition Booth (3F)	Johnson & Johnson Innovative Medicine

Events

① Participants with complimentary registration through sponsors are not eligible for the events.

Lucky Draw Event (Booth Stamp)

Every participant can apply to the lucky draw by submitting the lucky draw coupon. The Lucky Draw will be held twice during the event period.

Winners of the first Lucky Draw are not eligible to participate in the second Lucky Draw.


Lucky Draw Entry Submission

📍 **Event Desk (Inside Lobby, left of Room A, COEX 3F)**


Lucky Draw Prizes




Round 1




iPad Air 11inch



Dyson Supersonic
Nural



AirPods 4 (ANC)



Olive Young Gift Card
(KRW200,000)


🕒 **June 26 (Fri.), 17:50** 📍 **Room A, COEX 3F**

(Entry submission closes at 5pm on June 26)

Lucky Draw winners will be announced during the Booth Stamp Event prize drawing.




Round 2




Galaxy Tab
S11(Wi-Fi)




Apple Watch
Series 11 GPS



Dyson
Supersonic r



Shokz
OPEN FIT 2



Olive Young
Gift Card
(KRW200,000)

🕒 **June 27 (Sat.), 12:30** 📍 **Room A, COEX 3F**

(Entry submission closes at 12pm on June 27)

Lucky Draw winners will be announced at the Closing Ceremony.

Social Media Giveaway

Explore every corner of the venue!

How to Participate



Step 1 Share Your AOC2026 & IMKASID 2026 Experience

Upload a post to your personal social media account featuring at least three photos taken at any of the locations below and include the required hashtags.

- 📍 LED Display in front of the Grand Ballroom (1F)
- 📍 Photo Booth (Lobby, 2F)
- 📍 Exhibition Booths (1F, 2F, and 3F)
- 📍 Photo Wall (3F)

Required Hashtags:

#AOC2026 #IMKASID2026 #Korea #GutHealthBeyondToday



Step 2 Verify Your Post

Visit the Event Desk and have your post verified by a staff.




Step 3 Spin the Prize Wheel

Scan the QR code and spin the prize wheel for a chance to win exciting prizes.

Limited to one entry per person.

Prize Wheel Event



🕒 **June 25 (Thu.), 12:00 pm-27 (Sat.), 12:00 pm**

📍 **Event Desk (Inside Lobby, left of Room A, COEX 3F)**

Share Your Feedback (to be conducted after the event)

After the event, we will conduct a survey to gather your feedback on attending AOCC 2026.

All participants who complete the survey will receive an e-coupon, so we encourage your active participation.

For Korean participants	For overseas participants
	
Olive Young Gift Card (KRW 10,000)	Amazon Gift Card (USD 10)

Presentation Information

Preview Room - For Invited Speakers and Oral Presenters

Date & Time	June 25 (Thu.), 07:30-17:30
	June 26 (Fri.), 06:30-18:30
	June 27 (Sat.), 06:30-14:00
Place	Room 206 (2F)

- Please visit the Preview Room at least 1 hour before your session to upload and check your presentation file and ensure that all materials function properly. A staff member will be available to assist you.
- If you have made any revisions after submitting your presentation, please bring the updated file on a USB flash drive.
- If your presentation contains animations or video clips, you are strongly advised to review all materials and technical details with the technician in advance.

Faculty Room

Faculty members (Invited Speakers, Chairs, and Panelists) may use either faculty room for session preparation.

- **Faculty Room 1:** Room 207 (2F, next to the Preview Room)
- **Faculty Room 2:** VIP Room (1F, located on the left side when facing the entrance to Room C)

Audio-visual Equipment

- All speakers/presenters are required to use the venue's AV equipment. Each session room is equipped with:
 - Podium, Monitor
 - Microphone
 - Wireless presenter (laser pointer/slide advancer) and mouse
- Presentation display system (projector and screen or LED display, depending on the room)
- A presenter view / slide notes function will be available so that speakers may view their notes during the presentation.
- To avoid potential compatibility issues with the venue's AV system, presenters are kindly requested not to use personal laptops, particularly Apple/Mac computers.

Poster Exhibition – Printed Poster & e-Poster

Date & Time	June 25 (Thu.), 08:00-17:30 June 26 (Fri.), 07:30-18:00 June 27 (Sat.), 07:30-12:30
Place	Poster Exhibition Area 1 (GBR 105, 1F) Poster Exhibition Area 2 (201-203, 2F)

* No separate guided poster presentation time is scheduled.

Location	Topic	Presentation Code
Poster Exhibition Area 1 GBR 105 (1F)	IBD: Basic / Translational / Microbiome	P1-001~043
	IBD: Pediatric	P1-044~048
	IBD: Surgery	P1-049~052
	IBD: Others	P1-053~060
	Colorectal Neoplasia: Clinical - Epidemiology, Diagnosis and Prevention	P1-061~063
	Colorectal Neoplasia: Clinical - Treatment and Prognosis	P1-064~068
	Colorectal Neoplasia: Basic / Translational / Microbiome	P1-069~074
	Small Bowel Disease / Nutritional / Functional Disorder	P1-075~079
	Artificial Intelligence	P1-080~082
	Others	P1-083~089
Poster Exhibition Area 2 201-203 (2F)	IBD: Clinical – Epidemiology	P2-001~008
	IBD: Clinical - Diagnosis and Monitoring	P2-009~042
	IBD: Clinical - Treatment and Prognosis	P2-043~103
	IBD: Clinical - Intestinal Ultrasound	P2-104~110

[Setup and Removal for Printes Poster]

- Posters should be displayed as early as possible so that attendees arriving early at the Poster Exhibition Area can view them. Please refer to the operating hours at the top of this page.
- Presenters are responsible for mounting and removing their own posters.
- The secretariat will provide "cut-and-use" tape for attaching posters to the poster boards during the operating hours.
- All posters and materials must be removed from the Poster Exhibition Area between 12:30 and 13:30 on June 27 (Sat).
- The Organizing Committee is not responsible for any posters left behind. Any materials remaining after 13:30 on June 27 (Sat) will be permanently discarded by the secretariat.

Invited Faculty

Overseas

Australia	Yoon-kyo An	Mater Hospital Brisbane
	Robert V Bryant	The Queen Elizabeth Hospital
	Rupert Leong	University of Sydney
	Ryan Mathias	The Queen Elizabeth Hospital
Canada	Vipul Jairath	Western University
	Gilaad G. Kaplan	University of Calgary
	Sun-Ho Lee	University of Toronto
	Kerri Novak	University of Calgary
	Eytan Wine	The Hospital for Sick Children
China	Minhu Chen	Sun Yat-sen University
	Yan Chen	Zhejiang University
	Rui Feng	Sun Yat-Sen University
	Xiang Gao	Sun Yat-sen University
	Yubei Gu	Shanghai Jiao Tong University
	Yue Li	Peking Union Medical College Hospital
	Zhanju Liu	Tongji University
	Ren Mao	Sun Yat-sen University
	Jiaming Qian	Peking Union Medical College Hospital
	Zhihua Ran	Shanghai University
	Jun Shen	Shanghai Jiao Tong University
Hong Kong, China	Francis K.L. Chan	The Chinese University of Hong Kong
	Joyce Wing Yan Mak	The Chinese University of Hong Kong
India	Rupa Banerjee	AIG Hospitals
	Kayal Vizhi Nagarajan	Aster CMI Hospital
Indonesia	Rabbinu Rangga Pribadi	University of Indonesia, Cipto Mangunkusumo National Central General Hospital
Ireland	Marietta Iacucci	University College Cork

Italy	Mariangela Allocca	University Vita-Salute San Raffaele
	Silvio Danese	University Vita-Salute San Raffaele
Japan	Shintaro Akiyama	University of Tsukuba
	Fumihito Hirai	Fukuoka University
	Tadakazu Hisamatsu	Kyorin University
	Katsuro Ichimasa	Showa Medical University
	Takashi Ishige	Gunma University
	Takanori Kanai	Keio University
	Taku Kobayashi	Kitasato University
	Katsuyoshi Matsuoka	Toho University
	Hiroshi Nakase	Sapporo Medical University
	Shintaro Sagami	Kitasato University
	Yutaka Saito	National Cancer Center
	Masayuki Saruta	Jikei University
	Shinichiro Shinzaki	Hyogo Medical University
	Kento Takenaka	Institute of Science Tokyo
	Kiichiro Tsuchiya	University of Tsukuba
	Motoi Uchino	Hyogo Medical University
	Mamoru Watanabe	Juntendo University
	Hironori Yamamoto	Jichi Medical University
Malaysia	Ida Hilmi	University of Malaya
	Alex Hwong-Ruey Leow	Pantai Hospital Kuala Lumpur
Mongolia	Ariunzul Dashdondog	First Central Hospital of Mongolia
	Bayasgalan Luvsandagva	Ulaanbaatar Songdo Hospital
	Bayarmaa Ochirkhuree	First Central Hospital of Mongolia
Myanmar	Tin Moe Wai	Yangon General Hospital
Philippines	Jose D. Sollano	University of Santo Tomas
Portugal	Fernando Magro	University of Porto
	Joana Torres	University of Lisbon

Singapore	Jonathan W. J. Lee	National University Hospital
	Wee Chian Lim	Tan Tock Seng Hospital
	Choon Jin Ooi	Duke-NUS Medical School
Taiwan	Li-Chun Chang	National Taiwan University
	Wen-Feng Hsu	National Taiwan University
	Chao-Hung Kuo	Kaohsiung University
	Puo-Hsien Le	Chang Gung Memorial Hospital
	Yen-Hsuan Ni	National Taiwan University
	Tzung-Jiun Tsai	Kaohsiung Veterans General Hospital
	Shu-Chen Wei	National Taiwan University
Thailand	Julajak Limsrivilai	Mahidol University
	Satimai Aniwan	Chulalongkorn University
USA	Edward V. Loftus Jr.	Mayo Clinic College of Medicine and Science
	David T. Rubin	University of Chicago
	Siddharth Singh	Mayo Clinic Arizona
Vietnam	Luan Minh Dang	University Medical Center, Ho Chi Minh City University

Korea

Jung Ho Bae Seoul National University	Sung Wook Hwang University of Ulsan
Munhyung Bae Gachon University	Byung Ik Jang Yeungnam University
Dong Hoon Baek Pusan National University	Yoon Tae Jeon Korea University
Chang Seok Bang Hallym University	Seong Ran Jeon Soonchunhyang University
Jeong-Sik Byeon University of Ulsan	Kwangmin Joo Dong-A University
Jae Myung Cha Kyung Hee University	Young-Eun Joo Chonnam National University
Dong Kyung Chang Sungkyunkwan University	Jae Kyun Ju Chonnam National University
Jae Hee Cheon Yonsei University	Yu Kyung Jun Seoul National University
Young-Seok Cho The Catholic University of Korea	Sung Hoon Jung The Catholic University of Korea
A Reum Choe Ewha Womans University	Sung-Ae Jung Ewha Womans University
Chang Hwan Choi Chung-Ang University	Yunho Jung Soonchunhyang University
Geunhyuk Choi Soonchunhyang University	Sang-Bum Kang The Catholic University of Korea
Hyun-hee Choi Chonnam National University	Bora Keum Korea University
Jaeyoung Chun Yonsei University	Dae Sung Kim Konyang University
Chang Soo Eun Hanyang University	Dong Hyun Kim Chonnam National University
Soojin Gang Ewha Womans University	Eun Ran Kim Sungkyunkwan University
Dong Soo Han Hanyang University	Eun Soo Kim Kyungpook National University
Sung Noh Hong Sungkyunkwan University	Eun Young Kim Daegu Catholic University
Kyu Chan Huh Konyang University	Eunsun Kim Korea University

Hae Young Kim University of Ulsan	Tae Il Kim Yonsei University
Hyun Gun Kim Soonchunhyang University	Tae-Jong Kim Chonnam National University
Hyun Soo Kim Chonnam National University	Tae Oh Kim Inje University
Hyun-Soo Kim Yonsei University	You Sun Kim Hallym University
Ji Eun Kim Sungkyunkwan University	Young Sun Kim Seoul National University
Jinsu Kim The Catholic University of Korea	Young-Ho Kim Sungkyunkwan University
Ji Won Kim Seoul National University	Bong Min Ko Soonchunhyang University
Joo Sung Kim Seoul National University	Hong Koh Yonsei University
Kwang Soon Kim POSTECH	Seong-Joon Koh Seoul National University
Kyeong Ok Kim Yeungnam University	Ja Seol Koo Korea University
Kyung Mo Kim University of Ulsan	Hee Won Kwon Kyungpook National University
Mi Jin Kim Sungkyunkwan University	Beom Jae Lee Korea University
Minjee Kim Sungkyunkwan University	Chang Kyun Lee Kyung Hee University
Sang Hyun Kim The Catholic University of Korea	Han Hee Lee The Catholic University of Korea
Sang Wook Kim Jeonbuk National University	Hongsu Lee Inje University
Seong-Eun Kim Ewha Womans University	Jae Gon Lee Hanyang University
Seong-Jung Kim Chosun University	Jong Lyul Lee University of Ulsan
Sohyun Kim Yeungnam University	Jonghun Lee Dong-A University
Su Young Kim Yonsei University	Jun Lee Chosun University

Junghwa Lee Kyung Hee University	Sang Hyoung Park University of Ulsan
Kang-Moon Lee The Catholic University of Korea	Seunja Park Kosin University
Seung Bum Lee University of Ulsan	Soo Jung Park Yonsei University
Shin Ae Lee Yonsei University	Subum Park Pusan National University
Yeojin Lee University of Ulsan	Yehyun Park Ewha Womans University
Jong Pil Im Seoul National University	Young Sook Park Eulji University
Hyeji Lim Yonsei University	Dae-hee Pyo The Catholic University of Korea
Ki-Yun Lim Seoul Songdo Hospital	Geom-Seog Seo Wonkwang University
Yun Jeong Lim Dongguk university	Jeongkuk Seo Chung-Ang University
Won Moon Kosin University	Jae Seung Soh Hallym University
Seung-Jae Myung University of Ulsan	Eun Mi Song Ewha Womans University
Gyoung Tae Noh Ewha Womans University	Geun Am Song Pusan National University
Jung Hyun Noh Seoul National University	Joo Hye Song Konkuk University
Chang Kyo Oh Hallym University	Suk-Kyun Yang Daehang Hospital
Dong Jun Oh Dongguk University	Byong Duk Ye University of Ulsan
Shin Ju Oh Kyung Hee University	Jong Chul Ye KAIST
Dong Il Park Sungkyunkwan University	Jun Hwan Yoo CHA University
Eun Jung Park University of Ulsan	Hyuk Yoon Seoul National University
Jihye Park Yonsei University	

Our Partners



abbvie

SAMSUNG
BIOEPIS

Pharm
CELLTRION

Johnson&Johnson
Innovative Medicine



Takeda



FERRING
PHARMACEUTICALS

DAEWOONG



Pfizer HANLIM MS

Eisai Eisai Korea Inc.

YUHAN

GSK



Pharmbio Korea Inc.

TAEJOON

EVEREST MEDICINES



bio+ technology
bdttech

Samil

inno.N

Genomictree

Otsuka

Hanmi Hanmi Pharm.



HANALL
BIOPHARMA

Han Wha Pharma Co., Ltd.

npk
npk Inc.

DAESANG
Welllife

KP KOREA PHARMA

GLUNKANG
PHARMACEUTICALS

GC Wellbeing

JW Pharmaceutical

Ahngook pharm.

PSI

YUNGJIN PHARM

BIBRAUN

MedInTech

OLYMPUS

KUHNIL PHARM



DONG-A ST

MEFIS KOREA Co., Ltd.

KOREA UNITED PHARM

CKD
Pharm

CJ BIOSCIENCE




AOCC 2026

IMKASID 2026

Gut Health
Beyond
Today

Daily Program

- Day 1 - June 25 (Thu.)
 - Day 2 - June 26 (Fri.)
 - Day 3 - June 27 (Sat.)
- 

Daily Program

Day 1 - June 25 (Thu.)

Room C

08:30-12:30	AOCC-IBUS Intestinal Ultrasound Workshop – Advanced (Module 3)
Chair(s)	Kerri Novak (University of Calgary, Canada) Sung Wook Hwang (University of Ulsan, Korea)
08:30-08:35	Welcome Kerri Novak (University of Calgary, Canada)
08:35-08:45	IUS 2026: What's New for IUS in Crohn's Disease? Kayal Vizhi Nagarajan (Aster CMI Hospital, India)
08:45-09:05	Interactive Video Presentation 1: IUS in Crohn's Disease - What's Your Diagnosis? Yoon-kyo An (Mater Hospital Brisbane, Australia)
09:05-09:15	IUS 2026: What's New for IUS in Ulcerative Colitis? Alex Hwong-Ruey Leow (Pantai Hospital Kuala Lumpur, Malaysia)
09:15-09:35	Interactive Video Presentation 2: IUS in Ulcerative Colitis - What's Your Diagnosis? Joyce Wing Yan Mak (The Chinese University of Hong Kong, Hong Kong, China)
09:35-10:05	Interactive Video Case Presentations 3: Scoring Activity and Response in Crohn's Disease and Ulcerative Colitis Kerri Novak (University of Calgary, Canada)

Chair(s) Mariangela Allocca (University Vita-Salute San Raffaele, Italy)
Shintaro Sagami (Kitasato University, Japan)

10:20-10:45 **Interactive Case Presentation 4: Detecting Complications in Crohn's Disease**

IUS-6

Sung Wook Hwang (University of Ulsan, Korea)

10:45-11:10 **Interactive Case Presentation 5: TPUS**

IUS-7

Shintaro Sagami (Kitasato University, Japan)

11:10-11:35 **Interactive Case Presentation 6: Pregnancy, Post op, and beyond IBD**

IUS-8

Ryan Mathias (The Queen Elizabeth Hospital, Australia)

11:35-11:55 **IUS and Future Development**

IUS-9

Mariangela Allocca (University Vita-Salute San Raffaele, Italy)

11:55-12:00 **Summary and Closing Remarks**

IUS-10

Mariangela Allocca (University Vita-Salute San Raffaele, Italy)

12:00-12:30 **Module 3 Post-Course Test**

Jeongkuk Seo (Chung-Ang University, Korea)

Room D

09:30-11:30	RAPID Forum Changing Landscape of Intestinal Diseases in Asia
Chair(s)	Sang Hyoung Park (University of Ulsan, Korea) Tin Moe Wai (Yangon General Hospital, Myanmar)
09:30-10:00	Empowering IBD Care Through Education: Insights from the China Experience
RAPID-1	Yan Chen (Zhejiang University, China)
10:00-10:20	From First Symptom to Specialist: Reducing Delays in IBD Diagnosis
RAPID-2	Luan Minh Dang (University Medical Center, Ho Chi Minh City University, Vietnam)
10:20-10:40	Implementing Intestinal Ultrasound Service for IBD Patients in Indonesia: Challenges and Opportunities
RAPID-3	Rabbinu Rangga Pribadi (University of Indonesia, Cipto Mangunkusumo National Central General Hospital, Indonesia)
10:40-11:00	Management of Rectal Neuroendocrine Tumors in Mongolia
RAPID-4	Bayasgalan Luvsandagva (Ulaanbaatar Songdo Hospital, Mongolia)
11:00-11:20	Artificial Intelligence in Colonoscopy: Screening and Surveillance in Asia Perspective
RAPID-5	Satimai Aniwan (Chulalongkorn University, Thailand)
11:20-11:30	Discussion

Room B

	Kor AI Educational Workshop
10:30-12:00	Demystifying AI for Gastroenterologists: From Basics to Clinical Research
Chair(s)	Young-Seok Cho (The Catholic University of Korea, Korea) Ja Seol Koo (Korea University, Korea)
10:30-10:50	Past, Present and Future Directions in Medical AI
K-AI-1	Jong Chul Ye (KAIST, Korea)

- 10:50-11:10 **From Hypothesis to Model: How Clinicians Can Lead AI Study Design**
K-AI-2 Sang Hyun Kim (The Catholic University of Korea, Korea)
- 11:10-11:30 **From Data to Algorithm: How AI Models Are Developed and Validated**
K-AI-3 Jae Gon Lee (Hanyang University, Korea)
- 11:30-11:50 **Responsible AI Integration in Clinical Settings: Legal and Ethical Perspectives**
K-AI-4 A Reum Choe (Ewha Womans University, Korea)
- Panel Discussion**
- 11:50-12:00 Jung Ho Bae (Seoul National University, Korea)
Dong Jun Oh (Dongguk University, Korea)
Chang Kyo Oh (Hallym University, Korea)

Room D

11:30-12:30 KASID-MSID Joint Symposium

Chair(s) Jonghun Lee (Dong-A University, Korea)
Bayarmaa Ochirkhuree (First Central Hospital of Mongolia, Mongolia)

11:30-11:55 **Current Situation with Inflammatory Bowel Disease in Mongolia**

MSID-1 Ariunzul Dashdondog (First Central Hospital of Mongolia, Mongolia)

11:55-12:20 **The Changing Epidemiology of IBD in Korea: Past, Present, and Future**

MSID-2 Hongsub Lee (Inje University, Korea)

12:20-12:30 **Discussion**

Room B

Luncheon Symposium 1 FERRING PHARMACEUTICALS	
12:30-13:10	Deep Healing, Real Results: Redefining Success in Mild-to-Moderate UC
Chair(s)	Eun Young Kim (Daegu Catholic University, Korea)
12:30-12:50	From Endoscopic to Histological Healing: Can We Target Deeper with Optimized Mesalamine Therapy?
LS-1	Fernando Magro (University of Porto, Portugal)
12:50-13:10	The Power of Optimization – Implementation in Clinical Practice
LS-2	Sung Wook Hwang (University of Ulsan, Korea)

Lobby (1,3F), Exhibition Hall (2F)

13:10-13:20	Coffee Break
Poster Exhibition Area 1 (GBR 105, 1F)	
Poster Exhibition Area 2 (201-203, 2F)	
13:10-13:20	Poster Viewing

Room B

AOCC-ECCO Forum	
13:30-15:30	State-of-the-Art Perspectives on IBD Management
Chair(s)	Dong Il Park (Sungkyunkwan University, Korea) Fernando Magro (University of Porto, Portugal)
13:30-13:35	Opening Remarks
	Dong Il Park (Sungkyunkwan University, Korea)
13:35-14:00	IBD Epidemiology: Evolving Trends and Future Perspectives
AO-EC-1	Sung Noh Hong (Sungkyunkwan University, Korea)

- 14:00-14:25 **New Horizons in Therapeutic Targeting Beyond Endoscopic Remission**
AO-EC-2 Marietta Iacucci (University College Cork, Ireland)
- 14:25-14:50 **Standard of care: Practical Barriers and Overcoming Strategies**
AO-EC-3 Joyce Wing Yan Mak (The Chinese University of Hong Kong, Hong Kong, China)
- 14:50-15:15 **Personalized Treatment Strategies toward Precision Medicine**
AO-EC-4 Joana Torres (University of Lisbon, Portugal)
- 15:15-15:25 **Discussion**
- 15:25-15:30 **Closing Remarks**
 Fernando Magro (University of Porto, Portugal)

Room C

- Basic Forum (KASID-KAI)**
14:00-15:30 Beyond Microbiome, Beyond IBD: Expanding the Horizons of Gut Immunology
- Chair(s)** Seong-Joon Koh (Seoul National University, Korea)
 Kwang Soon Kim (POSTECH, Korea)
- 14:00-14:20 **From Microbes to Metabolites: Postbiotic Insights into Gut Immune-Metabolic Cross-Talk**
KAI-1 Munhyung Bae (Gachon University, Korea)
- 14:20-14:40 **Multi-Biome Analysis Identifies Distinct Gut Microbial Signatures and Their Crosstalk in IBD**
KAI-2 Shintaro Akiyama (University of Tsukuba, Japan)
- 14:40-15:00 **Anti-Commensal IgG as a Pathogenic Driver of Intestinal Inflammation in Inflammatory Bowel Disease**
KAI-3 Kwang Soon Kim (POSTECH, Korea)
- 15:00-15:20 **Multi-Omics Analysis for Early Prediction and Mechanistic Insights into GI-GVHD**
KAI-4 Seung Bum Lee (University of Ulsan, Korea)
- 15:20-15:30 **Discussion**

Lobby (1,3F), Exhibition Hall (2F)

15:30-15:50 Coffee Break

Poster Exhibition Area 1 (GBR 105, 1F)
Poster Exhibition Area 2 (201-203, 2F)

15:30-15:50 Poster Viewing

Room B

15:50-17:20	Clinical Symposium 1 (AI) AI Revolution in IBD Care: From Innovation to a Trusted Partner
Chair(s)	Marietta Iacucci (University College Cork, Ireland) Eun Soo Kim (Kyungpook National University, Korea)
15:50-16:10 CS1-1	AI Revolution in Ulcerative Colitis Endoscopy Kento Takenaka (Institute of Science Tokyo, Japan)
16:10-16:30 CS1-2	Training AI to Detect What Pathologists See: Inflammation in IBD Histology Ji Eun Kim (Sungkyunkwan University, Korea)
16:30-16:50 CS1-3	The LLM Revolution in IBD Chang Seok Bang (Hallym University, Korea)
16:50-17:10 CS1-4	Implementing AI in IBD Care: Challenges and Future Perspectives Marietta Iacucci (University College Cork, Ireland)
17:10-17:20	Discussion

Room C

	Kor KASID PG Course
15:50-17:20	Smarter and Deeper: Core Strategies for Optimized IBD Management
Chair(s)	Geun Am Song (Pusan National University, Korea) Seong-Eun Kim (Ewha Womans University, Korea)
15:50-16:10 K-PG-1	Practical Therapeutic Strategies for 5-ASA, Steroids, and Immunomodulators Dae Sung Kim (Konyang University, Korea)

- 16:10-16:30 **Initiating Advanced Therapy: Choosing the Right Biologic or Small Molecule for the Right Patient**
K-PG-2 Kang-Moon Lee (The Catholic University of Korea, Korea)
- 16:30-16:50 **Seeing Beyond the Lesion: IBD Dysplasia Management Today**
K-PG-3 Eun Ran Kim (Sungkyunkwan University, Korea)
- 16:50-17:10 **IBD as a Multisystem Disease: Managing Extraintestinal Manifestations**
K-PG-4 Han Hee Lee (The Catholic University of Korea, Korea)
- 17:10-17:20 **Discussion**

Room D

- 15:50-17:20 **MDT Case Discussion**
Multidisciplinary Approach in Challenging Cases
- Chair(s) Hyun Gun Kim (Soonchunhyang University, Korea)
Taku Kobayashi (Kitasato University, Japan)
- 15:50-16:20 **A 15-Year-Old Man Presented with Abdominal Pain**
MDT-1 Tae Hyeong Kim (Kyung Hee University, Korea)
- 16:20-16:50 **Perioperative Managements for Crohn's Disease in a 24-Year-Old Male Presenting with Fever**
MDT-2 Motoi Uchino (Hyogo Medical University, Japan)
- 16:50-17:10 **A 51-Year-Old Man with ASUC and Psoriasis**
MDT-3 Yubei Gu (Shanghai Jiao Tong University, China)
- Discussion**
- 17:10-17:20 Bora Keum (Korea University, Korea)
Hae Young Kim (University of Ulsan, Korea)
Tae-Jong Kim (Chonnam National University, Korea)

Day 2 - June 26 (Fri.), 2026

Room B

Breakfast with Master 1  **YUHAN**
07:30-08:00 Beyond the Clinical Trial Data : Impact of Real-World Experience of ZEPOSIA®
Chair(s) Hyun Soo Kim (Chonnam National University, Korea)

Refining Evidence-Based Strategies in UC Practice: Positioning Ozanimod Based on Real-World Experience in Korea
07:30-08:00
BM1-1 Dong Hyun Kim (Chonnam National University, Korea)

Room C

Breakfast with Master 2  **Eisai Korea Inc.**
07:30-08:00 Sequential Treatment in Ulcerative Colitis
Chair(s) Sang Wook Kim (Jeonbuk National University, Korea)

The Current Role of Filgotinib in Ulcerative Colitis
07:30-08:00
BM2-1 Fumihito Hirai (Fukuoka University, Japan)

Room D

Breakfast with Master 3  **abbvie**
07:30-08:00 Start Strong in Ulcerative Colitis with Upadacitinib
Chair(s) Xiang Gao (Sun Yat-sen University, China)
 Geom-Seog Seo (Wonkwang University, Korea)

When Time Matters in Ulcerative Colitis: Upadacitinib for Urgent Disease Control
07:30-07:45
BM3-1 Dong Hoon Baek (Pusan National University, Korea)

Connecting the Dots: Evidence to Insight with Upadacitinib
07:45-08:00
BM3-2 Sang-Bum Kang (The Catholic University of Korea, Korea)

Room E

Breakfast with Master 4

07:30-08:00 Transforming Bowel Preparation Strategies in IBD: A Change in Perspective Toward Mini Oral Sulfate Tablets

Chair(s) Jae Myung Cha (Kyung Hee University, Korea)

Transforming Bowel Preparation Strategies in IBD: A Change in Perspective Toward Mini Oral Sulfate Tablets

07:30-08:00

BM4-1

Jae Seung Soh (Hallym University, Korea)

Room F

Breakfast with Master 5

07:30-08:00 New and Now: Introducing Etrasimod in Ulcerative Colitis

Chair(s) Jae Hee Cheon (Yonsei University, Korea)

Etrasimod in Ulcerative Colitis: Clinical Evidence and Its Role in Therapy

07:30-08:00

BM5-1

David T. Rubin (University of Chicago, USA)

Room A

Clinical Symposium 2 (ADT)

08:30-10:00 Advanced IBD Therapies: Beyond Competition, Toward Optimization

Chair(s) Edward V. Loftus Jr. (Mayo Clinic College of Medicine and Science, USA)
Dong Soo Han (Hanyang University, Korea)

08:30-08:50 **Anti-TNF Therapy: Still Standing Strong and Getting Smarter**

CS2-1

Byong Duk Ye (University of Ulsan, Korea)

08:50-09:10 **Anti-Integrin Therapy: Ensuring Safety, Enhancing Efficacy**

CS2-2

Vipul Jairath (Western University, Canada)

09:10-09:30 **IL-23 Inhibitors: Navigating the Expanding Choices in IBD Care**

CS2-3

Silvio Danese (University Vita-Salute San Raffaele, Italy)

09:30-09:50 **JAK Inhibitors and S1P Receptor Modulators: Emerging Contenders Beyond Biologics**

CS2-4

Taku Kobayashi (Kitasato University, Japan)

09:50-10:00 **Discussion**

Room B

Clinical Symposium 3 (Big Data)

08:30-10:00 Transforming IBD Research Through Big Data and Large Cohort Studies

Chair(s) Gilaad G. Kaplan (University of Calgary, Canada)
Hyun-Soo Kim (Yonsei University, Korea)

08:30-08:50 **Seeing Patterns, Shaping Care: The Evolution of Big Data in IBD Research**

CS3-1

Gilaad G. Kaplan (University of Calgary, Canada)

- 08:50-09:10
CS3-2 **Real-World Data in Action: Unlocking Insights from the Korean National Claims Data**
Hyuk Yoon (Seoul National University, Korea)
- 09:10-09:30
CS3-3 **Nationwide Big Data Insights into the Epidemiology and Trends of IBD in Taiwan**
Shu-Chen Wei (National Taiwan University, Taiwan)
- 09:30-09:50
CS3-4 **Toward Prevention: Expanding Perspectives on Early-Life and Environmental Risk Factors in Inflammatory Bowel Disease**
Sun-Ho Lee (University of Toronto, Canada)
- 09:50-10:00 **Discussion**

Room C

- 08:30-10:00 **Translational Symposium (Microbiome/Omics)**
Microbiome & Omics in IBD: Translating Science into Care
- Chair(s) Jae Hee Cheon (Yonsei University, Korea)
Takanori Kanai (Keio University, Japan)
- 08:30-08:50
TRANS-1 **Microbial Signatures in IBD: Toward Precision Diagnosis and Subtype Stratification Through Multi-Layer Biomarker Discovery**
Chang Kyun Lee (Kyung Hee University, Korea)
- 08:50-09:10
TRANS-2 **Shaping the Gut Microbiome: Therapeutic Interventions and Clinical Implications for Inflammatory Bowel Disease**
Hong Koh (Yonsei University, Korea)
- 09:10-09:30
TRANS-3 **Microbiota-Mediated Intestinal Fibrosis In Crohn's Disease : From Correlation To Causality**
Ren Mao (Sun Yat-sen University, China)
- 09:30-09:50
TRANS-4 **Microbes as Targets, Mediators, and Predictors of Therapy Response in IBD**
Eytan Wine (The Hospital for Sick Children, Canada)
- 09:50-10:00 **Discussion**

Room D

Clinical Symposium 4 (Colorectal Neoplasm)

08:30-10:00 Toward Precision Colorectal Cancer Screening: Integrating Risk, Tools, and Innovation

Chair(s) Seung-Jae Myung (University of Ulsan, Korea)
Francis K.L. Chan (The Chinese University of Hong Kong, Hong Kong, China)

08:30-08:50 **FIT or Colonoscopy: What Is the Best Strategy for CRC Screening?**

CS4-1

Wen-Feng Hsu (National Taiwan University, Taiwan)

08:50-09:10 **Personalized Screening Strategies: Beyond Age-Based CRC Guidelines**

CS4-2

Jae Myung Cha (Kyung Hee University, Korea)

09:10-09:30 **Revolutionizing Biomarkers in Colorectal Cancer Screening**

CS4-3

Francis K.L. Chan (The Chinese University of Hong Kong, Hong Kong, China)

09:30-09:50 **Risk-Adapted Surveillance after Polypectomy & ESD: Who, When, and How**

CS4-4

Su Young Kim (Yonsei University, Korea)

09:50-10:00 **Discussion**

Lobby (1,3F), Exhibition Hall (2F)

10:00-10:20 **Coffee Break**

Poster Exhibition Area 1 (GBR 105, 1F)

Poster Exhibition Area 2 (201-203, 2F)

10:00-10:20 **Poster Viewing**

Room A

10:20-11:20 **Opening Ceremony**

11:20-12:10 AOCC Plenary Session

Chair(s) Dong Il Park (Sungkyunkwan University, Korea)
Sung-Ae Jung (Ewha Womans University, Korea)

11:20-11:32

AO-PL-1



Best AOCC AA

Mesenteric Inflammation-Associated Fibroblasts Drive Intestinal Barrier Dysfunction and Promote Crohn's Disease Progression

Jihye Park (Ewha Womans University, Korea)

11:32-11:44

AO-PL-2



Best AOCC AA

Integrated Metabolomic and Genetic Analyses Reveal Loss of Protective Docosahexaenoic Acid as a Key Driver Linking Ultra-Processed Food to Crohn's Disease Risk

Jie Chen (The Third Xiangya Hospital of Central South University, China)

11:44-11:56

AO-PL-3



Best AOCC AA

Childhood Exposure to a Sibling with Crohn's Disease Alters Gut Microbiome and Increases Crohn's Disease Susceptibility

Rirong Chen (University of Toronto, Canada)

11:56-12:08

AO-PL-4



Best AOCC AA

Efficacy and Safety of Obefazimod in Moderately to Severely Active Ulcerative Colitis: Pooled Phase 3 Results From ABTECT Trials, Including a Japan and Korea Subgroup Analysis

Tadakazu Hisamatsu (Kyorin University, Japan)

12:08-12:10

Closing

Lobby (1,3F), Exhibition Hall (2F)

12:10-12:20 Coffee Break

Room B

12:20-13:00	Luncheon Symposium 2 SAMSUNG BIOEPIS Beyond Similarity: Clinical and Real-World Insights into Ustekinumab Biosimilars
Chair(s)	Katsuyoshi Matsuoka (Toho University, Japan) Jonghun Lee (Dong-A University, Korea)
12:20-12:40	What is Same and Different? Clinical Value of the Ustekinumab Biosimilar SB17 (EPYZTEK®) Eun Soo Kim (Kyungpook National University, Korea)
12:40-13:00	From Evidence to Experience: Real-World Application of Ustekinumab Biosimilar in Inflammatory Bowel Disease Sang Hyoung Park (University of Ulsan, Korea)

Room C

12:20-13:00	Luncheon Symposium 3 Johnson & Johnson Innovative Medicine Evolving IBD Care in the Era of IL-23 Inhibitor
Chair(s)	Masayuki Saruta (Jikei University, Japan) Young-Ho Kim (Sungkyunkwan University, Korea)
12:20-12:35	Unmet Needs in Korean IBD Care: Evolving Expectations for New Therapeutic Options Seong-Joon Koh (Seoul National University, Korea)
12:35-13:00	Advancing IBD Care with Guselkumab: Insights from Clinical and Real World Evidence David T. Rubin (University of Chicago, USA)

Room B

13:00-13:40 Luncheon Symposium 4 
Fast-Acting, Long-Lasting Control: Upadacitinib in IBD

Chair(s) Zhihua Ran (Shanghai University, China)
Sung-Ae Jung (Ewha Womans University, Korea)

13:00-13:20
LS4-1 Optimizing Treatment Strategies in Ulcerative Colitis with Upadacitinib

Byong Duk Ye (University of Ulsan, Korea)

13:20-13:40
LS4-2 Shaping a New Paradigm in Crohn's Disease Management
Edward V. Loftus Jr. (Mayo Clinic College of Medicine and Science, USA)

Room C

13:00-13:40 Luncheon Symposium 5  Pharm
A New Era in IBD Treatment: Optimizing Infliximab Therapy

Chair(s) Zhanju Liu (Tongji University, China)
Yoon Tae Jeon (Korea University, Korea)

13:00-13:20
LS5-1 Real-World Experience with Subcutaneous Infliximab: Updated Global Evidence

Silvio Danese (University Vita-Salute San Raffaele, Italy)

13:20-13:40
LS5-2 Optimizing Remsima SC with Therapeutic Drug Monitoring
Sung Noh Hong (Sungkyunkwan University, Korea)

Room A

13:40-14:20 KASID General Meeting

Poster Exhibition Area 1 (GBR 105, 1F)
Poster Exhibition Area 2 (201-203, 2F)

13:40-14:20 Poster Viewing

Lobby (1,3F), Exhibition Hall (2F)

14:20-14:30 Coffee Break

Room A

14:30-15:10 Oral Presentation 1
IBD: Clinical - Treatment and Prognosis 1

Chair(s) Shinichiro Shinzaki (Hyogo Medical University, Japan)
Beom Jae Lee (Korea University, Korea)

14:30-14:38 OP01-1 Efficacy and Safety of Mirikizumab in Chinese Patients with Ulcerative Colitis Following 104 Weeks of Continuous Treatment: Results from the LUCENT-3 Open-Label Extension Study

Zhihua Ran (Shanghai University of Medicine and Health Sciences
Affiliated Zhoupu Hospital, Shanghai, China)

14:38-14:46 OP01-2 Comparative Long-Term Outcomes of Treatment Strategies in Biologic-Naive Patients with Crohn's Disease: Anti-TNF-First vs. Ustekinumab-First



Han Hee Lee (College of Medicine, The Catholic University of Korea, Korea)

14:46-14:54 OP01-3 Real-World Comparative Effectiveness and Safety of Upadacitinib Plus Vedolizumab Versus Upadacitinib Monotherapy During Induction in Moderate-to-Severe Ulcerative Colitis: A Multicenter Retrospective Cohort Study



Jiayin Yao (The Sixth Affiliated Hospital of Sun Yat-sen University, China)

14:54-15:02 OP01-4 Long-Term Outcomes Following Upfront Combination Therapy with Tofacitinib and Intravenous Corticosteroids in Acute Severe Ulcerative Colitis



Arshdeep Singh (Dayanand Medical College and Hospital, India)

15:02-15:10

OP01-5



Treatment Outcomes of Advanced Therapies in Patients with Refractory Ulcerative Proctitis: A Multicenter Cohort Study

Shin Ju Oh (Kyung Hee University College of Medicine, Korea)

Room B

14:30-15:10

Oral Presentation 2

IBD: Clinical - Epidemiology

Chair(s)

Ida Hilmi (University of Malaya, Malaysia)

Kyeong Ok Kim (Yeungnam University, Korea)

14:30-14:38

OP02-1



Combined Acetaldehyde Metabolism Burden Modifies IBD Susceptibility to Alcohol Consumption: A Cross-Population Multi-Ethnic Cohort Study with Validation from Integrated Genetic, Proteomics and Metabolomics Analyses

Yang Guo (The Third Xiangya Hospital of Central South University, China)

14:38-14:46

OP02-2



Integrating the Environmental and Genetic Architectures of Incident IBD: Comprehensive Exposome-Wide and Genetic Analyses

Kejia Ma (The Third Xiangya Hospital of Central South University, Tianjin Medical University, China)

14:46-14:54

OP02-3



Risk of Inflammatory Bowel Disease Following Hospital-Treated Infections and Modulatory Role of Host Genetics to Support a Multi-Hit Pathogenesis Model

Lintao Dan (Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, The Third Xiangya Hospital of Central South University, China)

14:54-15:02

OP02-4



Association Between Medication and Cancer Incidence in Patients with Inflammatory Bowel Disease: A Population-Based, Nested Case-Control Study

Jeongkuk Seo (Chung-Ang University College of Medicine, Korea)

15:02-15:10

OP02-5

Lonely Minds, Inflamed Guts: Metabolic and Circulating Protein Pathways Linking Social Isolation and Loneliness to Inflammatory Bowel Disease

Jianhui Zhao (Zhejiang University, Massachusetts General Hospital and Harvard Medical School, China)

14:30-15:10	Oral Presentation 3
	Colorectal Neoplasia: Clinical - Treatment and Prognosis
Chair(s)	Jinsu Kim (The Catholic University of Korea, Korea) Bong Min Ko (Soonchunhyang University, Korea)
14:30-14:38	Metachronous Advanced Neoplasia in Patients with Over 10 Adenomas: A Large Multicenter Cohort Analysis
OP03-1	Seung Wook Hong (Asan Medical Center, University of Ulsan College of Medicine, Korea)
	
Best IMKASID AA	
14:38-14:46	Impact of Topical Powder Application After ESD for Large Colorectal Lesions: A KASID Multicenter Randomized Controlled Trial
OP03-2	Yunho Jung (Soonchunhyang University Cheonan Hospital, Korea)
14:46-14:54	Clinical Significance of Close Vertical Resection Margin in T1 Colorectal Cancer After Endoscopic Submucosal Dissection: A Multicenter Retrospective Study
OP03-3	Hyung-Hoon Oh (Chonnam National University Medical School, Korea)
	
YIA	
14:54-15:02	Diagnostic Utility of Endoscopic Features and Endoscopic Ultrasonography for Ulcerative Colitis-Associated Neoplasia: A Retrospective Study on the Role of Endoscopic Submucosal Dissection as a Total Biopsy
OP03-4	Yoriaki Komeda (Kindai University Faculty of Medicine, Japan)
	
DIA	
15:02-15:10	Outcomes of Additional Surgery Versus Surveillance After Noncurative Endoscopic Resection of High-Risk T1 Colorectal Cancer: HASID Multicenter Study
OP03-5	Hyung-Hoon Oh (Chonnam National University Medical School, Korea)

14:30-15:10 Oral Presentation 4
IBD: Clinical – Intestinal Ultrasound

Chair(s) Yue Li (Peking Union Medical College Hospital, China)
Sung Wook Hwang (University of Ulsan, Korea)

14:30-14:38

OP04-1



Functional Photoacoustic/Ultrasound Imaging for Assessing the Treatment Target in Ulcerative Colitis

Yue Li (Peking Union Medical College Hospital, China)

14:38-14:46

OP04-2



PRISM: Integrating Intestinal Ultrasound Activity, Structural Features, and C-Reactive Protein to Predict Histological Activity in Ulcerative Colitis: A Prospective Cross-Sectional Study

Jing-Xing Li (China Medical University Hospital, Taiwan)

14:46-14:54

OP04-3



Patient Perceptions and Satisfaction with Intestinal Ultrasound in Inflammatory Bowel Disease: A Multicenter Cross-Sectional Survey

Jueon Hong (Asan Medical Center, University of Ulsan College of Medicine, Korea)

14:54-15:02

OP04-4



Transperineal Ultrasound for Early Identification of Corticosteroid Non-Response in Acute Severe Ulcerative Colitis (TRANSPiRE): A Prospective Pilot Study

Deloshaan Subhaharan (Gold Coast University Hospital, Bond University, Australia)

15:02-15:10

OP04-5



Early Quantitative Intestinal Ultrasound Response Predicts One-Year Endoscopic Remission in Crohn's Disease: A Prospective Treat-to-Target Cohort Study Using IBUS-SAS Score

Kayal Vizhi Nagarajan (Aster CMI Hospital, Hebbal, India)

14:30-15:10 Oral Presentation 5

Microbiome

Chair(s)

Takanori Kanai (Keio University, Japan)
Chang Soo Eun (Hanyang University, Korea)

14:30-14:38

OP05-1

Non-Toxin-Mediated Clostridioides difficile Colonization Drives Microbial Dysbiosis and Early Inflammatory Priming in IBD

Gwanghee Kim (Seoul National University Hospital, Korea)

14:38-14:46

OP05-2



AG

Microbial Metabolite Hyodeoxycholic Acid Induces Macrophage Immunometabolic Reprogramming and Alleviates Ulcerative Colitis

Yaping An (Tianjin Medical University General Hospital, China)

14:46-14:54

OP05-3



YIA

Age-Related Microbial Differences in Newly Diagnosed Crohn's Disease Reveal the Distinct Enrichment of Oral-Associated Taxa in Pediatric Patients

Yun-Seok Jeong (Kyung Hee University, Korea)

14:54-15:02

OP05-4

Heterogeneous Dysbiotic Pathotypes and Longitudinal Dynamics of the Gut Microbiome in Ulcerative Colitis Patients

Yeonjae Jung (CJ Bioscience, Inc., Korea)

15:02-15:10

OP05-5



YIA

Pyridoxamine Depletion and Redox-Associated Microbial Restructuring in Ulcerative Colitis

Sho Tanaka (Hokkaido University Hospital, Japan)

14:30-15:10 Oral Presentation 6

IBD: Pediatric & Surgery

Chair(s)

Yen-Hsuan Ni (National Taiwan University, Taiwan)

Eun Jung Park (University of Ulsan, Korea)

14:30-14:38

OP06-1

**Lymphoma and Colorectal Cancer in Pediatric-Onset Inflammatory Bowel Disease: A 15-Year Nationwide Population-Based Study in South Korea**

Eun Sil Kim (Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Korea)

14:38-14:46

OP06-2

**Patient Perspectives on Transitional Care for Childhood-Onset Inflammatory Bowel Disease in Japan: A Multicenter Cross-Sectional Survey (TransiSCAN)**

Hideki Kumagai (Jichi Medical University, Japan)

14:46-14:54

OP06-3

**Subcutaneous Versus Intravenous Double-Dose Infliximab for Dose Intensification in Pediatric-Onset Crohn's Disease: A Prospective Comparative Study**

Tae Jong Jeong (Samsung Medical Center, Korea)

14:54-15:02

OP06-4

**Preoperative Food-Related Quality of Life Associated with Clinical Outcomes in Patients with Ulcerative Colitis After Ileal Pouch-Anal Anastomosis: Results from China UC Pouch Center Union**

Weimin Xu (Xinhua Hospital, Shanghai Jiaotong University School of Medicine, China)

15:02-15:10

OP06-5

**Left-Sided Ileostomy Reduces Stoma Outlet Obstruction After Ileal Pouch-Anal Anastomosis for Ulcerative Colitis: A Randomized Controlled Trial**

Ryuichi Kuwahara (Hyogo Medical University, Japan)

14:30-16:00 IMKASID for Young Researchers

Chair(s) Jeong-Sik Byeon (University of Ulsan, Korea)
Young Sun Kim (Seoul National University, Korea)

14:30-14:45

YR-1

Optimizing IBD Outcomes Across the Lifespan: Differential Positioning of Biologics and Small Molecules from Pediatrics to Adulthood

Jung Hyun Noh (Seoul National University, Korea)

14:45-15:00

YR-2

Clinical Characteristics and Surgical Outcomes of Adolescent-Onset Crohn's Disease Compared with Pediatric-and Adult-Onset Disease A Nationwide Multicenter Retrospective Cohort Study (CONNECT Study Group)

Soojin Gang (Ewha Womans University, Korea)

Minjee Kim (Sungkyunkwan University, Korea)

15:00-15:15

YR-3

Tailoring Colorectal Cancer Screening for Older Adults: Strategies Beyond Routine Colonoscopy

Geunhyuk Choi (Soonchunhyang University, Korea)

15:15-15:30

YR-4

New Colorectal Cancer Screening—Moving Beyond Fit

Yejin Lee (University of Ulsan, Korea)

15:30-15:45

YR-5

Artificial Intelligence in Capsule Endoscopy: Current Landscape and Future Perspectives

Kwangmin Joo (Dong-A University, Korea)

15:45-16:00

YR-6

Gut Microbiome in Inflammatory Bowel Disease: From Dysbiosis to Personalized Therapy

Hee Won Kwon (Kyungpook National University, Korea)

15:10-16:00

Oral Presentation 7

IBD: Clinical - Treatment and Prognosis 2

Chair(s)

Puo-Hsien Le (Chang Gung Memorial Hospital, Taiwan)
Jong Pil Im (Seoul National University, Korea)

15:10-15:18

OP07-1

**Day 3 Stool Frequency Predicts Steroid Non-Response in Korean Patients with Acute Severe Ulcerative Colitis**

Sun Min Lee (Chonnam National University Hospital, Chonnam National University Medical School, Korea)

15:18-15:26

OP07-2

**Impact of Prior Anti-IL-12/23 Exposure on Anti-TNF Effectiveness in Crohn's Disease: A Propensity-Weighted Cohort Study**

Jiawei Zhan (The Sixth Affiliated Hospital, Sun Yat-sen University, China)

15:26-15:34

OP07-3

**Long-Term Outcomes of Prophylactic Scheduled Endoscopic Balloon Dilation for Crohn's Disease-Associated Intestinal Strictures**

Manabu Nagayama (Jichi Medical University, Japan)

15:34-15:42

OP07-4

**Integrated Blood miR-873-5p and Clinical Parameters Predict Stricturing Progression in Crohn's Disease: A Prospective Multi-Cohort Study**

Chang Liang (West China Hospital of Sichuan University, China)

15:42-15:50

OP07-5

**Cancer Risk with Advanced Therapies in Patients with Inflammatory Bowel Diseases: An Administrative Claims-Based Study**

Soo-Kyung Park (Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Korea)

15:50-16:00

Discussion

15:10-16:00 Oral Presentation 8	
IBD: Clinical - Diagnosis and Monitoring	
Chair(s)	Julajak Limsrivilai (Mahidol University, Thailand) Eunsun Kim (Korea University, Korea)
15:10-15:18 OP08-1	Performance and Treatment-Dependent Behavior of Clinically Available Biomarkers for Endoscopic Recurrence in Postoperative Crohn's Disease
	Kento Sadashima (Saga University, Saga chuo public hospital, Japan)
15:18-15:26 OP08-2	Distinct IFNG-Driven Inflammation and Epithelial Metabolic Reprogramming Differentiate Intestinal Tuberculosis from Ileocecal Crohn's Disease
	Lexi Wu (Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, China)
15:26-15:34 OP08-3	Clinical Significance of Small Bowel Capsule Endoscopy for Predicting Postoperative Endoscopic Recurrence in Patients with Postoperative Crohn's Disease: J-PROSPECT Study
	Motohiro Esaki (Saga University, Japan)
15:34-15:42 OP08-4	Admission Factors of Steroid Refractoriness in a Prospective Cohort of Patients with Acute Severe Ulcerative Colitis (ASUC): Preliminary Analysis of a KASID Multicenter Study
	Seoyoon Choi (Severance Hospital, Yonsei University College of Medicine, Korea)
15:42-15:50 OP08-5	Pharmacogenetics and Metabolite-Guided Optimization of Thiopurine Therapy in Taiwanese Inflammatory Bowel Disease
	Meng-Tzu Weng (National Taiwan University Hospital and College of Medicine, Hsin-Chu Branch, Taiwan)
15:50-16:00	Discussion

Oral Presentation 9

15:10-16:00 Colorectal Neoplasia: Clinical - Epidemiology, Diagnosis and Prevention

Chair(s) Li-Chun Chang (National Taiwan University, Taiwan)
Ji Won Kim (Seoul National University, Korea)

15:10-15:18

OP09-1



YIA

Comparison of Stool DNA Based SDC2 Methylation Testing and Repeat FIT for Advanced Colorectal Neoplasia in FIT Positive Individuals: A Multicenter Prospective Exploratory Study

Youngik Kim (Yonsei University Wonju college of Medicine, Korea)

15:18-15:26

OP09-2



DIA

Comparison of Extremely Early-Onset Colorectal Cancer (EEO-CRC) Versus Extremely Late-Onset Colorectal Cancer (ELO-CRC) in Chungcheongnam-do: The Chungcheong Association for the Study of Intestinal Disease (CHASID) Multicenter Study

Doohyuck Lee (Dankook University Hospital, Korea)

15:26-15:34

OP09-3



YIA

Bleeding Risk After Therapeutic Colonoscopy by Anticoagulant Type: A Retrospective Multicenter Cohort Study

Min-Jae Kim (Yonsei University College of Medicine, Korea)

15:34-15:42

OP09-4

Acceptance of Family-Based Interventions for Colorectal Cancer Screening: Assessing Adult Children as Digital Care Partners

Jeongkuk Seo (Chung-Ang University College of Medicine, College of Medicine, Seoul National University, Korea)

15:42-15:50

OP09-5



AG

Combined Application of Modified Colorectal Cancer Risk Scoring and Fecal Immunochemical Testing for Early Detection of Colorectal Cancer

Temuulen Tsedensodnom (Mongolian National University of Medical Sciences, Mongolia)

15:50-16:00

Discussion

15:10-16:00 Oral Presentation 10	
AI	
Chair(s) Wee Chian Lim (Tan Tock Seng Hospital, Singapore) Young-Eun Joo (Chonnam National University, Korea)	
15:10-15:18	Latent-Space Multimodal Deep Learning for Predicting Disease-Behavior Progression in Long-Standing Crohn's Disease: An Interpretable and Clinically Deployable AI Framework
OP10-1	
	Hanqiao Dai (Peking Union Medical College Hospital- Chinese Academy Medical Sciences & Peking Union Medical College, China)
15:18-15:26	Pathological Representation and Outcome Mapping for Anti-Integrin $\alpha 4\beta 7$ Sustained Efficacy (PROMISE): A Multicenter Study in Ulcerative Colitis
OP10-2	
	Yadi Lan (Tianjin Medical University General Hospital, China)
15:26-15:34	Development and Validation of a Computed-Tomography Enterography Radiomic Approach for Quantification of Small-Bowel Damage in Crohn's Disease
OP10-3	
	Linwei Wang (Zhongshan Hospital of Xiamen University, China)
15:34-15:42	Multimodal Deep Learning for Predicting High-Risk Pathological Features in Superficial Colorectal Cancer
OP10-4	
	Junghun Han (Yonsei University Wonju College of Medicine, Korea)
	Evaluating Multimodal Large Language Model Pipelines for Colonic Polyp Detection and Boundary Estimation
15:42-15:50	
OP10-5	Eue Young Kim (Seoul National University Hospital, Seoul National University College of Medicine, Korea)
15:50-16:00	Discussion

15:10-16:00 Oral Presentation 11

Basic/Translational

Chair(s) Seong-Joon Koh (Seoul National University, Korea)
Jun Hwan Yoo (CHA University, Korea)

15:10-15:18

OP11-1

Endothelial PIEZO1 Activates the HIF1A-Driven Lactate Shuttle That Reprograms Macrophage Transmigration and Polarization in IBD

Chang Liang (West China Hospital of Sichuan University, China)

15:18-15:26

OP11-2



Granzyme K CD8+ T Cells with Tissue-Resident Features Promote Intestinal Inflammation in Patients with Crohn's Disease

Yoonho Lee (Brain Korea 21 project, Asan Medical Center, University of Ulsan College of Medicine, Korea)

15:26-15:34

OP11-3



Anti-IL-12/23p40 Is Associated with Superior Anti-Fibrotic Effects Compared with Anti-TNF and Anti-alpha4beta7

Han Na Kim (Kyungpook National University, Korea)

15:34-15:42

OP11-4



Neutrophil-Secreted Grancalcin Reprograms Mesenchymal Stem Cell Fate via HSPA5 to Drive Pathologic Creeping Fat in Crohn's Disease

Fengfei Wu (Nanfang Hospital, Southern Medical University, China)

15:42-15:50

OP11-5



Suppression of CPT1A-mediated Fatty Acid β -Oxidation Promotes Fibroblast Activation and Intestinal Fibrosis in Crohn's Disease

Zhiyin Feng (The First Affiliated Hospital of Sun Yat-Sen University, China)

15:50-16:00

Discussion

15:10-16:00 Oral Presentation 12

Small Bowel Disease

Chair(s) Jose D. Sollano (University of Santo Tomas, Philippines)
Seong Ran Jeon (Soonchunhyang University, Korea)

- 15:10-15:18
OP12-1 **Synergistic Effects of Partial Enteral Nutrition Combined with Ustekinumab in Induction and Maintenance Therapy for Crohn's Disease: Real-World Experience from a Multicentre Cohort**



Yuan Zeng (The Sixth Affiliated Hospital, Sun Yat-sen University, China)

- 15:18-15:26
OP12-2 **Aligning Patient and Planetary Health: Planetary Health Diet Adherence and Inflammatory Bowel Disease Prognosis Across Western and Eastern Cohorts**



Haiting Shu (The Third Xiangya Hospital of Central South University, China)

- 15:26-15:34
OP12-3 **Barriers and Facilitators to Crohn's Disease Exclusion Diet Adoption in Malaysian Adults with Crohn's Disease**



Nazihah Wafi (University of Malaya, Malaysia)

- 15:34-15:42
OP12-4 **Small Bowel Rebleeding After Capsule Endoscopy: Effects of Device-Assisted Enteroscopy on Small Bowel Rebleeding Probability, Risk Factors, and Mortality in a Nationwide Big Data Cohort**



Joo Hye Song (Konkuk University Medical Center, Korea)

- 15:42-15:50
OP12-5 **Life-Course Psychosocial Stress and Incident Irritable Bowel Syndrome**



Jianhui Zhao (Massachusetts General Hospital and Harvard Medical School, Zhejiang University, United States)

- 15:50-16:00 **Discussion**

Exhibition (1F)

15:50-16:20 Meet the Expert 1  **Advancing IBD Care with Subcutaneous Infliximab**

15:50-16:20 Advancing IBD Care with Subcutaneous Infliximab
ME1-1 Rupert Leong (University of Sydney, Australia)

Exhibition (3F)

15:50-16:20 Meet the Expert 2  **Emerging Treatment in Crohn's Disease with Fistula**

15:50-16:20 Clinical Efficacy and Real World Experience with
ME2-1 Guselkumab in CD with Fistula
Vipul Jairath (Western University, Canada)

Lobby (1,3F), Exhibition Hall (2F)

16:00-16:20 Coffee Break

Poster Exhibition Area 1 (GBR 105, 1F)
Poster Exhibition Area 2 (201-203, 2F)

16:00-16:20 Poster Viewing

Room A

Clinical Symposium 5 (Pregnancy & Obesity)	
16:20-17:50	Global IBD Perspectives: Pregnancy and Obesity across East and West
Chair(s)	You Sun Kim (Hallym University, Korea) Joana Torres (University of Lisbon, Portugal)
16:20-16:40 CS5-1	Pregnancy in IBD: Essential Knowledge for Clinicians and Patients Joana Torres (University of Lisbon, Portugal)
16:40-17:00 CS5-2	IBD and Pregnancy in East Asia: Regional Insights and Clinical Experience Eun Mi Song (Ewha Womans University, Korea)
17:00-17:20 CS5-3	Epidemiology and Pathophysiology of Obesity and IBD: Asian Perspectives Jaeyoung Chun (Yonsei University, Korea)
17:20-17:40 CS5-4	Optimizing Medical Therapy in IBD Patients with Obesity Siddharth Singh (Mayo Clinic Arizona, USA)
17:40-17:50	Discussion

Room B

Clinical Symposium 6 (Small Bowel & Nutrition)	
16:20-17:50	Current Perspective on Diet and Nutrition in IBD
Chair(s)	Dong Kyung Chang (Sungkyunkwan University, Korea) Tadakazu Hisamatsu (Kyorin University, Japan)
16:20-16:40 CS6-1	Dietary and Environmental Risk Factors in IBD: Theory and Practice Rupa Banerjee (AIG Hospitals, India)
16:40-17:00 CS6-2	Impact of Diet and Urban Environment in Crohn's Disease: Diet-omics Cohort Study Rui Feng (Sun Yat-Sen University, China)

- 17:00-17:20 **Tools and Challenges of Dietary Assessment in IBD and Colorectal Diseases: Lessons From Clinical Experiences**
 CS6-3 Yun Jeong Lim (Dongguk university, Korea)
- 17:20-17:40 **Recent Advances in Enteral Nutrition for IBD: Beyond The Walls**
 CS6-4 Robert V Bryant (The Queen Elizabeth Hospital, Australia)
- 17:40-17:50 **Discussion**

Room C

- 16:20-17:50 KASID-GEST Joint Symposium**
 Current Status and Future Perspectives in Intestinal Diseases
- Chair(s)** Deng-Chyang Wu (Kaohsiung University, Taiwan)
 Jeong-Sik Byeon (University of Ulsan, Korea)
- 16:20-16:40 **Current Status and Treatment Trends of IBD in Taiwan**
 GEST-1 Tzung-Jiun Tsai (Kaohsiung Veterans General Hospital, Taiwan)
- 16:40-17:00 **Current Status and Treatment Trends of IBD in Korea**
 GEST-2 Joo Hye Song (Konkuk University, Korea)
- 17:00-17:20 **Current Status and Treatment Trends of Colorectal Cancer in Taiwan**
 GEST-3 Li-Chun Chang (National Taiwan University, Taiwan)
- 17:20-17:40 **Current Status and Treatment Trends of Colorectal Neoplasms in Korea**
 GEST-4 Seong-Jung Kim (Chosun University, Korea)
- 17:40-17:50 **Discussion**

Room D

16:20-17:50	Clinical Symposium 7 (AOCC for Pediatricians) Bridging Evidence and Practice in Pediatric IBD
Chair(s)	Eytan Wine (The Hospital for Sick Children, Canada) Kyung Mo Kim (University of Ulsan, Korea)
16:20-16:40 CS7-1	Early-Onset Pediatric IBD: From Immune Pathways to Clinical Application Takashi Ishige (Gunma University, Japan)
16:40-17:00 CS7-2	Pediatric Ulcerative Colitis: Key Updates from the Latest ECCO-ESPGHAN Guidelines Eytan Wine (The Hospital for Sick Children, Canada)
17:00-17:20 CS7-3	Real-World Practice of Nutritional Therapy in Pediatric Crohn's Disease Hyeji Lim (Yonsei University, Korea)
17:20-17:40 CS7-4	Practical Precision Medicine in Pediatric IBD: Advanced Therapies in Real-World Settings Mi Jin Kim (Sungkyunkwan University, Korea)
17:40-17:50	Discussion

Room A

17:50-18:10 Booth Stamp Event - Lucky Draw

18:30-20:00 **Presidential Dinner** *Invited Person Only

Day 3 - June 27 (Sat.), 2026

Room B

07:30-08:00 Breakfast with Master 6 
A Deep Dive into Shingles Prevention for IBD Patients

Chair(s) Chang Hwan Choi (Chung-Ang University, Korea)

07:30-08:00 A Deep Dive into Shingles Prevention for IBD Patients
BM6-1 Soo Jung Park (Yonsei University, Korea)

Room C

07:30-08:00 Breakfast with Master 7  
Advancing the Standard of Care in Ulcerative Colitis:
Safety-Driven and Patient-Centered Strategies

Chair(s) Tae Oh Kim (Inje University, Korea)

**07:30-08:00 Optimizing UC Management with Tofacitinib (Xeljanz):
Updated Safety Data and Practical Vaccine Checklist for
IBD Patients**
BM7-1 Yu Kyung Jun (Seoul National University, Korea)

Room D

07:30-08:00 Breakfast with Master 8 
Beyond Similarity: Decision Pathways in IBD Biosimilars

Chair(s) Kyu Chan Huh (Konyang University, Korea)

**07:30-08:00 The Role of Biosimilars in IBD : Guideline and Decision
Insights**
BM8-1 Shin Ju Oh (Kyung Hee University, Korea)

Room E

07:30-08:00	Breakfast with Master 9  PharmBio Korea Inc. Shifting Paradigms in Bowel Preparation: From Volume to Value
Chair(s)	Seunja Park (Kosin University, Korea)

07:30-08:00	Differential Clinical Conveniences of OST; Orafang, The First Mover
BM9-1	Eun Ran Kim (Sungkyunkwan University, Korea)

Room D

08:00-08:30	GO IMKASID Wrap up Session
-------------	-----------------------------------

Room A

08:30-10:00	IBD Guidelines Toward AOCC/KASID IBD Guidelines 2026
Chair(s)	Byong Duk Ye (University of Ulsan, Korea) Kiichiro Tsuchiya (University of Tsukuba, Japan) Minhu Chen (Sun Yat-sen University, China)

08:30-08:50	AOCC Guidelines for the Diagnosis of IBD IBDGL-1
	Jun Shen (Shanghai Jiao Tong University, China)

08:50-09:10	AOCC Guidelines for the Treatment of UC IBDGL-2
	Dong Hyun Kim (Chonnam National University, Korea)

09:10-09:30	AOCC Guideline for the Treatment of Crohn's Disease IBDGL-3
	Shintaro Akiyama (University of Tsukuba, Japan)

09:30-09:50	Shaping the Future of the KASID Guidelines IBDGL-4
	Won Moon (Kosin University, Korea)

09:50-10:00	Discussion
-------------	-------------------

08:30-10:00	Clinical Symposium 8 (AOCC for Surgeons) All about Surgical Management of IBD
Chair(s)	Hiroshi Nakase (Sapporo Medical University, Japan) Jae Kyun Ju (Chonnam National University, Korea)
08:30-08:50 CS8-1	Optimal Timing and Perioperative Care for IBD Surgery Gyoung Tae Noh (Ewha Womans University, Korea)
08:50-09:10 CS8-2	Surgical Techniques and Tips for Bowel Anastomosis in IBD Jong Lyul Lee (University of Ulsan, Korea)
09:10-09:30 CS8-3	Overcoming Postoperative Complications after IBD Surgery Sohyun Kim (Yeungnam University, Korea)
09:30-09:50 CS8-4	Surgery for IBD-Associated Cancer/Dysplasia Motoi Uchino (Hyogo Medical University, Japan)
09:50-10:00	Discussion

Clinical Symposium 9 (Colorectal Neoplasm)

08:30-10:00 Optimizing Treatment Decision Pathways for Early-Stage Colorectal Cancer

Chair(s) Tae Il Kim (Yonsei University, Korea)
Yutaka Saito (National Cancer Center, Japan)

08:30-08:50 **AI-Assisted Decision-Making in Early-Stage Colorectal Cancer: Current Applications and Future Directions**

CS9-1

Jonathan W. J. Lee (National University Hospital, Singapore)

08:50-09:10 **Optimizing Endoscopic Treatment for T1 Colorectal Cancer: How Far Can We Go?**

CS9-2

Yunho Jung (Soonchunhyang University, Korea)

09:10-09:30 **Expanding the Role of Endoscopic Treatment in T2 Colorectal Cancer: Opportunities and Limitations**

CS9-3

Katsuro Ichimasa (Showa Medical University, Japan)

09:30-09:50 **Selecting Surgery after Non-Curative ESD: Optimal Timing and Criteria**

CS9-4

Dae-hee Pyo (The Catholic University of Korea, Korea)

09:50-10:00 **Discussion**

Lobby (1,3F), Exhibition Hall (2F)

10:00-10:20 **Coffee Break**

Poster Exhibition Area 1 (GBR 105, 1F)

Poster Exhibition Area 2 (201-203, 2F)

10:00-10:20 **Coffee Break & Poster Viewing**

Room A

Clinical Symposium 10 (IBD Masters)

10:20-11:50 Future Directions in IBD: From Global Trends to Personalized Care

Chair(s) Sung-Ae Jung (Ewha Womans University, Korea)
David T. Rubin (University of Chicago, USA)

IBD Goes Global: Western Perspectives on the Rising Burden in Asia

10:20-10:50
CS10-1

Gilaad G. Kaplan (University of Calgary, Canada)

Emerging Therapeutics in IBD: Which Are the Most Promising?

10:50-11:20
CS10-2

Jae Hee Cheon (Yonsei University, Korea)

IBD Tomorrow: From Prediction to Prevention

11:20-11:50
CS10-3

David T. Rubin (University of Chicago, USA)

Room B

Clinical Symposium 11 (Strictures and Perianal Fistulas in CD)

10:20-11:50 Clinical Challenges in CD: Strictures and Perianal Fistulas

Chair(s) Choon Jin Ooi (Duke-NUS Medical School, Singapore)
Joo Sung Kim (Seoul National University, Korea)

Defining and Monitoring Small Bowel Strictures in Crohn's Disease

10:20-10:40
CS11-1

Kerri Novak (University of Calgary, Canada)

Opening the Way: Advanced Endoscopic Interventions for Crohn's Strictures

10:40-11:00
CS11-2

Hironori Yamamoto (Jichi Medical University, Japan)

Optimizing Medical Management for Perianal Fistulas

11:00-11:20
CS11-3

Siddharth Singh (Mayo Clinic Arizona, USA)

Surgical Therapies for Complex Perianal Fistula: A Surgeon's Perspective

11:20-11:40
CS11-4

Ki-Yun Lim (Seoul Songdo Hospital, Korea)

11:40-11:50 **Discussion**

Room C

Kor AOCC for Nurses and Dietitians

10:20-11:50 Empowering IBD Care Teams: The Evolving Roles of Nurses and Dietitians

Chair(s) Chang Soo Eun (Hanyang University, Korea)
Young Sook Park (Eulji University, Korea)

10:20-10:40 **Nutritional Management for IBD Patients**

K-NUR-1 Jihye Park (Yonsei University, Korea)

10:40-11:00 **Vaccination in IBD: Key Updates for Nursing Practice**

K-NUR-2 Yehyun Park (Ewha Womans University, Korea)

11:00-11:20 **IBD Nursing in Education and Psychological Support: Practical Approaches and Lessons from Experience**

K-NUR-3 Shin Ae Lee (Yonsei University, Korea)

Panel Discussion: IBD Nursing Today and Strategies for Sustainable Networking

11:20-11:50 Hyun-hee Choi (Chonnam National University, Korea)
Junghwa Lee (Kyung Hee University, Korea)

Room B

Luncheon Symposium 6

11:50-12:30 Redefining Treatment Targets in IBD: From Disease Clearance to Transmural Healing

Chair(s) Siddharth Singh (Mayo Clinic Arizona, USA)
Byung Ik Jang (Yeungnam University, Korea)

11:50-12:10 **Redefining UC Treatment Goals: Disease Clearance Insights from VERDICT**

LS6-1 Vipul Jairath (Western University, Canada)

12:10-12:30 **Transmural Healing as a Treatment Target in CD: Vedolizumab insights from VECTORS**

LS6-2 Jun Lee (Chosun University, Korea)

Room C

11:50-12:30 Luncheon Symposium 7  DAEWOONG
Improving Bowel Preparation: From Better Results to Greater Convenience


Chair(s) Chao-Hung Kuo (Kaohsiung University, Taiwan)
Dong Il Park (Sungkyunkwan University, Korea)

11:50-12:10
LS7-1 Efficacy and Safety of DWJ1609 (CLEANCOL): A New 20-Tablet Oral Sulfate Solution for Bowel Preparation
Sung Hoon Jung (The Catholic University of Korea, Korea)

12:10-12:30
LS7-2 Clinical Benefits of DWJ1609 (CLEANCOL): Enhancing Patient Compliance with Reduced Pill Burden
Subum Park (Pusan National University, Korea)

Room A

12:30-13:00 Closing Ceremony
*Lucky Draw



AOCC 2026

IMKASID 2026

Poster Exhibition

- Printed Poster
- e-Poster

Poster Exhibition



Best Poster Award



Academic Grant

Printed Poster

IBD: Basic / Translational / Microbiome

P1-001



Enrichment of *Segatella copri* and Upregulated Lipopolysaccharide Biosynthesis Predict Primary Non-Response to Biologic Therapy in Inflammatory Bowel Disease

Ji Eun Kim (Center for Crohn's and Colitis, Kyung Hee University Hospital, Kyung Hee University College of Medicine, Korea)

P1-003

TRIM27 Inhibits Intestinal Inflammation in Ulcerative Colitis by the USP7/TRIM27-IKK Double Negative-Feedback

Weimin Xu (Xinhua Hospital, Shanghai Jiaotong University School of Medicine, China)

P1-004

Decanoic Acid Acts as a Mincle Antagonist to Restrain Intestinal Inflammation

Hanxiao Tu (Sir Run Run Shaw Hospital- College of Medicine Zhejiang University, China)

P1-006

Porphyromonas gingivalis Outer Membrane Vesicles Inhibit Intestinal Fibrosis in Crohn's Disease by Downregulating ADAMTS2

Jing Lei (The Second Affiliated Hospital of Chongqing Medical University, China)

P1-007

Predictive Value of Adiponectin for Early Response to Anti-TNF Therapy in Crohn's Disease and Its Relevance in TNBS-induced Colitis

Zhe Xiong (West China Hospital, Sichuan University, China)

P1-008

Impaired Efferocytosis Links Macrophage Dysfunction to Persistent Inflammation in Creeping Fat of Crohn's Disease

Weidong Huang (The First Affiliated Hospital, Sun Yat-sen University, China)

P1-009

RNF187 Recombinant Protein Alleviates Intestinal Inflammation and Improves Therapeutic Efficacy of Infliximab by Inhibiting IKK Complex Formation

Weimin Xu (Xinhua Hospital, Shanghai Jiaotong University School of Medicine, China)

- P1-011 Distinct Causal Roles of Sarcopenia and Obesity in Ulcerative Colitis and Crohn's Disease: A Two-Sample and Multivariable Mendelian Randomization Study**
Ayako Fuchigami (Nippon Koukan Hospital, Japan)
- P1-012 CJRB-201: A Non Immunosuppressive Faecalibacterium Based Therapeutic for IBD Driven by Treg Induction and Metabolite Mediated Barrier Restoration**
Seungwon Lee (CJ Bioscience, Korea)
- P1-013 3D ENS Phenotyping Reveals Distinct NeuroMicrobial Interaction Patterns in IBS and IBD**
 Kee Young Chung (Seoul National University Hospital, Seoul National University College of Medicine, Korea)
- P1-014 Oral Administration of Low-Molecular-Weight Heparin Enhances Microbiota-Derived N-Acetyl-Glutamic Acid Level to Alleviate Chronic Colitis-Associated Intestinal Fibrosis Through the Nrf2 Pathway**
Hanxiao Feng (Nanfeng Hospital, Southern Medical University, China)
- P1-015 Localized Delivery of LGG-Derived p40 Rescues Treg Dysfunction in Immune Checkpoint Inhibitor-Related Colitis**
Jin Liu (Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Science, China)
- P1-016 Tertiary Lymphoid Structures in the Rectum: Key Promoters of Early Ulcerative Colitis**
Yu Zhang (Peking University People's Hospital, Peking University People's Hospital, China)
- P1-017 Exome-Wide Association Study Reveals Novel Genetic Risk Loci for Inflammatory Bowel Disease**
Jie Chen (The Third Xiangya Hospital of Central South University, Central South University, China)
- P1-018 Quinolinic Acid Aggravates Colitis by Directly Targeting ULK1 to Impair Intestinal Epithelial Autophagy**
Wenhao Xia (Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, China)

- P1-020 Klebsiella pneumoniae Exacerbates Colitis Through Suppressing REG1B+ Progenitor Cell Differentiation in Aged Ulcerative Colitis**
Jing Lei (The Second Affiliated Hospital of Chongqing Medical University, China)
- P1-021 Low Molecular Weight Heparin Optimizes Fecal Microbiota Transplantation for Inflammatory Bowel Disease Treatment via Enrichment of Bacteroides thetaiotaomicron and Its Metabolite 7-Ketolithocholic Acid**
Yunying Gong (Nanfang Hospital, Southern Medical University, China)
- P1-023 Phytosphingosine Derived from Faecalibacterium prausnitzii-Derived Extracellular Vesicles Attenuates Ulcerative Colitis via Targeting of LRP6**
Linjie Li (Nanfang Hospital, China)
- P1-024 Acetyl-L-Carnitine Alleviates DSS-induced Colitis by Reprogramming Epithelial-Macrophage Crosstalk and Macrophage Polarization via LGALS9/CD44 and MIF Signaling**
Kai Lin (Capital Medical University Affiliated Beijing Friendship Hospital, China)
- P1-025 Gut Microbiome Signatures to Predict Treatment Response in Inflammatory Bowel Disease**
Kwang Woo Kim (Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul National University College of Medicine, Korea)
- P1-026 CXCL16 Deficiency Reshapes the Gut Microbiota and Attenuates DSS-induced Colitis in Mice**
Yuta Shimomori (Sapporo Medical University, Japan)
- P1-027 Gut Microbiota Derived Indole-3-Acetic Acid Ameliorates Intestinal Fibrosis in Inflammatory Bowel Disease via AHR Signaling**
Jiayi Tu (Shanghai East Hospital, Tongji University School of Medicine, China)
- P1-028 Paneth Cell Metaplasia Promotes Mucosal Healing via REG3A-Mediated Epithelial Regeneration in Ulcerative Colitis**
Tomohiro Muto (Institute of Science Tokyo, Japan)

- P1-029 MEFLIN-Positive Fibroblasts Suppress Intestinal Fibrosis and Provide a Therapeutic Target in Crohn's Disease**
Keiko Maeda (Nagoya University, Japan)
- P1-030 FcRn-dependent IgG Signaling Drives Epithelial Barrier Dysfunction in Inflammatory Bowel Disease**
Xin Hong (Nagoya University Graduate School of Medicine, China)
- P1-031 SPRED2 Promotes Intestinal Inflammation by Inducing Macrophage Senescence via Inhibiting the ABL1-FOXO1 Axis**
Hua Jinghan (Shanghai Tenth People's Hospital, China)
- P1-032 Colchicine for Mild-Moderate Ulcerative Colitis: Clinical Efficacy and Omics-Based Predictors of Response**
Hiroki Kurumi (Sapporo Medical University School of Medicine, Tottori University, Japan)
- P1-033 Ulcerative Colitis Is Associated with Distinct Colonic Mucosa-Associated Microbial Profiles in a North Indian Cohort**
Arpita Bhatt (Postgraduate Institute of Medical Education and Research (PGIMER), India)
- P1-035 Picolinic Acid Ameliorates Colitis-Associated Intestinal Fibrosis by Inhibiting Macrophage-to-Myofibroblast Transition via AHR Signaling Pathway**
Jian Zeng (Chongqing Hospital of Traditional Chinese Medicine, China)
- P1-036 CHI3L1 Promotes Macrophage Pyroptosis in Ulcerative Colitis via the BCAT1/NF- κ B Axis**
Jie Feng (The First Affiliated Hospital of Soochow University, China)
- P1-037 Association Between Disease Activity and Blood Brain Barrier-Related Biomarkers in Patients with Ulcerative Colitis: A Prospective Observational Study**
Akio Nakashima (Fukuoka University Chikushi Hospital, Japan)
- P1-038 Kushenol A Ameliorates Ulcerative Colitis-Related Anxiety-Like Behaviors via Regulating Gut Microbiota and Its Metabolites**
Chenchen Liu (Tianjin Medical University General Hospital, Jining NO.1 Peoples' Hospital, China)

- P1-039 Colonic Galactose-Deficient IgA Induces Complement Activation and Reflects Disease Activity in Ulcerative Colitis**
Tsungyu Tsai (China Medical University Hospital, China Medical University, National Health Research Institutes, Taiwan)
- P1-040 SIK3 Deficiency Exacerbates Murine Colitis by Promoting Th1/Th17 Differentiation**
Zi-Xuan Xu (Center for IBD Research and Department of Gastroenterology, China)
- P1-041 Detection and Identification of Microplastics in Patients with Ulcerative Colitis: Effects on Disease Phenotype, Activity and Duration**
 **Wei Si Soong** (Sunway University, Malaysia)
- P1-042 Circadian Clock Component PER2 Negatively Regulates Th1 Cell IFN- Production in Ulcerative Colitis**
Liang Chen (Shanghai Tenth People's Hospital, Tongji University, China)
- P1-043 Pentose Phosphate Pathway Activation in Fibroblasts Exacerbates Intestinal Fibrosis in Crohn's Disease**
Longyuan Zhou (The First Affiliated Hospital of Sun Yat-Sen University, China)

IBD: Pediatric

- P1-044 Longitudinal Trends in Obesity Prevalence Among Korean Pediatric Patients with Inflammatory Bowel Disease: A Five-Year Nationwide Multicenter Cohort Study**
 **Tae Hyeong Kim** (Kyung Hee University Hospital At Gangdong, Korea)
- P1-045 Prior Biologic Exposure Alters Infliximab Pharmacokinetics and Trough Targets in Pediatric Crohn's Disease**
Yiyoung Kwon (Samsung Medical Center, Korea)
- P1-046 Differential Pharmacokinetic, Pharmacodynamic, and Immunologic Associations of Infliximab Trough Levels in Pediatric Crohn's Disease**
Yiyoung Kwon (Samsung Medical Center, Korea)

P1-047 The Role of Histologic Remission as Disease Clearance: An Emerging Treat-to-Target in Pediatric Ulcerative Colitis

Yoon Zi Kim (Samsung Medical Center, Korea)

P1-048 Parental Autoimmune Diseases and Risk of Inflammatory Bowel Disease in Offspring: A Nationwide Case-Control Study in Taiwan

Chih Cheng Lin (Taichung Veterans General Hospital, Taiwan)

IBD: Surgery

P1-050 Early Metabolic Effects of Roux-en-Y Gastric Bypass Versus Restrictive Surgery in Obese Patients with Concomitant Inflammatory Bowel Disease and Type 2 Diabetes

Pardeep Kumar (Shakuntla Hospital and Research Center, India)

P1-051 Revisiting the Novel Standard Reporting of Endoanal Ultrasonography: Challenges and Features in Mapping Complex Fistula-in-Ano in Crohn's Diseases



Aini Fahriza Ibrahim (Universiti Malaysia Sarawak, Malaysia)

IBD: Others

P1-053 Serum Micro- and Nano-Plastic Burden as an Independent Risk Factor for Crohn's Disease Progression: A Prospective Clinical Multi-Omics Study

Lili Huang (The First Affiliated Hospital of Sun Yat-Sen University, China)

P1-054 Segment Specific Magnetic Resonance Enterography Analysis Reveals Differential Therapeutic Responses in the Colon Versus Small Bowel of Crohn's Disease Patients

Cien Fan (The First Affiliated Hospital, Sun Yat-sen University, China)

P1-055 Energy Expenditure in Ulcerative Colitis: Disease Activity Does Not Increase Metabolic Rate



Samantha Plush (The Queen Elizabeth Hospital, Adelaide University, Basil Hetzel Institute, Australia)

- P1-056 Early Body Composition Abnormalities in Patients with Newly Diagnosed Inflammatory Bowel Disease: KASID Multicenter Study**
Young Joo Yang (Hallym University College of Medicine, Korea)
- P1-057 Evaluating the Efficacy, Safety, and Tolerability of Mini Oral Sulfate Tablets for Bowel Preparation in Patients with Inflammatory Bowel Disease (Prospective, Randomized, Investigator-Blinded, Multicenter Noninferiority Trial)**
Kwangwoo Nam (Dankook University Hospital, Dankook University College of Medicine, Korea)
- P1-058 Effectiveness and Associated Factors of Endoscopic Balloon Dilation for Bowel Strictures in Crohn's Disease: A Single-Center Retrospective Study**
Yi-Ling Ko (Faculty of Medicine, Fukuoka University, Japan)
- P1-059 Treatment Experiences, Physician Communication, and Unmet Needs Among Patients with Inflammatory Bowel Disease in Korea**
Seulji Kim (Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, Korea)
- P1-060 Feasibility and Safety of Home Biologics Infusion for Inflammatory Bowel Disease: A Pilot Program in a Tertiary Hospital Setting in Singapore**
Shu Kuan Pang (National University Hospital, Singapore)

Colorectal Neoplasia: Clinical - Epidemiology, Diagnosis and Prevention

- P1-062 Nutritional and Metabolic Determinants of Colorectal Cancer Burden: Implications for Surgical Disease Across Socio-Demographic Contexts**
 Zavia Putri Salsabila (Universitas Islam Indonesia, Indonesia)
- P1-063 Efficacy and Procedural Safety of GLP-1 Receptor Agonists in Colorectal Polyp Surveillance: A Systematic Review and Meta-Analysis**
Rahul Falodia (All India Institute of Medical Sciences, Jodhpur, India)

Colorectal Neoplasia: Clinical - Treatment and Prognosis

- P1-064**  **Predicting Proximal Synchronous Lesions in Obstructive CRC: A Novel Model to Optimize Perioperative Colonoscopy and Stenting Strategies**
Minjee Kim (Samsung Medical Center, Korea)
- P1-065**  **Clinical Characteristics and Treatment Outcomes of Colorectal Cancer in Patients with Inflammatory Bowel Disease**
Kazuki Dai (Asahikawa Medical University, Japan)
- P1-066** **Clinical Significance of Haggitt Classification in Pedunculated T1 Colorectal Cancer: A Multicenter Study by the Honam Association for the Study of Intestinal Diseases (HASID)**
Seong Jung Kim (College of Medicine, Chosun University, Korea)
- P1-067** **Impact of Gross Morphology on Clinical Outcomes of Colorectal Endoscopic Submucosal Dissection**
Chae-June Lim (Chonnam National University Medical School, Korea)
- P1-068** **Prognostic Impact of TP53 Mutation in Intestinal Diffuse Large B-Cell Lymphoma: Endoscopic Features and Molecular Characteristics**
Ying Fang (Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, China)

Colorectal Neoplasia: Basic / Translational / Microbiome

- P1-069** **Desulfovibrio vulgaris Flagellin Induces Epithelial-Mesenchymal Transition of Colorectal Cancer Through LRRC19/TRAF6/TAK1 Pathway**
Yue Dong (Tianjin Medical University General Hospital, China)
- P1-070** **Fusobacterium nucleatum Regulates Nicotinamide Metabolism via the Upregulation of NNMT to Activate PARP1/MAPK Signalling in Colitis-Associated Cancer**
Peiyu Yang (Department of Gastroenterology, The Second Affiliated Hospital of Chongqing Medical University, China)

- P1-071 SN38 PLGA Nanoparticles Provide Sustained Antitumor Efficacy and Ameliorate Colitis Severity in a Murine Colitis-Associated Cancer Model**
Meng-Tzu Weng (National Taiwan University Hospital and College of Medicine, Taiwan)
- P1-072 Microbiome and Metabolome Signatures Associated with Adenoma Promotion in Patients with Non-Hereditary Multiple Colorectal Adenomas**
Hye Sun Lee (Ewha Womans University, Korea)
- P1-073 The Role of Rab Coupling Protein (RCP) in Metastasis and Infiltration of Colorectal Cancer: A Chungcheong Association for the Study of Intestinal Disease (CHASID) Multicenter Study**
Dae Sung Kim (Konyang University College of Medicine, Korea)
- P1-074 Identification and Analysis of Microplastics Accumulation in Peritumoral Intestinal Tissues and Mesenteric Adipose Tissue in Colorectal Cancer**
Fengfei Wu (Nanfang Hospital, Southern Medical University, China)

Small Bowel Disease / Nutritional / Functional Disorder

- P1-075 Impact of Oral Glutathione Supplementation on Gut Microbiota and Intestinal Homeostasis in Functional Constipation**
 Pardeep Kumar (Shakuntla Hospital and Research Center, India)
- P1-076 Therapeutic Efficacy and Mechanistic Insights of Repetitive Transcranial Magnetic Stimulation in Patients with Diarrhea Predominant Irritable Bowel Syndrome: A Prospective Randomized Trial**
Xiuji Kan (The First Affiliated Hospital of Soochow University, China)
- P1-077 Small Intestinal T-Cell Lymphoma Poses the Greatest Diagnostic Challenge: A Multicenter Study from China**
 Ying Fang (Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, China)
- P1-078 Complications and Associated Factors in Device-Assisted Enteroscopy: Analysis of the KASID Multicenter Web-Based Registry**
Kwangwoo Nam (Dankook University College of Medicine, Korea)

- P1-079 Development, Validation and Usability Assessment of AI-Nutricare: Digital Health Tool for Nutritional Assessment of Diverse Indian Diets**
Amit Chavan (All India Institute of Medical Sciences, New Delhi, India)

Artificial Intelligence

- P1-080 Explainable Machine Learning for Predicting One-Year Complication Risk in Crohn's Disease: A Multicentre Retrospective Study**
 Kun Xia (The National Key Clinical Specialty, Zhongshan Hospital of Xiamen University, School of Medicine, Xiamen University, China)
- P1-081 A Comparative Study of Large Language Model Assisted Versus Real-World Multi-Disciplinary Team on Diagnostic Accuracy of Ileocecal Ulcers**
Yuzhe Zhou (Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, China)
- P1-082 Evaluating the Effectiveness of Large Language Models in Patient Education for Management of Pregnancy in IBD**
Gengfeng Li (The Second Affiliated Hospital, Zhejiang University School of Medicine, China)

Others

- P1-083 Gut Microbiome Remodeling and Clinical Improvement After Fecal Microbiota Transplantation in Autism Spectrum Disorder**
Jongbeom Shin (Inha University Hospital, Inha University School of Medicine, Korea)
- P1-084 Efficacy and Safety of Oral Sulfate Tablets Compared with 2-Liter Polyethylene Glycol Plus Ascorbic Acid According to Renal Function: A Retrospective Multicenter Study**
Min-Jae Kim (Yonsei University College of Medicine, Korea)
- P1-085 Efficacy of Freeze-Dried Bowel Cleansing Content in a Clostridioides difficile Infection Mouse**
Hongsub Lee (Busan Paik Hospital, Inje University College of Medicine, Hbiome Corp, Korea)

- P1-086 Intestinal Ultrasound Predicts Outcomes in Hospitalized Patients with Clostridioides difficile-Associated Diarrhea**
Hsin-Yun Wu (National Taiwan University, National Taiwan University Hospital Jinshan Branch, Taiwan)
- P1-087 Efficacy and Safety of GNS-212-E vs PEG + Ascorbate for Colonoscopy Bowel Preparation: A Phase III Randomized Trial**
Sihyun Kim (Seoul National University College of Medicine, Korea)
- P1-089 Compartment-Specific Skeletal Deficits in Chinese Patients with Inflammatory Bowel Disease Assessed by High-Resolution Peripheral Quantitative Computed Tomography (HR-pQCT)**
Ziyi Chen (Department of Gastroenterology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, China)

IBD: Clinical - Epidemiology

- P2-001 Pregnancy Outcomes in IBD: A Large-Scale Nationwide Analysis of 266,066 Women**
Subin Ann (Korea University College of Medicine, Korea)
- P2-002 Life-Course Body Size Trajectories from Birth to Adulthood and Risk of Incident Inflammatory Bowel Disease: A Prospective Cohort Study**
Bowen Tian (Peking Union Medical College Hospital, China)
- P2-003 Global Landscape of Extraintestinal Manifestations in Inflammatory Bowel Disease Across Five Transcontinental Cohorts: Phenotypic Clustering and Prognostic Implications**
Lintao Dan (Ruijin Hospital, China)
- P2-004 A Population-Based Study on the Incidence of Active Tuberculosis Following Inflammatory Bowel Disease Treatment in Taiwan**
Chi-Hsiang Chen (China Medical University Hospital, Taiwan)
- P2-005 Psychiatric Burden and Time-to-Diagnosis Patterns in Pediatric Inflammatory Bowel Disease: A 10-Year Nationwide Longitudinal Study**
Sung Hoon Jung (The Catholic University of Korea, Eunpyeong St. Mary's Hospital, Korea)

P2-006 Risk of Major Depressive Disorder Following Inflammatory Bowel Disease: A Nationwide Population-Based Cohort Study in Taiwan

Chen-Yu Wang (Department of Education, China Medical University Hospital, Taichung, Taiwan)

P2-007 Epidemiology, Disease Characteristics, and Evolving Treatment Patterns in Inflammatory Bowel Disease: Results from the First Nationwide Thai IBD Registry

Julajak Limsrivilai (Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand)

IBD: Clinical - Diagnosis and Monitoring

 P2-009 Evaluation of Polygenic Risk Scores as Biomarkers for Predicting the Development of Psoriasis and Rheumatoid Arthritis in Patients with Inflammatory Bowel Disease

Yoojoong Jung (Seoul National University College of Medicine, Korea)

P2-010 Anti-Integrin alphaVbeta6 Antibody as a Predictive Biomarker of Long-Term Clinical Remission in Ulcerative Colitis

Noriaki Oguri (Kyorin University School of Medicine, Japan)

P2-011 Incremental Value of MR Elastography in Characterizing Complicated Phenotypes in Crohn's Disease

Yuyang Zhao (The First Affiliated Hospital, Sun Yat-Sen University, China)

P2-013 Magnetic Resonance Cell Size Imaging Predicts Disease Progression in Crohn's Disease Patients Receiving Biologic Therapy

Xiaodi Shen (The First Affiliated Hospital, Sun Yat-Sen University, China)

P2-014 The Biomechanical Landscape of Creeping Fat: MR Elastography-Derived Stiffness Correlates with Piezo1 Mechanotransduction in Crohn's Disease

Qingzhu Zheng (The first affiliated hospital of Sun Yat-Sen University, China)

- P2-016 SDC2 Methylation as an Early Epigenetic Biomarker for Colitis-Associated Neoplasia in Inflammatory Bowel Disease**
Woo Suji (Severance Hospital, Yonsei University College of Medicine, Korea)
- P2-017 Characterization of Glycolytic Metabolic Reprogramming by 31P-MRS for Assessing Intestinal Fibrosis in Crohn's Disease**
Weikai Zheng (The First Affiliated Hospital of Sun Yat-Sen University, China)
- P2-018 Impaired Post-Exercise Phosphocreatine Recovery on 31P-MRS Is Linked to Unfavorable Clinical Course in Crohn's Disease**
Luyao Wu (The First Affiliated Hospital, Sun Yat-Sen University, China)
- P2-019 Quantification of Visceral Adipose Tissue Volume Predicts Both Short-Term and Long-Term Transmural Healing in Patients with Crohn's Disease Receiving Ustekinumab**
Xiaomin Wu (The First affiliated hospital of Sun Yat-sen University, China)
-  **P2-020 Prostaglandin E-Major Urinary Metabolite Diagnoses Crohn's Disease Activity Better than C-Reactive Protein and Leucine-Rich 2 Glycoprotein: A Prospective Observational Study**
Toshiyuki Sakurai (The Jikei University School of Medicine, Japan)
- P2-021 Differentiating Intestinal Tuberculosis from Crohn's Disease Using a Model Utilizing Clinical, Endoscopic Findings, and IGRA: A Multinational Multicenter Study**
Julajak Limsrivilai (Faculty of Medicine Siriraj Hospital, Thailand)
- P2-022 Exploring the Construction of a Composite Prediction Model for Perianal Fistula in Crohn's Disease Using Multimodal Integration Based on Machine Learning Methods**
Mengjie Lu (Affiliated Hospital of Nanjing University of Chinese Medicine, China)
- P2-023 Psychological Distress Links to Magnetic Resonance Enterography Abnormalities in Crohn's Disease**
Yaoqi Ke (The First Affiliated Hospital of Sun Yat-Sen University, China)
- P2-024 Intestinal Ultrasound as a First-Line Screening Tool for Pediatric Crohn's Disease: Segment-Based Diagnostic Performance Against Ileoscopic Findings**
Eun Joo Lee (Severance Children's Hospital, Korea)

- P2-025 Real-Time Calprotectin for Real-World IBD: Clinical Validation of a Point-of Care, App Based Fecal Calprotectin Test**
 Kayal Vizhi Nagarajan (Aster CMI Hospital, Hebbal, India)
- P2-026 Prognostic Value of Post-Treatment Simplified MaRIA Score in Bio-Naive Crohn's Disease**
 Ami Kawamoto (Institute of Science Tokyo Hospital, Japan)
- P2-027 Clinical Significance of Weight Change for Disease Outcomes in Newly Diagnosed Crohn's Disease: A Retrospective Landmark Analysis**
 Hong Shin Cho (Asan Medical Center, University of Ulsan College of Medicine, Korea)
- P2-028 Clinical Utility of Anti-Integrin Alpha ν beta6 and Anti-GM-CSF Antibodies in Taiwanese Patients with Inflammatory Bowel Disease**
 Meng-Tzu Weng (National Taiwan University Hospital and College of Medicine, National Taiwan University Hospital, Hsin-Chu Branch, Taiwan)
- P2-029 Predictive Value of Systemic Inflammatory Markers for Clinical Relapse in Ulcerative Colitis with Endoscopic Remission Stratified by Histologic Activity**
 Minjee Kim (Samsung Medical Center, Korea)
- P2-030 Prospective Evaluation of the Nancy Index and Optimal Biopsy Strategies for Predicting Outcomes in Ulcerative Colitis Patients with Clinical Remission**
 Hsin-Yun Wu (National Taiwan University Hospital Jin-Shan Branch, National Taiwan University, Taiwan)
- P2-032 Clinical Characteristics of Patients with Ulcerative Colitis During Biologic Therapy and Analysis of Risk Factors for Concurrent *Clostridioides difficile* Infection**
 Ying Xie (Shengjing Hospital of China Medical University, China)
- P2-033 Development and Validation of a Predictive Model for Diagnosing Crohn's Disease Based on a Novel Endoscopic Sign**
 Qinyu Feng (Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, China)

- P2-034 Toward Precision Phenotyping in Crohn's Disease: A Retrospective Validation of the Florence Classification System**
Yushu Cao (Zhejiang University School of Medicine, Sir Run Run Shaw Hospital, China)
- P2-035 Association Between Crohn's Disease and Pulmonary Nodule Patterns: An Inverse Probability-Weighted Analysis of Real-World Data**
He Gu (Key Laboratory of Gastroenterology and Hepatology, Ministry of Health, Inflammatory Bowel Disease Research Center; Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai Institute of Digestive Disease, NHC Key Laboratory of Digestive Diseases, China)
- P2-036 Predictive Value of CALLY Index and Hematological Markers for Disease Activity in Ulcerative Colitis**
Sileng Hu (The First Hospital of Jilin University, China)
- P2-037 A Diagnostic Model Combining Fecal Calprotectin and Intestinal Ultrasound Outperforms Fecal Calprotectin Alone for Assessing Endoscopic Activity in Ulcerative Colitis**
Xiaoyan Tang (Peking Union Medical College University, China)
- P2-039 Linked Colour Imaging Beyond White-Light Endoscopy for Histological Activity in Ulcerative Colitis Patients in Clinical Remission**
Arshdeep Singh (Dayanand Medical College and Hospital, India)
- P2-040 Diagnostic Performance of LETIA-Measured Fecal Calprotectin and Intestinal Ultrasound for Assessing Endoscopic Activity in Ulcerative Colitis and Crohn's Disease**
Gechong Ruan (Peking Union Medical College Hospital, China)
- P2-041 U-PREDICT: A Web-Based Machine Learning Tool to Forecast One-Year Efficacy of Upadacitinib 30 mg Maintenance in Crohn's Disease**
Jing Han (The Sixth Affiliated Hospital, Sun Yat-Sen University, China)
- P2-042 ITGAV Gene Polymorphisms Determine Anti-v6 Autoantibody Levels in Ulcerative Colitis**
Satoshi Ono (Aichi Medical University Hospital, Japan)

IBD: Clinical - Treatment and Prognosis

- P2-044**  **Baseline Infliximab Trough Level Predicts Pharmacokinetic Outcomes After Switching from Intravenous to Subcutaneous Infliximab in Inflammatory Bowel Disease**
Jeong Hwa Lee (Asan Medical Center, University of Ulsan College of Medicine, Kyungpook National University Hospital, Kyungpook National University School of Medicine, Korea)
- P2-045** **Adverse Events in Patients with Inflammatory Bowel Disease Treated with Advanced Therapies: A Nationwide, Population-Based, Propensity-Matched Cohort Study**
Hyung Il Choi (Kyung Hee University Hospital at Gangdong, Kyung Hee University College of Medicine, Korea)
- P2-046** **IFI27 Drives Intestinal Fibrosis by Inducing Fibroblast Senescence and Orchestrating GZMK+ T Cell Crosstalk**
Qiwen Chen (The First Affiliated Hospital of Wenzhou Medical University, China)
- P2-047**  **Long-Term Outcomes of Early Versus Delayed Postoperative Advanced Therapy in Patients with High-Risk Crohn's Disease**
Byung Chul Jin (Jeonbuk National University, Korea)
- P2-049** **Ustekinumab Versus Upadacitinib After Anti-TNF Failure in Crohn's Disease: A Prospective Comparison of Early Efficacy and Long-Term Treatment Persistence**
Jiawei Zhan (The Sixth Affiliated Hospital, Sun Yat-sen University, China)
- P2-050** **Interpretable Model Integrating MR Enterography and Clinical Factors to Predict Early Transmural Response to Ustekinumab Therapy in Crohn's Disease**
Lili Huang (The First Affiliated Hospital of Sun Yat-Sen University, China)
- P2-051** **Mucosal Galliccatechin Depletion Promotes Th17-Driven Resistance to Mesalazine in Ulcerative Colitis**
Wu Lexi (Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, China)
- P2-052**  **HLA-Wide Association Analysis Identifies DQB1*05:01 as a Predictor of Ustekinumab Persistence in Inflammatory Bowel Disease**
Hiroshi Meguro (Tohoku University Hospital, Japan)

- P2-053**  **High Burden of Difficult-to-Treat Crohn's Disease in Asia: Results from the Hong Kong IBD Registry**
Joyce Wing Yan Mak (The Chinese University of Hong Kong, Hong Kong, China)
- P2-055** **Real-World Evidence of Upadacitinib in Difficult-to-Treat Crohn's Disease: A Multicenter Study from China**
Shuowen Zhang (Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, China)
- P2-056** **Symptomatic Remission and Health-Related Quality of Life with Afimkibart Treatment for Moderately to Severely Active Ulcerative Colitis in the Phase IIb TUSCANY-2 Trial**
Rupert W. Leong (Concord Hospital, Macquarie University Hospital, Australia)
- P2-057** **Long-Term Outcomes of Subcutaneous Versus Intravenous Infliximab in Inflammatory Bowel Disease: A 4-Year Follow-up of a Single-Center Prospective Cohort Study with Proactive Therapeutic Drug Monitoring**
Sung Noh Hong (Samsung Medical Center, Sungkyunkwan University School of Medicine, Korea)
- P2-058** **Natural History and Treatment Trajectories of Ulcerative Colitis Across Disease Activity States: A Retrospective Cohort Study in China**
Wenjing Yang (Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, China)
- P2-059** **Tofacitinib 20 mg Versus 30 mg Daily in Acute Severe Ulcerative Colitis: A Randomized, Double-Blind, Placebo-Controlled Trial**
Arshdeep Singh (Dayanand Medical College and Hospital, India)
- P2-060**  **Cumulative Local and Metachronous Recurrence Rates After Endoscopic Submucosal Dissection of Ulcerative Colitis-Associated Neoplasia**
Hyunho Seol (Asan Medical Center, University of Ulsan College of Medicine, Korea)
- P2-061** **Exclusive Enteral Nutrition and Anti-TNF Combination Therapy Are Superior to Monotherapy in Inducing Clinical Remission in Active Adult Crohn's Disease**
Liang Chen (Shanghai Tenth People's Hospital, Tongji University, China)

- P2-062 Comparative Efficacy of Anti-TNF Agents and Ustekinumab for Postoperative Recurrence in Crohn's Disease: 10 Years of Experience**
Zihan Chen (The First Affiliated Hospital, Sun Yat-sen University, China)
- P2-063 Oral Low-Dose Methotrexate Improves Infliximab Pharmacokinetics, Immunogenicity, and Endoscopic Outcomes in Crohn's Disease: A Propensity Score-Adjusted Real-World Study**
Fang Xiao (Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, China)
- P2-064 Development of a Mechanism-Informed Treatment Selection Model Based on Leucine-Rich Alpha-2 Glycoprotein and Newly Developed Intestinally Produced Pro-Haptoglobin in Ulcerative Colitis**
Takeo Yoshihara (The University of Osaka, Graduate School of Medicine, Japan)
- P2-065 Indirect Comparison of Afimkibart and Adalimumab Treatment Effects Using Data from TUSCANY-2 and HIBISCUS in Patients with Ulcerative Colitis**
Xiang Gao (The Sixth Affiliated Hospital-Sun Yat-sen University, China)
- P2-066 Long-Term Efficacy and Safety of Upadacitinib for Ulcerative Colitis in East Asia: Post Hoc Analysis of Data Through Week 144 of the Phase 3 U-ACTIVATE Study**
Xiang Gao (The Sixth Affiliated Hospital, Sun Yat-sen University, China)
- P2-067 Combination Induction with Upadacitinib and Vedolizumab for Ulcerative Colitis: A Randomized Controlled Trial**
Jiayin Yao (Sun Yat-sen University Sixth Affiliated Hospital, China)
- P2-068 Ozanimod in Korean Ulcerative Colitis: A Real-World Prospective Multicenter Study: A Honam Association for the Study of Intestinal Disease (HASID) Multicenter Study**
Byung Chul Jin (Research Institute of Clinical Medicine, Jeonbuk National University, Korea)
- P2-069 Long-Term Safety and Effectiveness of Intravenous Vedolizumab for the Treatment of Inflammatory Bowel Disease in South Korea: Final Analysis of a Post-Marketing Surveillance Study**
Sang-Bum Kang (Daejeon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Korea)

- P2-070 Interim Phase 1 Results for SPY003, a Novel Half-Life Extended Monoclonal Antibody Targeting IL-23, Suggest Potential for Q3M or Q6M Maintenance Dosing for Inflammatory Bowel Disease**
Deanna Nguyen (Spyre Therapeutics, United States)
- P2-071 Clinical Outcomes and Relapse Risk Following Mandatory One-Year Discontinuation of Advanced Therapy in Inflammatory Bowel Disease: A Single-Centre Taiwanese Cohort Study**
Chen-Shuan Chung (Far Eastern Memorial Hospital, Yuan Ze University, Taiwan)
- P2-072 Real-World Evaluation of Patient Preference and Adherence Following Oral 5-Aminosalicylate Switch in Ulcerative Colitis**
Yu Kyung Jun (Seoul National University Bundang Hospital, Seoul National University College of Medicine, Korea)
- P2-073 Mediterranean Dietary Approaches to Stop Hypertension Intervention for Neurodegenerative Delay (MIND) Diet Is Associated with Reduced Inflammatory Bowel Disease-Related Surgery Risk: A Prospective Cohort Study**
Lintao Dan (The Third Xiangya Hospital, Central South University, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, China)
- P2-074 Ulcerative Proctitis Is an Under-Treated Entity: Adherence to British Society of Gastroenterology Guidelines in the Management of Active Ulcerative Proctitis and Its Impact on Clinical Outcomes**
Athanasios Malkopoulos (Queensland Health, Australia)
- P2-075 Development of MRI-Based Predictive Models for Monoclonal Antibody Treatment Failure in Perianal Fistulizing Crohn's Disease**
Xiaona Yang (Chongqing General Hospital, Chongqing University, China)
- P2-076 Unveiling the Power of Ustekinumab: A Promising Therapy for Crohn's Disease Patients with Symptomatic Intestinal Strictures**
Jingwen Liu (The Second Affiliated Hospital, Zhejiang University School of Medicine, China)

- P2-077 ABTECT Trials: Odefazimod 8-Week Efficacy in Patients with Moderate-to-Severe Ulcerative Colitis with or Without Prior Inadequate Response to Advanced Therapy**
Tadakazu Hisamatsu (Kyorin University School of Medicine, Japan)
- P2-079 External Applicability of Surgery-Associated Factors in Crohn's Disease: A Preliminary Multicenter Retrospective Cohort Study**
Byung Chul Jin (Jeonbuk National University Medical School, Korea)
- P2-080 Treatment Patterns and Persistence of Biologics and Small Molecules in Moderate-to-Severe Ulcerative Colitis: A Nationwide Real-World Data from the Thai IBD Cohort**
 Panu Wetwittayakhleng (Faculty of Medicine, Prince of Songkla University, Thailand)
- P2-081 Partial Responders to Intravenous Corticosteroids at Day 3 Benefit from Continued Therapy in Acute Severe Ulcerative Colitis**
Arshdeep Singh (Dayanand Medical College and Hospital, India)
- P2-082 Efficacy of Vedolizumab in Early Crohn's Disease (EARLY CD): Impact of Perianal Disease Status**
Jing Liu (Sir Run Run Shaw Hospital- Zhejiang University School of Medicine, China)
- P2-083 Guselkumab for Perianal Fistulizing Crohn's Disease: Week 24 Results from the Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter FUZION Study**
Tadakazu Hisamatsu (Kyorin University, Japan)
- P2-084 Endoscopic Healing with Guselkumab in Moderate-to-Severe Crohn's Disease: Findings from GALAXI 2, GALAXI 3 and GRAVITI**
Ting Zhao (Johnson & Johnson, China)
- P2-085 Fecal Lipidomics Identifies Lactosylceramide as a Disease-Associated Glycosphingolipid with Diagnostic and Mechanistic Relevance in Crohn's Disease**
Wenhua Lai (The First Affiliated Hospital, Sun Yat-sen University, China)

- P2-087 Effectiveness, Safety, and Post-Discontinuation Outcomes of Carotegrast Methyl in Ulcerative Colitis: A Real-World Multicenter Retrospective Cohort Study**
Takeshi Ueda (Gastroenterology and Proctology, Japan)
- P2-088 Circular RNA circFNDC3B Modulates M2 Macrophage Activation and Intestinal Inflammation in Crohn's Disease**
Yulan Ye (Suzhou Municipal Hospital Affiliated to Nanjing Medical University, China)
- P2-089 SKYLINE-UC: The First Platform Study in Ulcerative Colitis Assessing Efficacy and Safety of Three Long-Acting Antibodies Administered as Single Agents and in Combinations**
Taku Kobayashi (Kitasato University, Japan)
- P2-091 Clinical Features of Hypersensitivity-Like Manifestations During JAK Inhibitor Therapy for Ulcerative Colitis in LTT-Positive Cases**
Keiji Yagisawa (Sapporo Higashi Tokushukai Hospital, Japan)
- P2-092 Comparable Efficacy of Upadacitinib in Isolated Small Bowel Versus Non-Small Bowel Crohn's Disease: A Retrospective Cohort Study**
Xie Shuyi (The Sixth Affiliated Hospital of Sun Yat-sen University, Key Laboratory of Colorectal and Pelvic Floor Disease, China)
- P2-093 Proximal Disease Extension and Associated Risk Factors in Patients with Distal Ulcerative Colitis**
 Haluk Tarik Kani (Marmara University School of Medicine, Türkiye)
- P2-094 Efficacy and Safety of Guselkumab for Ulcerative Colitis Through Week 140 of the QUASAR Long-Term Extension Study**
Tadakazu Hisamatsu (Kyorin University School of Medicine, Japan)
- P2-095 Safety of Thiopurine Withdrawal in Biologic-Naïve Patients with Inflammatory Bowel Disease in Remission: A Nationwide Retrospective Study**
 Alan Chuncharunee (Division of Gastroenterology and Hepatology, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand)

- P2-096 Effectiveness and Safety of Janus Kinase Inhibitor Based Advanced Combination Therapy in Refractory Inflammatory Bowel Disease: A Retrospective Cohort Study**
Arshia Bhardwaj (Dayanand Medical College and Hospital, India)
- P2-097 EARLY CD Study: Vedolizumab Improves Clinical Outcomes Regardless of Crohn's Disease Location**
Jing Liu (Sir Run Run Shaw Hospital- Zhejiang University School of Medicine, China)
- P2-098 Effectiveness and Safety of Advanced Combination Therapy in Patients with Inflammatory Bowel Diseases: A Real-World Study**
Athanasios Malkopoulos (Queensland Health, Griffith University, Australia)
- P2-099 Etrasimod for the Treatment of Ulcerative Colitis: A Post-Analysis of Cardiovascular Adverse Events of Special Interest from the Asian Phase 3 ENLIGHT UC Study**
Xiang Gao (The Sixth Affiliated Hospital of Sun Yat-sen University, China)
- P2-100 Clinical Outcomes After Discontinuation of Biologics in Crohn's Disease Patients Achieving Deep Remission: A Retrospective Cohort Study**
Takahiro Ito (Sapporo Higashi Tokushukai Hospital, Japan)
- P2-101 Pattern of Biologic Use in Crohn's Disease: A Nationwide Thai IBD Registry**
 Sirasith Samanthai (Siriraj Hospital, Thailand)
- P2-102 A Metabolic-Immune Axis of Androsterone Deficiency and CXCL11+ Macrophages Predicts Non-Response to Ustekinumab in Crohn's Disease**
Wu Lexi (Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, China)

IBD: Clinical - Intestinal Ultrasound

- P2-104 Transperineal Ultrasonography in Detecting Perianal Complications of Crohn's Disease: A Systematic Review and Meta-Analysis**
 Chong-Teik Lim (Singapore General Hospital, Singapore)

- P2-105**  **Intestinal Ultrasound Guided Management Has Substantial Cost-Savings and Reduction in Carbon Footprint over Magnetic Resonance Imaging and Colonoscopy-Based Management in an Inflammatory Bowel Disease Service**
Timothy Ford (Gold Coast University Hospital, Australia)
- P2-106**  **Real-World Validation of Intestinal Ultrasound Scores in Korean Patients with Ulcerative Colitis**
Min Kyu Kim (Asan Medical Center, University of Ulsan College of Medicine, Korea)
- P2-107** **Who Deserves the Probe: A Negative Point-of-Care Intestinal Ultrasound Predicts Sustained Remission in Clinical-Only IBD Relapse**
Chong-Teik Lim (Singapore General Hospital, Singapore)
- P2-108** **INSPIRE: INtestinal ultraSound Parameters for Identifying Steroid Non-Response in Patients with Acute severe Ulcerative Colitis**
Deloshaan Subhaharan (Gold Coast University Hospital, Bond University, Australia)
- P2-109**  **Under One Roof: Intestinal Ultrasound Combined Clinic for Pediatric and Adult Gastroenterology, a Transformative Model for Integrated IBD Care Across Lifespan**
Hasan Alaali (University of Malay Medical center, Salmaniya Medical Complex, Malaysia)
- P2-110**  **Intestinal Ultrasound Reveals Differential Associations of Serum Immunoglobulins in IBD**
Bo-Hung Lee (China Medical University Hospital, Taichung, Taiwan)

Poster Exhibition



Academic Grant

e-Poster

IBD: Clinical - Epidemiology

- EP-001 Sex-Specific Differences in Malignancy Risk Among Korean Patients with Inflammatory Bowel Disease: A Nationwide Population-Based Study**
Jeongkuk Seo (Chung-Ang University College of Medicine, Korea)
- EP-002 Impact of Metabolic Dysfunction-Associated Steatotic Liver Disease on Adverse Clinical Outcomes in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis**
Jong Yoon Lee (Dong-A University College of Medicine, Korea)
- EP-003 Impact of Environmental Risk Factors in Early Life on the Development of Inflammatory Bowel Disease**
Ha Won Im (Seoul National University Hospital, Korea)
- EP-005 Comparison of Clinical Characteristics and Outcomes Between Ileal and Colonic Crohn's Disease in Korea: Results from the Prospective CONNECT Study**
Jiyoung Yoon (Kangdong Sacred Heart Hospital, Hallym University College of Medicine, Korea)
- EP-006 Dietary Patterns and Nutritional Inadequacy in Patients with Inflammatory Bowel Disease in Remission: A Comparative Analysis of Crohn's Disease and Ulcerative Colitis**
Tianjiao Zhang (Division of Gastroenterology and Hepatology, National University Hospital, Singapore)
- EP-007 Prevalence and Risk Factors of Low Bone Mineral Density and Low Muscle Mass in Patients with Inflammatory Bowel Disease**
I-Lun Shih (National Taiwan University Hospital, Taiwan)
- EP-008 Avoidant/Restrictive Food Intake Disorder Risk Is Associated with Depressive Symptoms in Inflammatory Bowel Disease**
Natchaporn Noppacroh (The Chinese University of Hong Kong, Phramongkutklao hospital, Thailand)



- EP-009 Risk of Myocardial Infarction in Patients with Inflammatory Bowel Disease: A Nationwide Population-Based Cohort Study**
Gisok Kang (Yonsei University Wonju College of Medicine, Korea)
- EP-011 The Perception of Diet Pattern and Therapy Among Patients with Inflammatory Bowel Disease in China: A Cross-Sectional Survey**
Ni Ding (The Sixth Affiliated Hospital, Sun Yat-sen University, China)
- EP-012 Higher Prevalence and Psychosocial Burden of IBS in IBD Patients: A Rome IV-Based Comparative Analysis**
Dong Woo Kim (Busan Paik Hospital, Inje University College of Medicine, Korea)
- EP-013 Epidemiological Study of Colitis-Associated Colorectal Cancer in Patient with Inflammatory Bowel Disease: A Single Institute Experience in Taiwan**
Jen-Wei Chou (China Medical University Hospital, China Medical University, Taiwan Association for the Study of Intestinal Diseases (TASID), Taiwan)
- EP-014 Determinants of Anxiety Toward Self-Injection Therapy in Patients with Inflammatory Bowel Disease**
Kento Imamura (Tohoku University Hospital, Japan)
- EP-015 Risk of Cerebral Infarction in Patients with Inflammatory Bowel Disease: A Nationwide Population-Based Cohort Study**
Hee Chan Moon (Yonsei University Wonju College of Medicine, Korea)
- EP-016 Psychological Morbidity in Asian IBD: Prevalence, Clinical Impact and Integration of Routine Psychosocial Screening**
Jonathan Tian En Koh (Tan Tock Seng Hospital, Singapore)
-  **EP-017 Antibiotic Marketplace Density and Ultra-Processed Food Exposure Are Linked to Younger-Age Inflammatory Bowel Disease Presentation Across Rapidly Urbanizing Corridors in Asia and Other Newly Industrialized Areas**
Irish Merlyn Alvarez (National University of Dasmarinas, Philippines)
- EP-019 Characterization of the Global Spatiotemporal Co-Burden and Geographic Inequality of Inflammatory Bowel Disease and Depressive Disorders, from 1990-2021: An Analysis of GBD 2021 Database**
Jingzheng Jin (General Hospital of Tianjin Medical University, China)

- EP-022 Cross-Cultural Adaptation and Clinical Psychometric Evaluation of the Chinese Version of the IBD-Control Questionnaire in Chinese Patients with Inflammatory Bowel Disease**
Zhenzhen Zhai (Qilu Hospital of Shandong University Dezhou Hospital, China)
- EP-024 Association Between ABO Blood Type and Clinical Characteristics in Inflammatory Bowel Disease in Taiwan**
Chien-Yun Hou (China Medical University Hospital, Taiwan)
- EP-029 Low Serum Uric Acid Levels Are Associated with Low Bone Mineral Density in Male Patients with Ulcerative Colitis**
Dongwoo Kim (Korea University College of Medicine, Korea)
- EP-030 Determinants of Vitamin D Deficiency and Supplementation Patterns in Patients with Inflammatory Bowel Disease**
Dongkyung Shin (St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Korea)
- EP-031 Inflammatory Bowel Disease (IBD) in an Emerging Gastroenterology Service Centre in Malaysia: Younger Age with Increased Severity**
Nabilah Izham (Gastroenterology and Hepatology Service Centre, Hospital Al-Sultan Abdullah, Universiti Teknologi MARA, Selangor, Malaysia, Malaysia)
- EP-035 Age and Sex Distribution of Inflammatory Bowel Disease Patients in Seoul Hospital of Mongolia**
Munkhzul Bolooj (Mongolia, Mongolia)

IBD: Clinical - Diagnosis and Monitoring

- EP-036 Atypical Distribution Independently Influences Fecal Calprotectin Levels in Ulcerative Colitis: Beyond Endoscopic Severity and Disease Extent**
Jae Eun So (Yonsei University College of Medicine, Severance Hospital, Korea)
- EP-037 The Risk Factor of Gastrointestinal Involvement in Patient with Behçet's Disease**
Jin Hwa Park (University of Hanyang College of Medicine, Korea)

- EP-038 Lack of Association Between Vitamin D Status and Bone Mineral Density in Patients with Inflammatory Bowel Disease**
Seong Jun Kim (St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Korea)
- EP-039 Predictive Value of Anti-Integrin alpha V beta 6 Antibody Titers for Therapeutic Escalation in Patients with Endoscopically Active Ulcerative Colitis**
Rika Shimizu (Kyoto University Hospital, Japan)
- EP-040 Diagnostic Accuracy of Blood Biomarkers for Predicting Small Bowel Mucosal Remission and Correlation with Endoscopic Activity in Crohn's Disease**
Yoshihiro Akita (The Jikei University School of Medicine, Japan)
- EP-041 Serum Amyloid a as a High-Resolution Indicator of Mucosal Healing in Ulcerative Colitis.**
Kotaro Akita (Sapporo Medical University School of Medicine, Japan)
- EP-042 Clinical Progression and Predictors of Significant Disease in Terminal Ileitis: A 20-Year Retrospective Cohort Study**
Panupong Luangsirithanya (Division of Gastroenterology, Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand)
- EP-044 Discordant Patterns of Lumbar Spine and Hip Bone Mineral Density in Patients with Inflammatory Bowel Disease**
Ji Min Lee (St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Korea)
- EP-045 Optimizing Fecal Calprotectin Thresholds for Endoscopic Activity in Ulcerative Colitis**
Ji Eun Kim (Samsung Medical Center, Korea)
- EP-046 Therapeutic Drug Monitoring of Upadacitinib in Inflammatory Bowel Disease: A Prospective Real-World Study**
Meng-Tzu Weng (National Taiwan University Hospital and College of Medicine, Taiwan)
- EP-047 A Multicenter Observational Study on Extraintestinal Malignancies Complicating Inflammatory Bowel Disease**
Ryunosuke Hayashi (Asahikawa Medical University, Japan)

- EP-048 Computed Tomography Enterography-Based Lemann Density Index as an Independent Predictor of Surgical Resection in Crohn's Disease: A Firth's Penalized Regression Analysis**
Linwei Wang (Zhongshan Hospital of Xiamen University, China)
- EP-049 Fecal Lipocalin-2 Complements Calprotectin in Detecting Residual and Low-Grade Inflammation in Inflammatory Bowel Disease**
Qing Li (The Sixth Affiliated Hospital, Sun Yat-sen University, China)
- EP-051 Efficacy of Balloon Assisted Enteroscopy Using an Ultrathin Endoscope for Intestinal Stricture**
Yusuke Onoyama (Kyoto University, Japan)
- EP-053 Intestinal Behçet's Disease as a Distinct Phenotype of Behçet's Disease**
Su Bum Park (Pusan National University Yangsan Hospital, Korea)
- EP-054 Longitudinal Cholesterol Patterns and the Risk of Relapse in Ulcerative Colitis**
Ji-Yeon Kim (Samsung Medical Center, Sungkyunkwan University School of Medicine, Korea)
- EP-055 Predictors of Steroid Resistance in Ulcerative Colitis: Added Value of the CRP/Albumin Ratio in a Vietnamese Cohort**
 Tien Hk (CK Clinic, Vietnam)
- EP-056 Comparative Analysis of Five Nutritional Tools and Construction of a Combined Nutrition-Inflammation Model for Assessing Disease Activity in Inflammatory Bowel Disease**
Tong Li (First Affiliated Hospital of Dalian Medical University, China)
- EP-057 Discrepancy Between MR Enterography and Endoscopy in Assessing Inflammation During Follow-up of Pediatric Crohn's Disease**
Hyeji Lim (Division of Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Severance Hospital, Yonsei University college of Medicine, Seoul, Korea, Korea)
- EP-058 Retrospective Analysis of Non-Caseating Granuloma Detection Rate in 1682 Biopsy Sites from 380 Patients with Crohn's Disease**
Wenwen Lu (People's Hospital of Suzhou New District, China)

- EP-059 Predictive Factors for 24-Week Therapeutic Response to Ustekinumab in Crohn's Disease**
Ye Zhao (First Affiliated Hospital of Zhengzhou University, China)
- EP-060 Baseline C-Reactive Protein as an Independent Predictor of Early Treatment Persistence with Upadacitinib in Ulcerative Colitis: A Real-World Study**
Kanako Ogasawara (Department of Gastroenterology, Japan)
- EP-061 ANA Seroconversion and Clinical Outcomes in Ulcerative Colitis Patients Initiating Advanced Therapies: A Prospective Multicenter Study**
Seung Yong Shin (Chung-Ang University College of Medicine, Korea)
- EP-063 A Predictive Model for Assessing Disease Activity in Inflammatory Bowel Disease: Integrating Serological Markers and Fecal Calprotectin**
Tong Li (First Affiliated Hospital of Dalian Medical University, China)
- EP-064 Prevalence, Types, and Quality of Life Impact of Anemia in Newly Diagnosed, Treatment-Naive Crohn's Disease Patients: A Cross-Sectional Study**
Kiran Josy Kanjamala (Lisie Hospital, India)
-  **EP-065 Results of Using Fecal Calprotectin in the Diagnosis of Inflammatory Bowel Disease**
Maral Boldbaatar (Mongolian National University of Medical Science, Mongolia)
- EP-066 Diagnostic Challenges of Crohn's Disease in a Tuberculosis-Endemic, Emerging Region: High Prevalence of Non-Specific and Malignancy-Mimicking Features**
Luan Minh Dang (University of Medicine and Pharmacy at Ho Chi Minh City, University Medical Center, Vietnam)
- EP-067 Burden and Risk Factors of Active Inflammatory Bowel Disease Among Patients in a Tertiary Care Setting**
Monirujjaman Biswas (National Institute of Respiratory Diseases, India)
- EP-068 Significance of Measuring Serum BDNF Concentration in Predicting Psychological Improvement in Patients with Refractory Ulcerative Colitis**
Kei Moriya (Nara Prefecture General Medical Center, Japan)

EP-069 The Relationship Between the Level of Calprotectin in Blood Serum and 1-Antitrypsin in Blood Serum in Patients with Inflammatory Bowel Diseases

Oleg Knyazev (Moscow Clinical Scientific Center named after A.S. Loginov, Russian Federation)

EP-070 Clinical Utility of Infliximab Therapeutic Drug Monitoring in Inflammatory Bowel Disease

Chih-Wen Huang (Changhua Christian Hospital, Taiwan)

EP-071 Whole Blood Transcriptomics-Based Screening of Diagnostic Markers for Ulcerative Colitis

Hongru Wu (Xinjiang Uygur Autonomous Region People's Hospital, China)

EP-073 HBV Reactivation Risk with JAK Inhibitors in IBD: Practice Implications in HBV-Endemic Asia

Huiyu Lin (Tan Tock Seng Hospital, Singapore)

EP-074 Ulcerative Colitis Mimic: Constipation-Associated Rectal Lymphoid Hyperplasia

Yoshiharu Yamaguchi (Aichi Medical University School of Medicine, Japan)

IBD: Clinical - Treatment and Prognosis

EP-076 Pre-Admission Oral Prednisolone Exposure and Rescue Therapy in Acute Severe Ulcerative Colitis

Jee Hyun Kim (Chonnam National University Hospital, Chonnam National University Medical School, Korea)

EP-077 Treatment Persistence After Switching Between Anti-TNF-alpha Agents and JAK Inhibitors in Ulcerative Colitis: A Nationwide Real-World Analysis from HIRA

Ji Eun Baek (St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Korea)

EP-078 Impact of IBD Medication Exposure Before and After Cancer Diagnosis on Cancer Recurrence and Survival in Patients with Inflammatory Bowel Disease

Jae Eun So (Yonsei University College of Medicine, Severance Hospital, Korea)

- EP-079 Systematic Review and Network Meta-Analysis: Safety of Advanced Therapies in Pregnant Women with Inflammatory Bowel Disease**
Caterina Prada (Gold Coast University Hospital, Australia)
- EP-080 Efficacy and Safety of Vedolizumab in Early Crohn's Disease: Final Results from the Prospective, Multicentre, Interventional EARLY CD Study**
Jing Liu (Sir Run Run Shaw Hospital - Zhejiang University School of Medicine, China)
- EP-081 Efficacy and Safety of Subcutaneous Guselkumab Rescue Therapy in Moderately to Severely Active Crohn's Disease and Inadequate Response to Ustekinumab: Results from GALAXI 1, 2, & 3 Long-Term Extension**
Rupert W Leong (Macquarie University Hospital, Australia)
- EP-083 De-Escalation Outcomes and Strategies After Advanced Combination Therapy in Difficult-to-Treat Inflammatory Bowel Disease: A Real-World Cohort Study from Taiwan**
Ming-Jung Meng (Linkou Chang Gung Memorial Hospital, Taiwan)
- EP-084 Real-World Effectiveness and Safety of Guselkumab During Induction of Remission in Patients with Ulcerative Colitis**
Masayuki Fukata (JCHO Tokyo Yamate Medical Center, Japan)
- EP-085 Upadacitinib as Rescue and Sequential Rescue Therapy for Acute Severe Ulcerative Colitis: An Observational Cohort Study**
Matthew Mansoor (Gold Coast University Hospital, Australia)
- EP-086 Clinical Outcomes of Cytomegalovirus Reactivation in Moderate-to-Severe Ulcerative Colitis in the Era of Biologics and Small Molecules**
Jihye Park (Yonsei University College of Medicine, Korea)
- EP-087 Baseline Plasma Proteomics Predicts Natural Disease Course Progression in Treatment-Naive Crohn's Disease**
Yu Wang (The First Affiliated Hospital of Sun Yat-sen University, Zhongnan Hospital of Wuhan University, China)
- EP-089 Real-World Effectiveness and Safety of Etrasimod in Ulcerative Colitis: Interim Analysis of the EFFECT-UC Study**
Michelle Segovia (Pfizer Inc, United States)

- EP-090 Long-Term Etrasimod Efficacy in Patients with Ulcerative Colitis Stratified by Prior Biologic/JAKi Experience: 2-Year Outcomes from the ELEVATE UC OLE**
Michelle Segovia (Pfizer Inc, United States)
- EP-091 Impact of Concomitant Immunomodulator Use by UST-CDST Classification on Clinical Relapse in Crohn's Disease Patients Treated with Ustekinumab: A Multicenter Study**
Jongbeom Shin (Inha university hospital, Inha University School of Medicine, Korea)
- EP-092 Preoperative Cellularity-Scale Diffusion MRI for Risk Stratification of Postoperative Anastomotic Recurrence in Crohn's Disease**
Qiaochu Zhao (The First Affiliated Hospital of Sun Yat-sen University, China)
- EP-093 Comparative Effectiveness and Safety of Risankizumab vs Ustekinumab in Crohn's Disease: A Real-World Retrospective Cohort Study from Taiwan**
Ming-Jung Meng (Linkou Chang Gung Memorial Hospital., Taiwan Association for the Study of Intestinal Diseases (TASID), Chang Gung Inflammatory Bowel Disease Center, Taiwan)
- EP-094 Disease Clearance with Etrasimod in Asian Patients with Moderately to Severely Active Ulcerative Colitis: A Post Hoc Analysis of the Phase 3 ENLIGHT UC Trial**
Xiang Gao (The Sixth Affiliated Hospital of Sun Yat-sen University, China)
- EP-095 Dose Intensification Versus Switching Therapy for Secondary Loss of Response to Infliximab in Crohn's Disease: A Real-World Comparative Study**
Tong Li (First affiliated hospital of Dalian Medical University, China)
- EP-096 Ten-Year Trends in Steroid Use and Barriers to Achieving Treat-to-Target in Inflammatory Bowel Disease: A Real-World Longitudinal Study**
Jung Hyun Noh (Seoul National University Bundang Hospital, Seoul National University College of Medicine, Chung-Ang University Gwangmyeong Hospital, Korea)

- EP-097 A Real-World Application Pattern and Efficacy of Ustekinumab (UST) in Crohn's Disease (CD) Based on Physician Assessment**
Yuan Yuan Long (Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology, China)
- EP-098 Granulomatous Inflammation as an Independent Predictor of Secondary Loss of Response to TNF-alpha Inhibitors in Crohn's Disease: A Long-Term Cohort Study**
Eunjo Kim (Seoul National University Bundang Hospital, Korea)
- EP-099 Improved Pregnancy Outcomes in Crohn's Disease in the Biologic Era: A Single-Center Retrospective Study**
Minako Sako (Tokyo Yamate Medical Center, Japan)
- EP-100 Drug Persistence and Safety of Biologic Therapy in Inflammatory Bowel Disease: A Real-World Analysis from the TSIBD Registry**
Chih-Wen Huang (Changhua Christian Hospital, Taiwan)
- EP-101 Efficacy of Guselkumab for Small Bowel Lesions Using Balloon Assisted Enteroscopy: A Phase 3, Open-Label, Multicenter Study**
Teppei Omori (Kyorin University Suginami Hospital, Kyorin University School of Medicine, Japan)
- EP-102 Development of Predictive Models for Optimized Intravenous Ustekinumab Therapy in Real-World Patients with Crohn's Disease**
Yuan Yuan Long (Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology, China)
- EP-103 Combination Therapy with Biologics or Small-Molecules for Inflammatory Bowel Disease: A Case Series and Meta-Analysis**
Zihan Chen (The First Affiliated Hospital, Sun Yat-sen University, China)
-  **EP-104 Pooled Colectomy Rates Following Upadacitinib Rescue Therapy in Steroid-Refractory Acute Severe Ulcerative Colitis: A Systematic Review and Meta-Analysis of Real-World Studies**
Winston Christopher Wiweko (Atma Jaya Catholic University of Indonesia, Indonesia)
- EP-105 Clinical Characteristics and Treatment Patterns of Ustekinumab in Korean Patients with Crohn's Disease: Subgroup Analysis from a Prospective Nationwide KSTAR Study**
Byunk Ik Jang (Yeungnam University College of Medicine, Korea)

- EP-106 Clinical Effectiveness of Vedolizumab in Chinese Patients with Ulcerative Colitis: Final Results from the VALUE, a Multicenter Prospective Study**
Fang Zhou (Takeda (China) Holdings Co., Ltd., China)
- EP-107 Vedolizumab Demonstrated Significant Improvements in Symptomatic Relief and Quality of Life in Patients with Crohn's Disease: Results from VALUE, a Prospective, Multicenter, Observational Study**
Xiaoyu Qian (Takeda (China) Holdings Co., Ltd., China)
- EP-108 Combination of Vedolizumab and Short-Course Infliximab in the Treatment of Crohn's Disease in Induction Remission Period: A Single-Center Real-World Retrospective Analysis**
Hongxue Lu (Xiangya Hospital, Central South University, China)
- EP-109 Long-Term Clinical Outcomes of Thiopurine Therapy According to NUDT15 Genotype in Ulcerative Colitis**
Ji Young Chang (Ewha Womans University Seoul Hospital, Korea)
- EP-111 Etrasimod for the Treatment of Ulcerative Colitis: Up to 5 Years of Safety Data from the Global Clinical Program**
Ken Takeuchi (Tsujioka Hospital Kashiwanoha, Japan)
- EP-112 Tulisokibart in Patients with Moderately to Severely Active Crohn's Disease: Efficacy and Safety Through Week 146 from the Phase 2 APOLLO-CD Study**
Rupert W. Leong (Concord Hospital, Australia)
- EP-113 Three Year Efficacy and Safety of Mirikizumab Treatment in Chinese Patients with Crohn's Disease: A Subpopulation Analysis from the VIVID-2 Extension Study**
Qian Cao (Sir Run Run Shaw Hospital, China)
- EP-114 Relationship Between Clinical and Histologic Findings with Tulisokibart Induction at Week 12 and Maintenance Dosing at Week 50 in the Randomized Controlled ARTEMIS-UC Study in Participants with Ulcerative Colitis**
Rupert Leong (Macquarie University, Australia)
- EP-115 Sustained Symptomatic Relief and Disease Clearance Through 50 Weeks of Treatment with Tulisokibart in Participants with Moderately to Severely Active Ulcerative Colitis in the Phase 2 ARTEMIS-UC Study**
Jin Oh Kim (MSD AP Region, Korea)

- EP-116 A Phase Ib Study of TQH3906 Capsule for the Induction Therapy of Moderate to Severe Active Ulcerative Colitis**
Jiawei Zhang (Chia Tai Tianqing Pharmaceutical Group Co Ltd, China)
- EP-117 Symptomatic Improvement with Intravenous Guselkumab Induction Therapy Is Observed Early in Patients with Moderately to Severely Active Ulcerative Colitis: Post-Hoc Analysis of QUASAR**
Masayuki Saruta (The Jikei University School of Medicine, Japan)
- EP-118 Impact of Cytomegalovirus Infection on Rescue Therapy in Acute Severe Ulcerative Colitis: A Prospective Multicenter Korean Cohort**
Sung-Ju Bang (Chonnam National University Hospital, Chonnam National University School, Korea)
- EP-119 Risk Factors for Intestinal Surgery and the Impact of Early Postoperative Biologic Therapy in Crohn's Disease**
Byung Chul Jin (Jeonbuk National University, Korea)
- EP-120 Long-Term Clinical Outcomes and Prognostic Factors in Crohn's Disease with Internal Fistulas**
Woo Suji (Severance Hospital Yonsei University College of Medicine, Korea)
- EP-121 Ustekinumab Offers an Effective Treatment Option for Chinese Patients with Moderately to Severely Active Crohn's Disease**
Xiaoou Li (Janssen Research & Development, LLC, China)
- EP-122 Use of Carotegrast Methyl in 15 Patients with Ulcerative Colitis: A Single-Center Experience**
Kentarō Onishi (Aichi Medical University Hospital, Japan)
- EP-123 Machine Learning-Based Prediction of Surgery in Stricturing Crohn's Disease**
Haluk Tarik Kani (Marmara University School of Medicine, Türkiye)
- EP-124 Acute Severe Ulcerative Colitis (ASUC) Management in a Southeast Asian Tertiary Hospital: Low Prognostic Scores but High Rescue Therapy Use**
Jonathan Koh (Tan Tock Seng Hospital, Singapore)

- EP-125 Real-World Comparison of Four-Year Outcomes in Patients with Crohn's Disease Treated with Vedolizumab Versus Infliximab**
Masayuki Fukata (JCHO Tokyo Yamate Medical Center, Japan)
- EP-126 Analysis of Risk Factors for Improvement of Intestinal Mucosa in Patients with Moderate to Severe Crohn's Disease After Treatment with Ustekinumab**
Hongyan Li (The First Hospital of Jilin University, China)
- EP-127 Physician Opinions on Treatment Preferences and Long-Term Treatment Goals in Moderate to Severe Ulcerative Colitis in China**
Xiaoxiao Alice Lu (Johnson & Johnson Innovative Medicine, United States)
- EP-128 Early Mucosal Healing and Risk of Proximal Extension in Ulcerative Proctitis: A Single-Center Retrospective Cohort Study**
Tetsuya Shiraishi (Hyogo Medical University Hospital, Japan)
- EP-129 Physicians' Treatment Preferences and Long-Term Treatment Goals in Ulcerative Colitis and Crohn's Disease: Insights from Physician Surveys in Japan and China**
Xiaoxiao Alice Lu (Johnson & Johnson Innovative Medicine, United States)
- EP-131 Physician Opinions on Treatment Preferences and Long-Term Treatment Goals in Moderate to Severe Ulcerative Colitis and Crohn's Disease in Japan**
Katsuyoshi Matsuoka (Toho University Sakura Medical Center, Japan)
- EP-132 Treatment Patterns and Medication Adherence in Older Adults with Mild-to-Moderate Ulcerative Colitis: A Multicenter, Comparative, Real-World Study**
He Gu (Key Laboratory of Gastroenterology and Hepatology, Ministry of Health, Inflammatory Bowel Disease Research Center; Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai Institute of Digestive Disease, NHC Key Laboratory of Digestive Diseases, China)
- EP-133 Clinical Outcomes and Mucosal Healing of Carotegrast Methyl in an IBD Clinic**
Toshihide Ohmori (Ohmori Toshihide GI Clinic, Japan)

- EP-134 Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Crohn's Disease in Japan: Safety and Efficacy over 44 Weeks**
Ken Takeuchi (Tsujioka Hospital Kashiwanoha, Japan)
- EP-135 Efficacy and Tolerability of Amitriptyline in Mild-to-Moderate Ulcerative Colitis: A Double-Blind Randomized Placebo-Controlled Trial**
Amitkumar Chavan (All India Institute of Medical Sciences, India)
- EP-136 Comparative Efficacy of Structured Dietary Therapies and Fasting Protocols for the Induction of Remission in Adult Crohn's Disease: A Systematic Review and Network Meta-Analysis**
Rahul Falodia (All India Institute of Medical Sciences, Jodhpur, India)
- EP-137 Treatment Pathway of Advanced Therapies in Patients with Inflammatory Bowel Disease: A Nationwide Population-Based Cohort Study in Korea**
Hyoungh Il Choi (Kyung Hee University Hospital at Gangdong, Kyung Hee University College of Medicine, Korea)
- EP-138 Recapturing Disease Control with Subcutaneous Infliximab After a Drug Holiday Following Intravenous Infliximab Induction: A Post Hoc Analysis of LIBERTY-CD and -UC Studies**
Noehyun Myung (Celltrion Inc., Korea)
- EP-139 Impact of up to 3 Years of Continuous Etrasimod Treatment: Long-Term Efficacy Results from the ELEVATE UC Open-Label Extension**
Ken Takeuchi (Tsujioka Hospital Kashiwanoha, Japan)
- EP-140 Poor Adherence to International Guidelines for Preventing Post-Operative Recurrence in Crohn's Disease in an Australian Tertiary Centre**
Damjana Bogatic (The Queen Elizabeth Hospital, Australia)
- EP-141 Efficacy of Etrasimod in Ulcerative Colitis Patients Previously Treated with 5-Aminosalicylates and/or Thiopurines: Post Hoc Results from the Phase 3 ENLIGHT UC Study**
Xiang Gao (The Sixth Affiliated Hospital of Sun Yat-sen University, China)

- EP-142 Short-Term Effectiveness of Mirikizumab in Crohn's Disease Patients with Perianal Involvement**
Masayuki Fukata (JCHO Tokyo Yamate Medical Center, Japan)
- EP-143 Early Introduction of Advanced Therapy in Crohn's Disease with Perianal Fistula According to the Hughes Classification: A Single-Center Retrospective Study**
Tsutomu Masuda (Ikoma Sakura Clinic, Japan)
- EP-145 Long-Term Treatment Persistence of Vedolizumab in Ulcerative Colitis: Impact of Age at Disease Onset - a Retrospective Study**
Masatsugu Sato (Tsuinaka Hospital Kashiwanoha, Japan)
- EP-146 Difficult-to-Treat Inflammatory Bowel Disease: Experience of a Single Medical Center**
Tsui-Chun Hsu (Changhua Christian Hospital, Taiwan)
- EP-147 Effectiveness and Safety of Upadacitinib in Patients with Crohn's Disease and Ulcerative Colitis: A Korea Multicenter Retrospective Cohort Study**
Won-Hee Lee (Chosun University, Korea)
- EP-148 Filgotinib After Initial Systemic Steroid Therapy Demonstrated Non-Inferiority to Steroid Re-Escalation for 3-Month Steroid Free Status in Ulcerative Colitis: A Japanese Claims Database Study**
Masayuki Saruta (The Jikei University School of Medicine, Japan)
- EP-149 Drug Persistence of Ustekinumab in Patients with Inflammatory Bowel Disease: Findings from the Multicenter Taiwan Real-World Study**
Shih-Hua Lin (New Taipei Municipal TuCheng Hospital (Built and Operated by Chang Gung Medical Foundation), Taiwan)
- EP-150 Vedolizumab and Upadacitinib in Combination as Salvage Therapy for Anti-TNF-alpha Refractory Crohn's Disease**
Xiaomin Sun (Shanghai Tenth People's Hospital Affiliated with Tongji University, China)
- EP-151 How to Evaluate the Long-Term Therapeutic Effects of Biologics?**
Yu Peng (Xiangya Hospital of Central South University, China)

- EP-152 Does Extent of Disease Affect Outcomes in Ulcerative Patients on Advanced Therapy? A Real World Study from Singapore**
Jonas Ho (Singhealth, Singapore)
- EP-153 One-Year Real-World Effectiveness and Tolerability of Adjunctive Oral Calcium Butyrate in Inflammatory Bowel Disease: A Retrospective Cohort**
 Tarkan Karakan (Gazi University Faculty of Medicine, Türkiye)
- EP-154 Guselkumab for Active Crohn's Disease: Efficacy and Safety Outcomes at Week 12 in a Prospective Cohort Study**
Jiayin Yao (The Sixth Affiliated Hospital of Sun Yat-Sen University, China)
- EP-155 The Role of Immunosuppressant Agents in the Era of Anti-TNF and Non-Anti-TNF Biologics for Inflammatory Bowel Disease: Multicenter Study from the TSIBD Registration**
Tzu-Wen Chen (MacKay Memorial Hospital, Taiwan)
- EP-156 Clinical Outcomes of Long-Term Infliximab Treatment for 15 Years in Patients with Crohn's Disease: A Retrospective Study**
Zihan Chen (The First Affiliated Hospital, Sun Yat-sen University, China)
- EP-157 Clinical Effectiveness of Vedolizumab in Chinese Patients with Crohn's Disease: Final Results from VALUE, a Multicenter Prospective Study**
Xiaoyu Qian (Takeda (China) Holdings Co., Ltd., China)
- EP-158 Spectrum of IBS Symptoms in Ulcerative Colitis Patients in Remission**
Nitin R (ABVIMS and RML Hospital, India)
- EP-159 The Safety of Vedolizumab in the Management of Chinese Patients with Inflammatory Bowel Disease: Findings from a Multicenter, Prospective, Observational, VALUE Study**
Xiaoyun Qian (Takeda (China) Holdings Co., Ltd., China)
- EP-160 Short-Term Efficacy of Risankizumab and Ustekinumab for Fistulizing Crohn's Disease: A Real-World Cohort Study in Taiwan**
Ching-Huang Su (Chang Gung Memorial Hospital, Taiwan)

- EP-161 Ustekinumab as First Line Biologic in Indian Patients with Moderate to Severe Crohn's Disease: Safety and Efficacy from a Multicentre Phase IV Study**
Gourdas Choudhuri (Fortis Memorial Research Institute, India)
- EP-162 Temporal Trends in Clinical Outcomes of Ulcerative Colitis Stratified by Cytomegalovirus Status Across Three Successive Therapeutic Eras**
Hiroki Kitamoto (Kyoto University Hospital, Japan)
- EP-163 Caloric Restriction During Hospitalization Is Associated with Improved Mucosal Healing in Patients with Ulcerative Colitis**
Tomoyuki Nagai (Kindai University, Japan)
- EP-164 Impact of Ileocecal Resection on Quality of Life in Patients with Crohn's Disease: A Cross-Sectional Study**
Jueon Hong (Asan Medical Center, Korea)
- EP-165 Efficacy of Guselkumab in Moderately to Severely Active Ulcerative Colitis by Extent of Disease and Inflammatory Burden: Subgroup Analysis of the Phase 3 QUASAR Maintenance Study**
Tadakazu Hisamatsu (Kyorin University, Japan)
- EP-166 Effect of Proton Pump Inhibitor Versus Potassium Competitive Acid Blocker for Clinical Course of Ulcerative Colitis**
Kwang Woo Kim (Seoul Metropolitan Government - Seoul National University Boramae Medical Center, Seoul National University College of Medicine, Korea)
- EP-167 Efficacy and Safety of Tulisokibart Maintenance Treatment in Induction Responders vs Reinduction and Delayed Induction Responders: Results from the Phase 2 ARTEMIS-UC Trial Open-Label Extension in Participants with Ulcerative Colitis**
Jin Oh Kim (MSD AP Region, Korea)
- EP-169 Real-World Comparative Effectiveness of Ferric Carboxymaltose and Iron Sucrose for Iron Deficiency Anemia in Inflammatory Bowel Disease**
Jeong Hwa Lee (Asan Medical Center, University of Ulsan College of Medicine, Kyungpook National University Hospital, Korea)
- EP-170 The Importance of Endoscopic Surveillance in Ulcerative Colitis Patients with Primary Sclerosing Cholangitis**
Mio Namikawa (Kyoto University Graduate School of Medicine, Japan)

- EP-172 Mucosa Healing in Bio-Naive and Bio-Exposed Patients with Ulcerative Colitis Receiving Ustekinumab Monotherapy and in Combination with Mesalazines**
Oleg Knyazev (Moscow Clinical Center named after A.S. Loginov, Russian Federation)
- EP-173 Vedolizumab Demonstrated Effectiveness in Improving Symptom Relief and Quality of Life in Chinese Patients with Ulcerative Colitis: Results from the Real-World VALUE Study**
Fang Zhou (Takeda (China) Holdings Co., Ltd., China)
- EP-174 Outcomes of Early Versus Delayed Advanced Therapy Initiation in Patients with Ulcerative Colitis: A Multicenter Retrospective Study**
Hongsub Lee (Busan Paik Hospital, Inje University College of Medicine, Korea)
- EP-176 A Real-World Study on Psychiatric Adverse Events Induced by Biologics for Inflammatory Bowel Disease**
Chong Pan (People's Hospital of Xinjiang Uygur Autonomous Region, China)
- EP-178 The Efficacy of Dual-Targeted Therapy in Patients with Crohn's Disease**
Oleg Knyazev (GBUZ Moscow Clinical Scientific Center named after Loginov MHD, Russian Federation)
- EP-179 Achieving Mucosal Healing in Patients with Mild-to-Moderately Active Ulcerative Colitis with Oral Mesalazine**
Bolette Christophersen (Ferring Pharmaceuticals A/S, Denmark)
- EP-180 Effectiveness of Add-on Upadacitinib in Advanced Combination Therapy for Refractory Inflammatory Bowel Disease: A Retrospective Cohort Study in Taiwan**
Shih-Hua Lin (New Taipei Municipal TuCheng Hospital (Built and Operated by Chang Gung Medical Foundation), Taiwan)
- EP-181 Restarting Etrasimod After Treatment Interruption Is Not Associated with Cardiovascular Events: Analysis from the ELEVATE UC Clinical Program**
Michelle Segovia (Pfizer Inc, United States)
- EP-182 Two-Year Clinical Outcomes of Upadacitinib Maintenance Therapy in Patients with Ulcerative Colitis**
Hiroyuki Tamaki (Takamatsu Red Cross Hospital, Japan)

- EP-184 Guselkumab Maintenance Dose Regimens in Patients with High Disease Activity and Severity: Subgroup Analysis of Participants with Moderately to Severely Active Crohn's Disease in the GALAXI Phase 3 Studies**
Keira Herr (Johnson & Johnson Asia Pacific, Singapore)
- EP-185 Combined Advanced Therapies in Patients with Inflammatory Bowel Disease in Thailand: Prescribing Patterns and Clinical Outcomes**
Thanaboon Chaemsupaphan (Siriraj Hospital, Mahidol University, Thailand)
- EP-186 Prognostic Risk Assessment in Ulcerative Colitis Based on Multivariate Regression and Qualitative Comparative Analysis**
Shichen Zhu (Zhejiang University School of Medicine, China)
- EP-188 Safety and Efficacy of Glucagon-Like Peptide-1 Receptor Agonists in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis**
Mohamed Hamouda Elkasaby (Faculty of Medicine, Al-Azhar University, Egypt)
- EP-189 Real World Effectiveness and Safety of Vedolizumab in the Treatment of Patients with Ulcerative Colitis: The Updated Data from Our Single Center Study**
Cui Zhang (Tongji University, China)
- EP-190 Retrospective Study of Cases After Induction Therapy with Tacrolimus in Our Hospital**
Yasuhisa Murai (Hirosaki University, Graduate School of Medicine, Hirosaki University Hospital, Japan)
- EP-192 Infectious Complications in Hospitalized Patients with Inflammatory Bowel Disease and Associated Risk Factors**
Lth Thu (Thai Nguyen University Of Medicine And Pharmacy, Vietnam)
- EP-193 Characteristics of Anemia and Response to Iron Therapy in Patients with Inflammatory Bowel Disease: A Single-Center Study in Vietnam**
Lth Thu (Thai Nguyen University Of Medicine And Pharmacy, Vietnam)
- EP-194 Upadacitinib in Inflammatory Bowel Disease: Single Center Experience**
Filiz Akyuz (Istanbul University Istanbul Faculty of Medicine, Türkiye)

- EP-195 Real-World Use of Concomitant Immunomodulators with Biologics in Patients with Inflammatory Bowel Disease**
Wei-Chen Lin (Mackay Memorial Hospital, Taiwan)
- EP-196 Effectiveness of Ustekinumab Maintenance Therapy Administered Every 12 Weeks in Patients with Moderate-to-Severe Ulcerative Colitis**
Kohei Sugiyama (Sapporo IBD Clinic, Sapporo Central Hospital, Japan)
- EP-197 Early Clinical Improvement with Upadacitinib in Moderate-to-Severe Ulcerative Colitis, Including Refractory Cases: Implications for Week-4 Treatment Decision- a Single-Center Experience**
Yukako Komori (Kitasato University School of Medicine, Japan)
- EP-198 Quantifying the Benefits of Full Dose Time-Dependent Mesalazine for the Induction and Maintenance of Remission in Mild-to-Moderate Ulcerative Colitis in Adults: A Systematic Literature Review and Meta-Analysis**
Bolette Christophersen (Ferring Pharmaceuticals A/S, Denmark)
- EP-199 Pharmacologic and Dietary Interventions for Upper Gastrointestinal Involvement in Crohn's Disease: A Systematic Review**
Noha Hammad (Faculty of Medicine, Port-Said University, Egypt)
- EP-200 Hemorrhagic Shock Despite Clinical and Endoscopic Improvement with Upadacitinib in Acute Severe Ulcerative Colitis: A Three-Case Series**
Keita Suzuki (Kitasato University Kitasato Institute Hospital, Kitasato University Kitasato Institute Hospital, Japan)
- EP-202 Evaluation of the Rate of Changes, Persistency, and Safety in a Prospective Observational Study Based on Patient-Preferred Selection in Patients with Ulcerative Colitis (VIVSC Study)**
Shingo Kato (Saitama Medical Center, Saitama Medical University, Japan)
-  **EP-203 Protective Effects of Statin Therapy on Clinical Outcomes in Inflammatory Bowel Disease: A Propensity Score Matched Analysis**
Pragya Gautam (Territorial manager, Nepal)
- EP-205 Psychological Support in Patients with Ulcerative Colitis for Adherence to Drug Therapy**
Oleg Knyazev (Moscow Clinical Center named after A.S. Loginov, Russian Federation)

- EP-206 Mucosal Healing and Outcomes of Pregnancy**
Oleg Knyazev (Moscow Clinical Center named after A.S. Loginov, Russian Federation)
- EP-209 Etrasimod in an Elderly Ulcerative Colitis Patient with Pre-Existing Sinus Bradycardia: A Case Report from the ENLIGHT UC Study**
Zhe Zhang (Shengjing Hospital of China Medical University, China)
- EP-210 Etrasimod in the Treatment of Severe Ulcerative Colitis with Extraintestinal Manifestations: A Case Report from the ENLIGHT UC Study**
Zhe Zhang (Shengjing Hospital of China Medical University, China)
- EP-211 A Case of Takayasu Arteritis Associated with Ulcerative Colitis in an Elderly Man**
Kumiko Uchida (Gastroenterology, Japan)
- EP-212 Therapeutic Efficacy and Safety of Fecal Microbiota Transplantation in Ulcerative Colitis: A Systematic Review and Meta-Analysis**
Noha Hammad (Faculty of Medicine, Port-Said University, Egypt)
- EP-214 Ulcerative Colitis Complicated by Primary Sclerosing Cholangitis and Anti-TNF-Induced Psoriasis: A Case Report**
Mustafa Kaplan (Sultan 2. Abdulhamid Han Training and Research Hospital, Türkiye)
- EP-216 Mucosal Healing Is a Predictor of Favorable Outcomes in Ulcerative Colitis**
Oleg Knyazev (Moscow Clinical Center named after A.S. Loginov, Russian Federation)
- EP-217 Efficacy of Thiamine for Fatigue in Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis of RCTs**
Ahmad Fariz Malvi Zamzam Zein (Fatmawati Hospital, Faculty of Medicine, Universitas Swadaya Gunung Jati, Indonesia)
- EP-218 Effectiveness of Upadacitinib in Bio-Naive Patients with Crohn's Disease: A Case Series Focused on Patient Preference for Oral Therapy and Long-Term Endoscopic Remission**
Moe Ogawa (Kitasato University School of Medicine, Japan)

- EP-219 A Case of Fistulising Crohn's Disease Complicated with Disseminated Tuberculosis**
Wilson Wai Shun Cheng (Caritas Medical Centre, Hong Kong, China)
- EP-220 Medical Therapy for Ulcerative Colitis Unmasks Sporadic Colorectal Neoplasia: Two Case Reports**
Sae Nakayama (Sagamihara Kyodo Hospital, Kitasato University School of Medicine, Japan)
- EP-221 Diagnostic Value of Fecal Calprotectin in Differentiating Inflammatory Bowel Disease from Irritable Bowel Syndrome**
Hk Tien (CK Clinic, Vietnam)
- EP-222 Vedolizumab Achieved Durable Steroid-Free Clinical, Endoscopic, and Histological Remission in Difficult-to-Treat Ulcerative Colitis Refractory to Tofacitinib and Ustekinumab**
Akira Madarame (Tokyo Medical University, Japan)
- EP-225 The Perfect Storm: Surgical Rescue in Severe Ulcerative Colitis Complicated by CMV and Severe Systemic Infection**
Ratchanok Suppawat (Bhumibol Adulyadej Hospital, Thailand)
- EP-226 Comparative Efficacy of Advanced Therapies in Fistulizing Crohn's Disease: An Updated Network Meta-Analysis**
Satinder Singla (Kalinga Institute of Medical Sciences, Bhubaneswar, India)
- EP-441 Predictors of Week-14 Primary Nonresponse and Moderate-to-Severe Relapse in Patients with Ulcerative Colitis Treated with Vedolizumab**
A Young Cho (Severance Hospital, Yonsei University College of Medicine, Korea)

IBD: Clinical - Intestinal Ultrasound

- EP-227 Accuracy of the Milan Ultrasound Criteria in Assessing Endoscopic Activity of Ulcerative Colitis**
Ye Zhao (The First Affiliated Hospital of Zhengzhou University, China)

EP-228 Predictive Value of Intestinal Ultrasound Combined with Fecal Calprotectin for the Response to Biologic Therapy in Ulcerative Colitis

Wei Chen (The 7th Medical Center, Chinese PLA General Hospital, China)

EP-229 Use of Intestinal Ultrasound and Other Imaging Tests in Ulcerative Colitis and Crohn's Disease: Insights from a Japan Physician Survey

Katsuyoshi Matsuoka (Toho University Sakura Medical Center, Japan)

EP-230 Real-World Experience of the International Bowel Ultrasound Segmental Activity Score for Assessing Disease Activity in Crohn's Disease

Arshdeep Singh (Dayanand Medical College and Hospital, India)

EP-231 Comparison of Intestinal Ultrasonography (IUS) and Colonoscopy in Assessing Disease Activity and Severity in Ulcerative Colitis

Pradip Kafle (Tribhuvan university teaching hospital (TUTH), Nepal)

EP-232 Intestinal Ultrasound Characteristics and Symptom Correlation in Ulcerative Colitis and Non-IBD Colitis: A Comparative Analysis

Chih-Wen Huang (Changhua Christian Hospital, Taiwan)

EP-233 Bowel Wall Thickness Reduction Following Risankizumab Therapy Assessed by Intestinal Ultrasonography in Crohn's Disease

Maki Miyakawa (Sapporo IBD Clinic, Japan)

EP-234 Construction and Analysis of an Endoscopic Activity Prediction Model for Ulcerative Colitis Based on Intestinal Ultrasound Combined with Biomarkers

Zhexuan Liu (Hebei Medical University, China)

EP-235 Monitoring Disease Activity Using Intestinal Ultrasonography in Patients with Ulcerative Colitis Treated with Mirikizumab

Masanao Nasuno (Sapporo IBD Clinic, Japan)

EP-236 Diagnostic Performance of Intestinal Ultrasound for Disease Activity Assessment in Ulcerative Colitis

Chih-Wen Huang (Changhua Christian Hospital, Taiwan)

- EP-237 Real-World Implementation of Intestinal Ultrasound for IBD Management in a Tertiary Public Hospital in Hong Kong**
Tsz Fai Cheng (Tuen Mun Hospital, Hong kong, China)
- EP-238 First Experience of Intestinal Ultrasound for the Diagnosis and Monitoring of Inflammatory Bowel Disease in Mongolia**
Ariunzul Dashdondog (The First Central Hospital of Mongolia, Mongolia)
- EP-240 TB or Not TB: The Role of Intestinal Ultrasound in Differentiating Intestinal Tuberculosis from Crohn's Disease**
Hasan Alaali (University of Malay Medical center, Malaysia)

IBD: Basic / Translational / Microbiome

- EP-242 Healthy Donor-Derived Alistipes shahii CKDB500 Enhances 5-Aminosalicylic Acid Efficacy by Modulating Host Drug Metabolism and Inflammatory Signaling in Colitis**
Ye Won Kim (Brain Korea 21 Project, Yonsei University College of Medicine, Korea)
- EP-243 Single-Cell Profiling of the Spatial Immune Landscape in Pediatric Crohn's Disease: Focus on Rectal Th1 Cytotoxicity**
Jin Gyu Lim (Seoul National University College of Medicine, Korea)
- EP-244 Bifidobacterium infantis Derived Extracellular Vesicles Protect Against NSAID-induced Colonic Injury in Colitis Models**
Hyeon-Jeong Jeon (Ewha Womans University College of Medicine, Korea)
- EP-245 Spatially Resolved Tumor Heterogeneity and Fibroblast Coupling in Colitis-Associated Colorectal Cancer**
Yoonho Lee (Brain Korea 21 project, Asan Medical Center, University of Ulsan College of Medicine, Korea)
- EP-246 Endothelial Cell PTPN14-AHR Axis Maintains the Gut Vascular Barrier to Alleviate Colonic Inflammation**
Qi Chen (Tianjin Medical University General Hospital, China)
- EP-247 Bacteroides uniformis Ameliorates Intestinal Fibrosis and Improves Serum Metabolites Profiles in Crohn's Disease**
Caiguang Liu (The First Affiliated Hospital, Sun Yat-sen University, China)

EP-249 Prevotella copri OmpA Associates with VAMP8 in Intestinal Epithelial Cells and Aggravates Ulcerative Colitis

Shushan Chen (General Hospital, Tianjin Medical University, National Key Clinical Specialty, Tianjin Institute of Digestive Diseases, Tianjin Key Laboratory of Digestive Diseases, China)

EP-250 The Combination of Thalidomide and Azathioprine Synergistically Inhibits T Cell Activation and Proliferation in Crohn's Disease

Tong Li (First affiliated hospital of Dalian Medical University, China)

EP-251 microRNA-21 Knockout Protects Against DSS-Induced Acute Colitis and Is Associated with Distinct Gut Microbiota Composition

Jae Gon Lee (Hanyang University Guri Hospital, Korea)

EP-252 Distinct Transcriptomic Profiles of Tonsil-Derived and Adipose-Derived Mesenchymal Stem Cells Under Intestinal Stem Cell-Like Differentiation with Implications for IBD Therapy

Ju Ran Byeon (Ewha Womans University, Korea)

EP-253 Inflammatory and Fibrotic Microenvironments of Mesenteric Adipose Tissue in Crohn's Disease: An Electron Microscopy-Based Analysis

Yang Hee Joo (Ewha Womans University College of Medicine, Korea)

EP-254 Treatment Effect of Extracellular Vesicles Extracted from Tonsil-Derived Mesenchymal Stem Cells in Murine Colitis Model

So Yeon Park (Ewha Womans University College of Medicine, Korea)

EP-255 Rapid Gut Microbiota-Associated Lipidome Profiling in Inflammatory Bowel Disease: A Novel Approach for Disease Molecular Characterization and Therapeutic Monitoring

Hongsub Lee (Busan Paik Hospital, Inje University College of Medicine, Korea)

EP-256 The Role and Mechanisms of SLC6A19 in the Pathogenesis of Ulcerative Colitis Through Regulation of Intestinal Epithelial Barrier Homeostasis

Xiaomei Song (Chongqing General Hospital, China)

- EP-257 Oral Microbiome Diversity and Composition in Inflammatory Bowel Disease Patients with Periodontitis**
Weiwei Zheng (The First Affiliated Hospital, Fujian Medical University, China)
- EP-259 PAR2 Regulates Colitis in IL-10-deficient Mice by Modulating Pyroptosis and Gut Microbiota Dysbiosis.**
Geunhyung Yang (Pusan National University, Korea)
- EP-261 ME1-Promoted Macrophage Pyroptosis Influences Intestinal Cell Differentiation and Exacerbates Inflammatory Bowel Disease**
Huan Zhang (The First Affiliated Hospital of Soochow University, China)
- EP-262 The Biological and Mechanistic Study of ZNF384-MUC2 Transcriptional Axis to Enhance Intestinal Inflammation**
Yiqing Yang (Xinhua Hospital, Shanghai Jiaotong University School of medicine, China)
- EP-263 Mechanistic Study of Branched-Chain Amino Acid Transaminase 1 (BCAT1) in Promoting Macrophage M1 Polarization and Exacerbating Inflammatory Bowel Disease**
Rufang Dong (Department of Gastroenterology, The First Affiliated Hospital of Soochow University, Suzhou, China, China)
- EP-264 ROS-Mediated p32 Degradation Drives Goblet Cell Depletion in Imiquimod-Induced Colitis**
Jeng-Jer Shieh (National Chung-Hsing University, Taiwan)
- EP-265 Astragalus Polysaccharide Protects Against Intestinal Epithelial Injury in IBD via Inhibiting Cuproptosis in Caco-2 Cells**
Sihui Zou (The First Affiliated Hospital of Soochow University, China)
- EP-270 Music Suppresses Intestinal Inflammation as a Novel Histone Methylation Modulator**
Dong Yan (Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, China)
- EP-273 ZNF267 Attenuates Intestinal Epithelial Inflammation Through TRIM28-dependent SUMOylation**
Fangyuan Liu (Shanghai Jiao Tong University School of Medicine, China)

- EP-274 Differential Analysis of Ulcerative Colitis Based on Non-Targeted Metabolomics**
Wenli Fu (People's Hospital of Xinjiang Uygur Autonomous Region, China)
- EP-275 Clostridium butyricum Regulates T-Helper 17 Cells-Related Immune Response in Dextran Sodium Sulfate-Induced Colitis Mice by Targeting Toll-Like Receptor 2**
Ying Xie (Shengjing Hospital of China Medical University, China)
- EP-277 The Environmental-Gut Axis: Cold Adaptation Mitigates IBD Progression via Parallel Ileal Antimicrobial Defense and Colonic Stem Cell Regeneration**
Yuzhu Di (The Second Affiliated Hospital of Harbin Medical University, China)
- EP-278 FDPS Regulates Apoptosis and Autophagy of Intestinal Epithelial Cells in Ulcerative Colitis**
Guangxi Zhou (Affiliated Hospital of Jining Medical University, China)
- EP-279 DAP12 Deficiency Alleviates Intestinal Inflammation by Regulating Mitochondrial Homeostasis in Macrophages**
Guangxi Zhou (Affiliated Hospital of Jining Medical University, China)
- EP-280 Single-Cell Sequencing Analysis of the Interaction Between B Lymphocytes and Regulatory T Cells in Patients with Crohn's Disease.**
Chuyue Zhong (The First Affiliated Hospital of Wenzhou Medical University, China)
- EP-282 Hypoxanthine Aggravates DSS-Induced Colitis and Associated Anxiety/Depressive Behaviors in Mice**
Ruifang Luo (Chongqing General Hospital, Chongqing University, Chongqing, China, China)
- EP-283 Metaproteomics and Crotonylation in Gut Microbial and Its Alterations During Fecal Microbiota Transplantation for the Treatment of Ulcerative Colitis**
Xin Liu (First Affiliated Hospital of Kunming Medical University, China)
- EP-284 Single-Cell Sequencing Analysis of Fibroblast Subset Heterogeneity in Inflammatory Bowel Disease**
Shihao Duan (Chongqing General Hospital, Chongqing University, China)

- EP-285 Epithelial DUOX2-Driven Oxidative Stress Remodels the Gut Redox Niche to Shape Dysbiosis in Crohn's Disease**
Rui Feng (The First Affiliated Hospital of Sun Yat-sen University, China)
- EP-287 Sleep Disturbance as a Factor in Intestinal Inflammation**
Kohei Kiso (Tohoku University School of Medicine, Japan)
- EP-289 The Role and Mechanism of Aerobic Exercise on Improving DSS-induced Intestinal Inflammation by Regulating Mitophagy Through AMPK-SIRT1-FOXO1 Pathway**
Fang Xiao (Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, China)
- EP-290 Remodeling the Apical Brush Border: The TRPV1/ATF3/CALML4 Axis Stabilizes the Intermicrovillar Adhesion Complex and Drives Deep Mucosal Healing in Ulcerative Colitis**
Yuzhu Di (The Second Affiliated Hospital of Harbin Medical University, China)
- EP-291 EPS Deficiency Aggravates Intestinal Mucosal Inflammation and Microbiota Disruption Through Restoring Macrophage Polarization Balance in Ulcerative Colitis**
Fengqin Zhu (Affiliated Hospital of Jining Medical University, China)
- EP-294 Metagenomic Characterization of the Gut Microbiota in Ulcerative Colitis Patients from Xinjiang**
Aizizai Palihati (Xinjiang Uygur Autonomous Region People's Hospital, China)
- EP-296 HMGCS2 Alleviates Ulcerative Colitis by Inhibiting Mitochondrial Apoptosis via Ketone Body Metabolism**
Wan Yuhong (The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan Province, China, China)
- EP-298 Metabolic Plasticity in *Fusobacterium nucleatum* Rewires Sulfur Metabolism to Elevate H₂S and Exacerbate Colitis**
Xiaochen Zhu (The First Affiliated Hospital, Sun Yat-sen University, China)
- EP-299 Targeting PPAR Signaling-Mediated Lipid Metabolism in Macrophages Attenuates Colitis**
Xin Wang (Tianjin Medical University General Hospital, China)
- EP-300 Microbiome Diversity and Taxonomic Differences in Quiescent Ulcerative Colitis: A Comparative Study of Proximal Extension**
Sung Hoon Jung (The Catholic University of Korea, Korea)

- EP-301 Therapeutic Effects of Umbilical Cord Mesenchymal Stem Cells on Ulcerative Colitis**
Qinpei Zhang (First Affiliated Hospital of Soochow University, China)
- EP-302 Active Targeted Delivery of Magnetic-Driven Micro-Nanorobots Alleviates Ulcerative Colitis by Penetrating Mucus Barrier and Inhibiting Epithelial Ferroptosis**
Yuzhu Di (The Second Affiliated Hospital of Harbin Medical University, China)
- EP-304 The Role of Aeromonas Species as Enteropathogens in Patients with IBD**
Daein Kim (Department of Internal Medicine, Hallym University Kangdong Sacred Heart Hospital, Korea)
- EP-307 HDAC3 Promotes mtDNA Leakage to Activate cGAS/STING Signaling and Worsen Intestinal Barrier Injury in Ulcerative Colitis**
Yuan Xia (West China Hospital, Sichuan University, China)
- EP-311 Necroptosis in Inflammatory Bowel Disease: Mechanisms, Immune Amplification, and Therapeutics**
Wanyu Bao (The First Affiliated Hospital of Soochow University, China)

IBD: Pediatric

- EP-313 Exploratory Analysis of Vedolizumab Trough Levels in Pediatric-Onset Ulcerative Colitis**
Tae Jong Jeong (Samsung Medical Center, Korea)
- EP-314 Monitoring CT-P17 (Yuflyma) Drug Levels and Remission Rates in Pediatric Crohn's Disease: A Single Center Observational Preliminary Study**
Yoon Zi Kim (Samsung Medical Center, Korea)
- EP-315 Proactive TDM-Guided Infliximab Induction in Pediatric Ulcerative Colitis: Results from a Multicenter Randomized Trial**
Seon Young Kim (Kyung Hee University Hospital, Kyung Hee University College of Medicine, Korea)

EP-316 Impact of Body Mass Index Changes on Perianal Disease Outcomes in Korean Children with Crohn's Disease: A Retrospective Cohort Study

Hansol Kim (Samsung Medical Center, Sungkyunkwan University School of Medicine, Pusan National University Children's Hospital, Pusan National College of Medicine, Korea)

EP-319 Treatment Withdrawal and Relapse in a Pediatric Patient with Inflammatory Bowel Disease

Temuulen Byambadorj (National center for Maternal and Child Health, Mongolia)

EP-320 Distinct Gut Microbiota and Bile Acid Profiles in Pediatric Inflammatory Bowel Disease Versus Functional Gastrointestinal Disorders: Implications for Non-Invasive Differential Diagnosis

Xi He (Capital Center for Children's Health, Capital Medical University, Capital Institute of Pediatrics, China)

IBD: Surgery

EP-321 Correlation of Colectomy Pathology with Preoperative Colonoscopy in Patients with Inflammatory Bowel Disease

Hyun Seok Lee (School of Medicine, Kyungpook National University, Virginia Mason Medical Center, Korea)

EP-322 More Severe Natural Course of Crohn's Disease in Yunnan Province Compared with Asian and Western Countries

Yan Tao (The First Affiliated Hospital of Kunming Medical University, China)

IBD: Others

EP-323 Cognitive, Psychological, and Sleep Impairments in Inflammatory Bowel Disease

Yan Liu (Chongqing general hospital, China)

EP-324 Perceptions of Established Nutritional Therapies Among Patients with Crohn's Disease in Korea: A Chungcheong Association for the Study of Intestinal Disease (CHASID) Multicenter Study

Kwangwoo Nam (Dankook University Hospital, Korea)

- EP-325 Perception and Real-World Practice of Thromboembolism Prophylaxis in Inflammatory Bowel Disease Among Korean Gastroenterologists: A Web-Based National Survey**
Dae Sung Kim (Konyang University College of Medicine, Korea)
- EP-327 Clinical Characteristics and Treatment Outcomes of Pyoderma Gangrenosum in Inflammatory Bowel Disease in Korea**
Ji Yun Oh (Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Korea)
- EP-328 Clinical Characteristics of Chronic Intestinal Failure in Crohn's Disease Requiring Long-Term Parenteral Nutrition: A 20-Year Experience from a Single Tertiary Center**
Jung-Bin Park (Soonchunhyang University College of Medicine, Korea)
- EP-329 Clinical Characteristics and Disease Outcomes of 5-ASA-Induced Myocarditis in Inflammatory Bowel Disease: A Single-Center Retrospective Small Cohort Study**
Won Hee Lee (College of Medicine, Chosun University, Korea)
- EP-330 Clinical Spectrum and Diagnostic Considerations of Symptomatic Terminal Ileal Lesions: A Retrospective Analysis of 224 Cases**
Woo Jin Kim (Pusan National University Yangsan Hospital, Korea)
- EP-331 A Cost-Effective Novel Diagnostic Method for Detecting Pancreatic Exocrine Insufficiency in Patients with Inflammatory Bowel Disease**
Mustafa Kaplan (Sultan 2. Abdulhamid Han Training and Research Hospital, Türkiye)
- EP-332 Clinical Manifestations, Endoscopic Findings and Outcomes of Cytomegalovirus Colitis in Hospitalized Patients at a Single Tertiary-Care Center**
Natchaporn Noppacroh (Phramongkutklao hospital, Thailand)
- EP-333 The Role and Impact of the Inflammatory Bowel Disease Counsellor: A Qualitative Study on Patient Experiences, Communication Gaps, and Holistic Care Needs**
Arshia Bhardwaj (Dayanand Medical College and Hospital, India)
- EP-334 Tumor Necrosis Factor Alpha Inhibitors Reduce Staged Surgery Rate and Prevent Postoperative Endoscopic Recurrence in Crohn's Disease Patients**
Xiaomin Sun (Shanghai Tenth People's Hospital, China)

- EP-335 Risk Factor Analysis and Risk Assessment Model Development for Crohn's Disease with Metabolic Dysfunction-Associated Fatty Liver Disease in a Chinese Population**
Xueyun Zhang (Baoshan Branch, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, China)
- EP-336 Assessing Dietary Adequacy and Nutrition Status in Adults with Crohn's Disease**
Hui-Chuen Chen (National Taiwan University Hospital, Taiwan)
- EP-338 Physician Practices and Perceptions of Biosimilar Monoclonal Antibody Use in Inflammatory Bowel Disease: A Real-World Survey**
Yoo Jin Lee (Keimyung University School of Medicine, Korea)
- EP-339 Health-Related Quality of Life in a Southeast Asian Inflammatory Bowel Disease Cohort: A Single-Center Study**
Jia Hong Koh (National University Hospital, Singapore)
- EP-342 Factors Associated with Engagement in a Mini-AppBased Self-Management Platform for IBD**
Ye Chen (Baoshan Branch of Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, China)
- EP-345 A Case of Crohn's Disease Requiring Surgical Resection During Treatment with Ofatumumab for Multiple Sclerosis**
Yutaro Fujihira (Hyogo Medical University Hospital, Japan)
- EP-346 Cytomegalovirus Colitis in Patients with Inflammatory Bowel Disease on Upadacitinib: A Case Series**
Tuan Duong (Wollongong Hospital, Australia)
- EP-348 Cronkhite-Canada Syndrome: A Case Series of Diverse Outcomes from Complete Remission to Life-Threatening Complications at a Malaysian Tertiary Centre**
Wah Loong Chan (University Malaya Medical Centre, Malaysia)
- EP-349 Semen Discoloration Following Upadacitinib Therapy in Patients with Inflammatory Bowel Disease**
Jeong Hwa Lee (Asan Medical Center, Kyungpook National University Hospital, Korea)

EP-351 Secondary Amyloidosis Presenting as Nephrotic Syndrome in a Patient with Crohn's Disease: A Rare Extraintestinal Complication.

Nitin Rustogi (ABVIMS and RML Hospital, India)

Colorectal Neoplasia: Clinical - Epidemiology, Diagnosis and Prevention

EP-352 Impact of Position Change on Polyp Detection During a Second Look at the Right Colon: A Multicenter, Randomized Controlled Trial

Jiyoung Yoon (Kangdong Sacred Heart Hospital, Hallym University College of Medicine, Korea)

EP-353 Characteristics of Colorectal Cancer Detected by Screening Methods in Older Population: A Nationwide Cohort Study

Jaeyoon Yeom (Yonsei Univ. Wonju College of Medicine, Korea)

EP-355 Clinical Predictors of Colorectal Cancer in Patients with Hematochezia Undergoing Colonoscopy: A Retrospective Study in Eastern Indonesia

Resha Dermawansyah Rusman (Hasanuddin University, Indonesia)

EP-356 Association Between Metabolic Syndrome and Histological Subtypes of Colorectal Adenomas: A Single-Center Retrospective Study

Delgertsog Gantumur (Intermed Hospital, Mongolia)

EP-357 Colorectal Cancer Risk in Ulcerative Colitis: A Decade-Long Real-World Cohort from Southern India

Kiran Josy Kanjamala (Lisie Hospital, India)

EP-359 Demographic and Metabolic Difference Between Left-Sided Colorectal Cancer (LCRC) and Right-Sided Colorectal Cancer (RCRC) Initially Diagnosed in Health Check Up

You Kyoung Lee (Healthcare Research Institute, Seoul National University Hospital Healthcare System Gangnam Center, Korea)

EP-360 Diagnostic Value of i-SCAN with JNET Classification for Predicting Histology of Colorectal Polyps Under 10 mm: A Single-Center Study in Vietnam

Dat Le Ba Ho (An Binh Hospital, Vietnam)

- EP-361 Serum Trefoil Factor Family 3 as an Effective Biomarker for the Detection of Early Colorectal Cancer**
Hyun Seok Lee (School of Medicine, Kyungpook National University, Korea)
- EP-362 Determinants of Colorectal Cancer Screening Intention Among Russian Adults: The Central Role of Self-Efficacy**
Iuliia Movsesova (Inje University, Korea)
- EP-363 Unusual Presentations of Gastrointestinal Stromal Tumors of Rectum: A Case Series**
Arvind Ahuja (Atal Bihari Vajpayee Institute of Medical Science and Dr. Ram Manohar Lohia Hospital, India)
- EP-365 Colorectal Neoplasia Screening Collapse After Out-of-Pocket Price Shocks Widens Age and Geographic Inequity, Leaving Older Adults in Peripheral Districts with Lower Uptake and More Advanced Lesions at Diagnosis**
Irish Merlyn Alvarez (National University of Dasmarinas, Philippines)
- EP-366 Study on the Correlation Between Histopathological Diagnosis Following Colonic Polypectomy and Adenoma Detection Rate (ADR)**
Munkhchimieg Damdinsuren (General hospital for state special servants, Mongolia)

Colorectal Neoplasia: Clinical - Treatment and Prognosis

- EP-367 Optimal Endoscopic Treatment for Rectal Neuroendocrine Tumors, Confirmed After Forceps Biopsy: A Korean Association for the Study of Intestinal Diseases Multicenter, Randomized Non-Inferiority Trial**
Tae-Geun Gweon (College of Medicine, The Catholic University of Korea, Korea)
- EP-368 Comparative Efficacy of Hemoclipping and Snare Tip Soft Coagulation for Prevention of Post-Polypectomy Bleeding: A Chungcheong Association for the Study of Intestinal Disease (CHASID) Multicenter Study**
Geunhyuk Choi (Soonchunhyang University College of Medicine, Korea)

- EP-369 Optimizing Indications and Diagnostic Performance of Computed Tomography Angiography in Acute Gastrointestinal Bleeding: A Large Cohort Study**
Hye Kyung Hyun (Yonsei University College of Medicine, Yonjin Severance Hospital, Korea)
- EP-370 The Effectiveness and Safety of Endoscopic Submucosal Dissection for the Treatment of Rectal Gastrointestinal Stromal Tumors: A Pilot Feasibility Study**
Jae Woong Kim (College of Medicine, Chosun University, Korea)
- EP-371 Clinical Characteristics, Treatment Patterns, and Recurrence of Colorectal Mucosa-Associated Lymphoid Tissue Lymphoma: A HASID Multicenter Study**
Byung Chul Jin (Jeonbuk National University, Korea)
- EP-372 Chemotherapy Exposure and Crude Mortality in Early-Onset Colorectal Cancer: A Population-Based SEER Analysis**
Zavia Putri Salsabila (Universitas Islam Indonesia, Indonesia)
- EP-373 Endoscopic Submucosal Dissection of Very Large Early Colorectal Cancer (>4 cm)**
Kwangwoo Nam (Dankook University Hospital, Korea)
- EP-375 Comparative Clinical Outcomes of Various Colorectal Endoscopic Submucosal Dissection Techniques: A Systematic Review and Network Meta-Analysis**
Seung Min Hong (Pusan National University Hospital, Korea)
- EP-376 Efficacy and Safety of Radiofrequency Ablation for Hemorrhagic Radiation Proctitis: A Retrospective Cohort Study**
Lingling Xu (Affiliated Hospital of Jiangnan University, China)
- EP-377 Effect of Negative Pressure Wound Therapy on Surgical Wound Outcomes in Colorectal Cancer Surgery Patients: A Systematic Review and Meta-Analysis.**
Mohamed Elkasaby (Faculty of Medicine, Al-Azhar University, Egypt)
- EP-378 Rectal Neuroendocrine Tumors Case Report**
Sugarmaa Purevsuren (Central Hospital of MNUMS, Mongolia)

Colorectal Neoplasia: Basic / Translational / Microbiome

- EP-380 In vitro Immune Prediction Model for Early Tumorigenesis in Lynch Syndrome Using Colon Organoids and Autologous Immune Cells**
Hyonee Lee (Yonsei University College of Medicine, Korea)
- EP-381 Elucidating the Role of CP1-mediated G1/S Cell Cycle Arrest in Colorectal Cancer Cells**
Sihyun Jeong (Pusan National University, Korea)
- EP-382 MUC13 Expression Is Associated with an Immune-Active Tumor Microenvironment via the KLF4 Axis in Colorectal Cancer.**
Seung Wook Hong (Asan Medical Center, University of Ulsan College of Medicine, Korea)
- EP-384 Unveiling Cathepsin E: A Key Driver of Colorectal Cancer Progression and Immune Evasion.**
Huan Zhang (The First Affiliated Hospital of Soochow University, China)
- EP-385 Investigating the Role of a Novel Phosphorylation Site on SOX2 in Colorectal Cancer**
Dong Keon Kim (Institute of Gastroenterology, Severance Hospital, Yonsei University College of Medicine, Korea)
- EP-387 Desulfovibrio vulgaris Flagellin Enhances Metabolite TDA-Driven KDM2A Epigenetic Remodeling to Promote Colorectal Cancer**
Yadi Lan (Tianjin Medical University General Hospital, China)

Colorectal Neoplasia: Others

- EP-390 Multi-Omics Identification and Functional Validation of STK17A as a Regulator of TRAIL Sensitivity in Colorectal Cancer**
Se Lim Kim (Research Institute of Clinical Medicine of Jeonbuk National University, Biomedical Research Institute of Jeonbuk National University Hospital, Korea)

- EP-391 A Comprehensive Analysis of the Diagnostic Process of Lynch Syndrome in Korea: A 10-Year Retrospective Study at a Tertiary Hospital**

Jung-Bin Park (Soonchunhyang University College of Medicine, Korea)

- EP-394 Clinicopathological Features and Modifiable Risk Factors of Colorectal Polyps: A Single-Center Study from Mongolia**

Suvdantsetseg Borkhuu (General hospital of Special State Servants, Mongolia)

- EP-395 Endoscopic Resection of a Sigmoid Colon Inflammatory Myofibroblastic Tumor in a Patient with Ulcerative Colitis: A Rare Case Report**

Delgertsog Gantumur (Intermed hospital, Mongolia)

Small Bowel Disease / Nutritional / Functional Disorder

- EP-396 Optimizing Clinical Management to Prevent Candidemia in Patients Receiving Total Parenteral Nutrition via Peripherally Inserted Central Catheters: A 10-Year Retrospective Cohort Study**

Jung Hwan Lee (Inha University Hospital, Inha University Hospital, Korea)

- EP-397 Altered Serum Microelement Profiles and Their Association with Disease Activity in Taiwanese Patients with Crohn's Disease**

Tien-Yu Huang (Tri-Service General Hospital, National Defense Medical University, Taiwan)

- EP-400 Validation of Prediction Models for Obscure Gastrointestinal Bleeding**

Sung Chul Park (Kangwon National University College of Medicine, Korea)

- EP-402 Early Clinical Impact of Double-Balloon Enteroscopy for Small-Bowel Disease in Mongolia**

Tsevelnorov Khurelbaatar (Mongolian National University of Medical Sciences, Mongolia Japan Hospital of Mongolian National University of Medical Sciences, Mongolia)

- EP-403 Why Do Patients with Inflammatory Bowel Disease Avoid Certain Foods? A Systematic Review**

Nazihah Wafi (University of Malaya, Malaysia)

- EP-404 Hemostasis of Refractory Small Bowel Angiodysplasia Bleeding Using Enteroscopy-Guided Argon Plasma Coagulation (APC): A Longitudinal Case Study**
 Uyanga Bilegt (First Central Hospital of Mongolia, Mongolia)

Artificial Intelligence

- EP-405 Evaluation of a Retrieval-Augmented Generation-Based Large Language Model for Dietary Counseling in Patients with Inflammatory Bowel Disease**
 Jae Gon Lee (Hanyang University Guri Hospital, Korea)
-  **EP-406 Artificial Intelligence-Enhanced Video Capsule Endoscopy for Detecting Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis of Diagnostic Accuracy**
 Mohamed Hamouda Elkasaby (Faculty of Medicine, Al-Azhar University, Egypt)
-  **EP-408 AI-Based Stochastic Epigenetic Modeling Distinguishes Low- and High-Grade Colorectal Adenomas**
 Javad Alizargar (National Taipei University of Nursing and Health Sciences, Taiwan)
- EP-412 Optimization of Machine Learning-Based Prediction for Adverse Events After Colonoscopy in the Elderly: A Multicenter Retrospective Study.**
 Min-Jae Kim (Yonsei University College of Medicine, Korea)
- EP-413 MRI-Based Radiomics Analysis for the Diagnosis of PFCD: An Artificial Intelligence Approach**
 Yu Xiang (The Affiliated Hospital of Nanjing University of Chinese Medicine, China)
- EP-414 An Ordinal Deep Learning Framework for Automated Endoscopic Grading of Crohn's Disease**
 Yujie Zhou (Zhongshan hospital of Xiamen University, Xiamen University, China)

Others

- EP-419 Potential and Limitations of Pre-Transplant Gut Microbiome Profiles for Predicting Acute GVHD After Allogeneic HSCT**
 Yujin Hyun (Kyungpook National University, Korea)

- EP-420 Clinical Outcomes of Endoscopic Vacuum Therapy for Gastrointestinal Leakage, Perforation, and Fistula: A Single-Center Experience**
Seung Min Hong (Pusan National University Hospital, Korea)
- EP-421 Metabolomic Shifts in Blood and Feces Following Fecal Microbiota Transplantation**
Jung Newv (Inha University Hospital, Inha University Hospital, Korea)
- EP-422 Endoscopic Features and Clinical Course of Immune-Related Colitis After Durvalumab Plus Tremelimumab Therapy for Hepatocellular Carcinoma: A Single-Center Retrospective Study**
Kanako Higaki (Department of gastroenterology and hepatology, Japan)
- EP-423 Clinical Efficacy of Macrolide Antibiotics in Autoinflammatory Diseases with Gastrointestinal Involvement: A Retrospective Study**
Jiahui Zeng (The First Affiliated Hospital of Sun Yat sen University, China)
- EP-424 Occupational Risk Factors and Health Status Among Endoscopy Physicians and Staff: Results of a Questionnaire Survey**
Amarjargal Enkhbold (Chinggis Avenue 41, Khan-Uul District, Ulaanbaatar 17040, Mongolia, Mongolia)
- EP-427 Oral Sulfate Solution in Obese Patients as Preparation for Colonoscopy: A Prospective, Multicenter Trial**
Hyun Seok Lee (School of Medicine, Kyungpook National University, Korea)
- EP-429 Revisiting Goodsall's Rule in Complex Anterior Fistula-in-Ano in Immunocompromised Patients: Changing the Treatment Armamentarium of Surgeons**
Aini Ibrahim (Universiti Malaysia Sarawak, Sarawak General Hospital, Malaysia)
- EP-433 Studying the Significance of Brown Slits Sign in Colon Adenoma Using NBI and Magnification Function of OLYMPUS X1**
Bilguun Jargalsaikhan (Central Hospital of MNUMS, Mongolia)

- EP-434 A Case of Pediatric Eosinophilic Esophagitis with IgE-mediated Allergic Response to Probiotics**
Hyo-Jeong Jang (School of Medicine Keimyung University, Dongsan Medical Center, Korea)
- EP-435 Eosinophilic Gastrointestinal Disease with Ascites Mimicking Crohn's Disease in a Patient with Prior Intestinal Tuberculosis: A Case Report**
 Phat Luu (Tam Anh General Hospital, Vietnam)
- EP-436 Case Report: Rectal Neuroendocrine Tumor Treated with Endoscopic Submucosal Dissection at Nguyen Trai Hospital**
Thi Xuan Dung Do (Nguyen Trai Hospital, Vietnam)
- EP-437 Phytochemical Analysis of the Traditional Medicine Khamba TD-8 Used for Inflammatory Bone Diseases**
Sarana Enkhsaikhan (Otoch Manramba University, Mongolia)
- EP-438 Gastrointestinal Amyloidosis: Diagnostic and Therapeutic Challenges in Vietnam**
 Toan Dang Vo (Tam Anh general hospital, Vietnam)
- EP-439 "Severe Hypoalbuminemia and Polyserositis as Rare Complications of Pseudomembranous Colitis: A Case Report"**
Misheel Boldbaatar (Second Central Hospital of Mongolia, Ulaanbaatar, Mongolia, Mongolia)
- EP-440 Dasatinib-Associated Gastrointestinal Toxicity: A Case Series and Review**
Shyn Yi Tan (Singapore General Hospital, Singapore)

ONCE-DAILY PILL IN CD & UC*

FAST. DURABLE.
MUCOSAL HEALING.^{1-5*†}



***INDICATION** RINVOQ® should be used only in patients who have had an inadequate response or were intolerant to prior therapy in the following populations: Patients aged ≥ 65 years. Patients at high cardiovascular risk. Patients at risk of malignancy. **[CD]** RINVOQ® is indicated for the treatment of adult patients (≥ 18 years) with moderately to severely active Crohn's disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent. **[UC]** RINVOQ® is indicated for the treatment of adult patients (≥ 18 years) with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

***Fast:** CD, CR-100 [clinical response: 100% decrease of ≥ 100 points in the Crohn's Disease Activity Index score from baseline] at Induction Week 2 (U-EXCEL: $p = 0.002$, U-EXCEED: $p < 0.001$).¹ UC, Clinical response per partial adapted Mayo score a decrease in Partial Adapted Mayo score of ≥ 1 point and $\geq 30\%$ from baseline, and a decrease in RBS of ≥ 1 point or an absolute RBS of ≤ 1 at Induction Week 2 ($p < 0.0001$).² ***Durable:** CD, Maintenance of clinical remission [SF/APA clinical remission was defined as an average daily frequency of very soft or liquid stools of 2.8 or less and an average daily abdominal pain score of 1.0 or less, with both not greater than baseline at Week 52 ($p < 0.0001$);³ UC, Maintenance of clinical remission [clinical remission per Adapted Mayo score at week 52 in those who achieved clinical remission at the end of the induction studies at Week 52 ($p < 0.0001$);⁴ ***Mucosal healing:** Mucosal healing (defined as SES-CD ulcerated surface subscore of 15 in patients with SES-CD ulcerated surface subscore 1 at baseline at Week 12 ($p < 0.001$) and at Week 52 (nominal $p < 0.001$)).⁵

[Study design] In two phase 3 induction trials (U-EXCEL and U-EXCEED) we randomly assigned patients with moderate-to-severe Crohn's disease to receive 45 mg of upadacitinib or placebo (2:1 ratio) once daily for 12 weeks. Patients who had a clinical response to upadacitinib induction therapy were randomly assigned in the U-ENDURE maintenance trial to receive 15 mg of upadacitinib, 30 mg of upadacitinib, or placebo (1:1:1) once daily for 52 weeks. The primary end points for induction (week 12) and maintenance (week 52) were clinical remission and endoscopic response. A total of 526 patients underwent randomization in U-EXCEL, 495 in U-EXCEED, and 502 in U-ENDURE.

[Study design] This phase 3, multicentre, randomised, double-blind, placebo-controlled clinical programme consisted of two replicate induction studies (U-ACHIEVE induction [UC1] and U-ACCOMPLISH [UC2]) and a single maintenance study (U-ACHIEVE maintenance [UC3]). The studies were conducted across Europe, North and South America, Australasia, Africa, and the Asia-Pacific region at 199 clinical centres in 39 countries (UC1), 204 clinical centres in 40 countries (UC2) and 195 clinical centres in 35 countries (UC3). Patients aged 16-75 years with moderately to severely active ulcerative colitis [Adapted Mayo score 5-9; endoscopic subscore 2 or 3] for at least 90 days were randomly assigned (2:1) to oral upadacitinib 45 mg once daily or placebo for 8 weeks [induction studies]. Patients who achieved clinical response following 8-week upadacitinib induction were re-randomised (1:1:1) to upadacitinib 15 mg, upadacitinib 30 mg, or placebo for 52 weeks [maintenance study]. All patients were randomly assigned using web-based interactive response technology. The primary endpoints were clinical remission per Adapted Mayo score at week 8 (induction) and week 52 (maintenance). Between Oct 23, 2018, and Sept 7, 2020, 474 patients were randomly assigned to upadacitinib 45 mg once daily ($n = 319$) or placebo ($n = 155$) in UC1. Between Dec 6, 2018, and Jan 14, 2021, 522 patients were randomly assigned to upadacitinib 45 mg once daily ($n = 345$) or placebo ($n = 177$) in UC2. In UC3, a total of 451 patients (21 from the phase 2b study, 278 from UC1, and 152 from UC2) who achieved a clinical response after 8 weeks of upadacitinib induction treatment were randomly assigned again to upadacitinib 15 mg ($n = 148$), upadacitinib 30 mg ($n = 154$), and placebo ($n = 149$) in the primary analysis population.

References 1. RINVOQ® 15mg 제품설명서 [개정년월일: 2026년 2월 3일]. RINVOQ® 30mg 제품설명서 (개정년월일: 2026년 2월 3일). 2. Loftus EV Jr; et al. N Engl J Med. 2023;388(21):1966-1980. 3. Danese S, et al. Lancet. 2022;399(10341):2113-2128.

※ 최신 전체 제품정보는 QR code 또는 제품설명서를 참조하십시오.
[수입원/판매처] 한국에브비(주) 서울특별시 강남구 영동대로 421 삼탄빌딩 6층
의약품 부작용 신고 및 피해구제 신청: 한국약물안전센터 (1644-6223 또는 14-3330, www.drugsafe.or.kr)

린브코 서방정 15mg
(유파다시티닙반수화물)
제품설명서

린브코 서방정 30mg
(유파다시티닙반수화물)
제품설명서



abbvie

한국에브비(주) 서울특별시 강남구 영동대로 421 삼탄빌딩 6층
전화: [02] 3429-9300, www.abbvie.co.kr

KR-RNQG-260098 / May 2026



People. Passion. Possibilities.®

애브비는 환자, 지역사회 및
세상을 돕는 의약품과 솔루션을
개발하여 사람들의 삶을
변화시키는 데 전념하고 있습니다.

EPYZTEK[®]

130mg

90mg

(Ustekinumab)



에피즈텍[®]
정맥주사
Epyztek IV injection
130mg



에피즈텍[®]
프리필드주
Epyztek Pre-filled syringe
90mg

For detailed product information,
please scan the QR code.

*For detailed information about the product, please refer to the product manual
linked through the QR code, which can also be viewed on the website below.
(samsungbiopharm.com/kr)

SAMSUNG

삼성바이오에피스

[SBMA_2024_07_08_509_E]

Remaloce™ 100 mg

(Infliximab)



레마로체™
Remaloce

For detailed product information,
please scan the QR code.

The detailed instructions about the product, Remaloce, is the product insert of Remaloce (100 mg vial), and you can see the insert in the package insert.

SAMSUNG

삼성바이오페이스

GO
BEYOND

- ✓ **DUAL FORMULATION INFLIXIMAB¹**
- ✓ **LONG-TERM CLINICAL REMISSION WITH INFLIXIMAB SC²**

References

1. 셀트리온바이오. 신약 허가사항 (<https://nedrug.mfds.go.kr/bpb/CCBB001/getItemDetailCache?cacheSeq=202203940updateTs2026-02-10%24:31:10.00>) accessed on 26.03.10




Because

YU Matter

The First High-Concentration Adalimumab Biosimilar

With proven outcomes, reduced pain, and improved convenience, Yuflyma™ offers patient-centric treatment for your patients.^{1,2}

1. 유플라이마(40mg/0.4mL, 식약처 허가사항(제25년)발달 2021. 10. 15) 2. Koy J. et al. (Nov. 2020). A Randomized, Double-Blind, Phase 3 Study to Compare the Efficacy and Safety of a Proposed High Concentration (100 mg/mL) Adalimumab Biosimilar (CT-P17) with Reference Adalimumab in Patients with Moderate-to-Severe Active Rheumatoid Arthritis. [Poster presentation], ACR Convergence 2020.



LASTING REMISSION ISN'T EVERYTHING. IT'S THE ONLY THING.^{1,2}

For rapid response and ongoing remission, STELARA® can be your first — choice biologic for adult patients with moderately to severely active Crohn's disease or ulcerative colitis.

References 1. Sandborn WJ, et al. *Clin Gastroenterol Hepatol*. 2022;20(3):578-590.e4. 2. Afif W, et al. *Am J Gastroenterol*. 2024 May 1;119(5):910-921.



스텔라라®에 대한 자세한 정보는
상기의 QR code 접속을 통해
확인하실 수 있습니다.

Johnson & Johnson
Innovative Medicine

서울특별시 용산구 한강대로 92 LS용산타워 25층
Tel. 02.2094.4500 | www.janssen.com/korea



CP-354815 11/27/2025



What if you could get to the root of IL-23 inflammation?¹⁻³

TREMFYA® is the only **dual-acting** IL-23 inhibitor designed to neutralize inflammation at its cellular source^{1-3*}
TREMFYA® works by **BLOCKING IL-23**,
a cytokine responsible for inflammation,^{2,3}
and **BINDING to CD64**, a receptor on cells that produce IL-23²

• Based on in vitro studies in an inflammatory monocyte model.² The clinical significance of these findings is unknown.
CD64+ cells are the predominant source of IL-23 in UC. Cells not expressing CD64 may also contribute to IL-23 production but to a lesser extent.^{2,4}
*“Only” based on approved selective IL-23 inhibitors for ulcerative colitis (UC) and Crohn’s disease (CD) as of April 2026.^{1,2,5,6}

For illustrative purposes only.

CD64, cluster of differentiation 64; **IL-23**, interleukin 23.

References 1. TREMFYA® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc. 2. Sachen KL, et al. *Front Immunol.* 2025;16:1532852. 3. Sewell GW, et al. *J Crohns Colitis.* 2022;16(suppl 2):ii3-ii19. 4. Krueger JG, et al. *Front Immunol.* 2024;15:1331217. 5. Skyrizi® [Prescribing Information]. North Chicago, IL: AbbVie Inc. 6. Omvoh® [Prescribing Information]. Indianapolis, IN: Eli Lilly and Company.

**Johnson&Johnson
Innovative Medicine**

(주)한국안센, 존슨앤드존슨 제약부문 법인
서울특별시 용산구 한강대로 92 LS 용산타워 25층
Tel: 02.2094.4500
<https://innovativemedicine.jnj.com/korea/>

제품 관련 자세한 정보는 하단의 QR코드를 통해 확인하실 수 있습니다.



트렘피어®
프리미엄 시린지주



트렘피어®
원프레스오토인젝터주



트렘피어®
정맥주사

HELP YOUR PATIENTS
Enjoy the Silence
OF LONG-TERM REMISSION IN UC/CD

Kynteles® can help your patients achieve the silence of:



- **Symptom improvement as early as Week 2** vs placebo in UC and CD^{2†}
- **Visible mucosal healing at Week 52** vs adalimumab in UC and open label, no comparison study in CD^{3,4,5}
- **Long-term remission at Week 52** vs adalimumab in UC and placebo in CD^{5,6,7}

CD, Crohn's disease; CDAI, Crohn's disease activity index; CI, confidence interval; Q4W, every 4 weeks; Q8W, every 8 weeks; RHI, Roberts Histopathology Index; TNFα, tumour necrosis factor-α; UC, ulcerative colitis.

² Post hoc exploratory analysis. Symptomatic improvement in UC (composite score of rectal bleeding and stool frequency) 19% at Week 2 with Kynteles® (n=225) vs 10% with placebo (n=149) (95% CI: 2.0-16.1%). Symptom improvements in CD (combined abdominal pain and loose stool frequency score) -14.2% at Week 2 with Kynteles® vs -7.2% (95% CI: -11.0 to -2.9%).²

³ Post hoc exploratory analysis. Mucosal healing in UC (composite outcomes of histologic remission or minimal histologic disease activity and endoscopic improvement [defined as a Mayo endoscopic subscore of ≤1 point]) Geboes grade <2: 25.6% with Kynteles® vs 6.7% with adalimumab; p<0.0001; RHI ≤2: 30.5% vs 14.5%, respectively, nominal p<0.0001. Study limitations included gut variability in histopathologic severity due to diffuse mucosal inflammation in UC and a lack of patient long-term follow-up.³

⁴ Phase 3b open-label study with no comparator arm. Complete mucosal healing in CD (the absence of any ulcers, including aphthae) 17.9% with Kynteles® (n=10/56). A protocol amendment during the study required analysis of two study populations (a 26-week primary and a 52-week sub-study population).⁴

⁵ Clinical remission in UC (total Mayo Score ≤2 points and no individual subscore >1 point) 31.3% at Week 52 with Kynteles® (n=120/383) vs 22.5% with adalimumab (n=87/386); p=0.006.⁵

⁶ Clinical remission in CD (CDAI ≤150) 39% and 36% with Kynteles® at Week 52 (Q8W n=60/154 and Q4W n=56/154, respectively) vs 22% with placebo (n=33/153); p<0.001 and p<0.05 vs placebo, respectively.⁶

STUDY DESIGN

VARITY: Patients in VARITY were randomized 1:1 to maintenance with vedolizumab IV 300 mg every 8 weeks or adalimumab SC 40 mg every 2 weeks to compare clinical remission and endoscopic improvement in ulcerative colitis.

GEMINI 1, 2, 3: Eligible patients were aged 18-80 years and had UC for 6 months with a Mayo Clinic Score (MCS) of 6-12 points and endoscopic subscore of 2 in GEMINI 1, or had CD for 3 months and a Crohn's disease activity index (CDAI) score of 220-450 in GEMINI 2 and 3. Patients were randomized to induction treatment for 6 weeks (GEMINI 1 and 2) or 10 weeks (GEMINI 3) and received 300 mg intravenous vedolizumab or placebo at Weeks 0 and 2 (GEMINI 1 and 2) or Weeks 0, 2, and 6 (GEMINI 3).

REFERENCES

1. Takeda Data on File 2, Feagan BG, et al Rapid Response to Vedolizumab Therapy in Biologic-Naïve Patients With Inflammatory Bowel Diseases. *Clin Gastroenterol Hepatol* 2019 Jan;17(1):130-138.e7. 3. Peyrin-Biroulet L, et al Histologic Outcomes With Vedolizumab Versus Adalimumab in Ulcerative Colitis: Results From An Efficacy and Safety Study of Vedolizumab Intravenous Compared to Adalimumab Subcutaneous in Participants With Ulcerative Colitis (VARITY). *Gastroenterology* 2021 Oct;161(4):1156-1167.e3. 4. Damese S, et al Endoscopic, Radiologic, and Histologic Healing With Vedolizumab in Patients With Active Crohn's Disease. *Gastroenterology* 2019 Oct;157(4):1007-1018.e7. 5. Sands BE, et al Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis. *N Engl J Med* 2019 Sep 26;381(13):1215-1226. 6. Kynteles® 주, Kynteles® 프리필드펜 주 제품 설명서, available at <https://nedrug.mfds.go.kr/index>, accessed on Mar 6, 2026.



킨텔레스®(베들리주맙) 주

제품설명서

제품설명서 전문은 식약처 의약품 안전나라의 제품허가사항 또는 QR 코드를 참고하시기 바랍니다.



킨텔레스®(베들리주맙) 프리필드펜 주

제품설명서

제품설명서 전문은 식약처 의약품 안전나라의 제품허가사항 또는 QR 코드를 참고하시기 바랍니다.



한국제약제약(주) 서울특별시 송파구 올림픽로 300 롯데빌딩 37층 Tel: (02) 3484-0800

• 제품관련 의약품(학술)문의 Tel: 080-0931 / E-mail: medinfoAPAC@takeda.com

• 이상사례보고 AE.SouthKorea@takeda.com

Copyright© 2026 Takeda Pharmaceutical Company Limited. All rights reserved.

Takeda and the Takeda Logo are trademarks of Takeda Pharmaceutical Company Limited, used under license.

All trademarks are the property of their respective owners.

The information on this material is intended for healthcare professionals only



PENTASA®
MESALAZINE



HIGH FIVE PENTASA



The highest dose of 5-ASA
available in both oral and suppository
formulations in Korea¹⁻⁴

HIGH EFFICACY OF PENTASA® *5 WITH EASY HIGH-DOSE ADMINISTRATION^{6,7}

* High-dose Pentasa® ($\geq 4\text{g/day}$) significantly reduced the risk of UC relapse compared to low-dose ($2\sim 4\text{g/day}$)
(26.6% vs 62.5%, $p=0.04$, $\geq 4\text{g/day}$ is based on the induction dose)

Approved Indication Pentasa® Extended-Release Granules (1g, 2g): For the treatment of active ulcerative colitis in adults: Up to 4g per day, administered once daily or in divided doses (2 to 4 times per day). For maintenance therapy in adults: 2g once daily, taken orally. Pentasa® Suppository (1g): For the treatment of ulcerative colitis in adults: Insert one suppository into the rectum once daily.

REFERENCES 1. Pentasa® extended-release granules (2g) product information (2022.10.11) 2. Drug Safety Korea Drug Information Search, mesalazine single-agent search results, <https://nedrug.mfds.go.kr>, accessed on 25 Feb, 2025 3. Pentasa® suppositories product information (2018. 07. 25) 4. Korea Pharmaceutical Information Center, mesalazine suppository search results, <https://www.health.kr>, accessed on 25 Feb, 2025 5. West R, et al. J Gastrointest Liver Dis 2022;31(1):18-24. 6. Nakagawa S, et al., Digestion, 2019;99(2):133-139. 7. W Moon, et al., Journal of Crohn's and Colitis, Volume 18, Issue Supplement_1, January 2024, Pages i1049-i1051.

KR-GAS-2500015



Pentasa®
Prolonged-release
granule 2g



Pentasa®
Tablets 1g



Pentasa®
Suppositories 1g

Scan QR code for
full PI

FERRING
PHARMACEUTICALS

Korea Ferring Pharmaceuticals

Songpa-Gu, Olympic Ro 35-Gil, Korea Advertising Culture Center,
14th Fl. Seoul, Korea.

TEL. 02-534-2761 www.ferring.co.kr

A Novel Bowel Preparation Proven in a Phase 3 Trial

- Improved **Patient Compliance** with **Fewer Tablets**¹
- Favorable **Safety** Profile¹
- Proven **Bowel Cleansing Efficacy**¹

CLEANCOL® Tab.
Product Information

2026-159
CLCT.260511.N

Ref. > Park SB, et al. *World J Gastroenterol*. 2026;32(6):113880.

JAK1 Selective Action¹⁻³



 **Jyseleca®**
Filgotinib maleate

[References] 1. Traves PG, et al. *Ann Rheum Dis*. 2021;80(7):865-875. 2. Tanaka Y, et al. *Mod Rheumatol*. 2022;32(1):1-11. 3. 식품의약품안전처
의약품통합정보시스템 자선헤카정 100mg, 200mg 제품정보 <https://nedrug.mfds.go.kr/index> (accessed on April 03, 2025)



한국에자이주식회사

서울시 강남구 봉은사로 86길 6 빌딩 레베앙트 10층
TEL: 02-3451-5500 FAX: 02-3451-5599 www.eisai.co.kr

지셀레카정 100 mg



지셀레카정 200 mg



상세 제품 정보는 QR코드 또는 식품의약품안전처 의약품통합정보시스템
(<https://nedrug.mfds.go.kr/>)을 참조하여 주시기 바랍니다.



- UC, ulcerative colitis; S1P, sphingosine-1-phosphate

* ZEPOSIA® has indication that treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional (Treatment with corticosteroids, immunosuppressants, etc.) or a biologic agent. 제포시아®는 2023-02-29 기준 심중도~심각도 환자(아급성)에 허가된 바 있습니다. * 제포시아® 용량 변경 요율 17.3% [Symptomatic Response Rate] Symptomatic Response Rate (Symptomatic response is defined as a decrease from baseline of ≥1 point and ≥30% in the adapted partial Mayo score of the RBS, SFS, and Patient Global Assessment subscore) and a decrease of ≥1 point from baseline in RBS or an absolute RBS ≤1 point)

[SAFETY INFORMATION]

※ 처방하시기 전 식품의약품안전처 의약품통합정보시스템 (<https://oncd.mfds.go.kr>)을 통해 상세 제품 정보를 참조하시기 바랍니다.

계포시아® 제품 정보





GC 녹십자

GSK

IBD 환자의 앞길에 대상포진 예방의 손길을^{2,3}

IBD 환자에서 대상포진이 발생하면 감염 중증도 및 임상적 상황에 따라 면역억제 치료가 일시 중단, 지연될 수 있습니다.^{4,5}

50세 이상이거나, 면역억제 치료를 받고 있는 18세 이상의 환자에게
대상포진 예방을 위해

싱그릭스[®] 접종을 고려해주세요!

Shingrix

#싱그릭스 효능 효과

대상포진 (HZ, herpes zoster)의 예방

- 만 50세 이상의 성인

- 만 18세 이상에서 질병 혹은 치료로 인한 면역저하 또는 면역억제로 인하여 대상포진의 위험이 높거나 높을 것으로 예상되는 사람 (예, 자가면역질환, 이식, 고령인, 혈액, 고령자기 이식 환자)

[References] 1. 싱그릭스 제품설명서 2. Caldera F, et al. Clin Transl Gastroenterol. 2025 Nov 1;16(11):e00924. 3. Tseng HF, et al. Hum Vaccin Immunother. 2025 Dec;21(12):25769814. Kucharzik T, et al. J Crohns Colitis. 2021 Jun 22;15(6):879-913. 5. Cullen G, et al. Inflamm Bowel Dis. 2012;18(12):2392-2403.

[Integrated Safety Information] 1. 다음 환자에는 투여하지 말 것: 이 백신의 구성 성분에 과민반응이 있는 자 2. 다음 환자에는 신중히 투여할 것 1) 급성 중증 질환을 앓고 있는 자 (급성 중증 질환이란 또는 급성 감염이 있는 경우, 이 백신의 접종을 연기해야 한다. 감기와 같이 경미한 감염으로 이 백신의 접종을 연기할 필요는 없다.) 2) 혈소판 감소증이나 다른 혈액응고장애가 있는 환자(신속한지시) 출혈이 일어날 수 있으므로 주의하여 투여하여야 한다.) 3. 약물이상반응을 ①만 50세 이상의 성인 만 50세 이상 성인 17,000명에서 17명의 이상반응이 최소 1회 이 백신을 투여 받았다. 이 백신의 이상반응은 만 50세 이상 성인 20,200명에서 대상으로 조사한 2명의 주위 3명 이상 대조 대상자 200~500 (Zoster-008) 및 200~500 (Zoster-022)의 데이터를 통해 확인이 확인되었다. 시험대상자 0.2%의 주위 2명 이상에 대한 이 백신 (N = 14,645) 또는 위약 (N = 14,660)을 최소 1회 투여 받았다. 예상된 약물이상반응은 한 70세 이상 시험대상자에게 비해 만 50~69세 시험대상자에게서 주사부위 통증 및 종창, 피로, 근육통, 두통, 열, 발진 및 위장관이상 등의 발생률이 더 높았다. 이들 약물이상반응은 대부분은 오래 지속되지 않았다 (지속시간 2~3일), 중증 약물이상반응으로 보고된 반응은 1~2건만 지속되었다. ②만 18세 이상의 질병 혹은 치료로 인한 면역저하 또는 면역억제로 대상포진의 위험이 높거나 높을 것으로 예상되는 자 (이하 "면역저하" (immunocompromised)로 지칭함) 예상된 약물이상반응을 자가면역질환이 있는 환자 대상으로 한 연구 Zoster-002에서, 이 백신 투여 후 7일 이내 만 18~49세, 만 50세 이상에서 각각 보고된 예상된 국소 약물이상반응은 통증 (87.5%, 82.7%), 발진 (29.9%, 34.8%), 근육통 (20.5%, 18.0%)이었고, 예상된 전신 약물이상반응은 피로 (41.9%, 53.8%), 근육통 (57.8%, 52.4%), 두통 (43.9%, 30.1%), 위장관이상 (21.1%, 28.2%), 열 (31.4%, 24.8%) 그리고 열 (22.8%, 17.8%)이었다 (혈소판 감소증과 보고된 대상자의 비율을 기함). 4. 알레르기 주의 1) 이 백신을 함유한 모든 제제는 투여하지 않는다. 2) 이 백신은 수두의 예방을 목적으로 하지 않는다. 3) 다른 백신과 마찬가지로, 백신 접종 후 약 10일 이내에 투여할 경우의 대변하여 예방의 임상적 효과와 정확도가 향상 증명되어 있어야 한다. 4) 만 65세 이상을 대상으로 한 시험 후 권장 연구(연구 2017001 - 2020.02.29)에서, 이 백신 접종 후 42일 동안 감염병-예방후군의 발생 위험 증가가 관찰되었다 (백신투여량 1000,000 dose 당 발생 건수가 약 32건 증가, 이 백신 투여자의 인과관계를 판단하기에는 정보가 충분하지 않다. 5. 일부 및 수두에 대한 투여 1) 일부: 일부에서 이 백신을 사용한 치료는 없다. 동물시험에서는 임신, 배아기 발달, 분만 또는 출생 후 발달과 관련하여 치명적 또는 간접적인 유해한 영향이 나타나지 않았다. 예방적 조치로서, 임신 중에는 이 백신의 사용을 피하는 것이 좋다. 2) 수두: 이 백신의 접종이 수두 중증인 영아나 모체에 미치는 영향은 연구된 바 없다. 이 백신이 사람의 모유로 분비되는지 여부는 알려져 있지 않다. 3) 수태: 동물시험에서 수컷 또는 암컷의 수태는 면역에서 직접적 또는 간접적인 유해한 영향이 나타나지 않았다.

자세한 사항은 (주)글락소스미스클라인 백신 담당자에게 문의하여 주십시오.

GSK 제품 사용 중 발생한 이상사례(부작용)은 080-901-4100 또는 koreasafetyreporting.co.kr으로 보고해 주시기 바랍니다. Trademarks are owned by or licensed to the GSK group of companies. ©2026 GSK group of companies or its licensors.

수입판매원

GSK

(주)글락소스미스클라인
서울특별시 용산구 한강대로 92
161-080-901-4100

공동판매원

Kwangdong
광동제약

공동판매원

경기도 과천시 과학로7가길62 (금천동)



GC 녹십자

GC녹십자

경기도 용인시 기흥구 이현로 30번길 107 (보통동)

PM-KR-GSK-PRC-280009 Mar 2026



[Product Information]

싱그릭스주
[대상포진백신(유전자재조합)]

치명하지가진 QR 코드 또는 식품의약품안전처
의약품통합정보시스템 (http://heding.mfds.go.kr)을
통해 상세제품정보를 참조하시기 바랍니다.

The better! The easier!

수프렘미니에스[®]정

SUPREP mini S[®] TABLET



Add

- Simethicone 함유¹⁾
- 전해질 균형을 위한 조성변경¹⁾
- “당일 분할 복용”허가 획득¹⁾

Reduce

- 복용횟수(1차 8포²⁾ → 1차 6포)
- 총 복용량 감소(2.8L²⁾ → 2.5L)
- 위장관 부작용 감소³⁾

1) 수프렘미니에스정 허가정보 2) 수프렘미니정 허가 정보 3) 청구항1항(=특허권리)



Restore *calm* in UC



[South Korea_3_4_P_202606_00175]

APROGEN

(주)에이프로젠바이오토크스

Dual Action

Easy to ADD-ON

Less Anticholinergic



진경 및 가스제거제

가베스판

30 Cap.
300 Cap.

연질캡슐

Alverine citrate 60mg, Simethicone 300mg

Anti-secretory action **ON**

Gastro-protective action **ON**

With **STOGAR[®]**,
Dual Action ON!

**Anti-secretory
action**

..... **+**

**Gastro-protective
action**



Dual Action H₂RA

STOGAR[®] Tab.

[Lafutidine 10mg]

Strong antisecretory & gastroprotective action

Protection of NSAIDs-induced mucosal damage

NSAIDs, Non-Steroidal Anti-Inflammatory Drugs; H₂RA, Histamine-2 Receptor Antagonist.

Reference

1. Shim YK et al. Korean J Gastroenterol. 2017;70(1):4-12.
2. Shimatani T et al. Dig Dis Sci. 2006;51(1):114-120.
3. Kato M et al. J Gastroenterol Hepatol. 2010;25(10):1631-1635.

BORYUNG

(주)보령 | 서울특별시 종로구 창경궁로 136 (원남동)
고객센터 전화문의 : 080-708-8088 <http://www.boryung.co.kr>




본건복지부 인증
혁신형 제약기업
ROKALINDO THE PHARMACEUTICAL COMPANY

FLOSPANTM

Phloroglucin

| Good taste | Quick Antispasmodic | Safety for Children |



위·장관 등의 평활근의 통증성 경련에 탁월한 효과
빠르게 흡수되어 신속한 진경효과
IBS에 탁월한 효과를 발휘



Phloroglucin
FLOSPANTM Tab.
후로스판디정

제품코드: 645604690



Phloroglucin
FLOSPANTM Tab.
후로스판정

제품코드: 645602250



Phloroglucin
FLOSPANTM Soln.
후로스판액

제품코드: 645602241

※기타 자세한 사항은 **대화제약** 마케팅팀(080-855-0114, 02-586-6451)로 문의하시기 바랍니다.



DAEHWAE
PHARMACEUTICAL

AOCC 2026

IMKASID 2026



AOCC 2026 in conjunction with IMKASID 2026 Secretariat

| Convene International Convention Services, inc.

#815, Gasan Urban Work I, 135, Gasan digital 2-ro, Geumcheon-gu, Seoul 08504, Korea

Tel. +82-2-6278-8593 E-mail. aocc_info@aocc2026.org